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Background
Life expectancy is increasing in the Organisation for Economic Co-operation and Devel-
opment (OECD) countries. Simultaneously, however, many countries have experienced 
rising health care expenditure, albeit at a reduced rate during the last years due to the 
global economic recession.1-3 For instance, health care expenditure in The Netherlands 
has increased from 6.5 billion to 46.9 billion and 94.2 billion euro in 1972, 2000 and 2013, 
respectively.4 More apprehensively, not only absolute expenditure but also the relative 
share of Gross Domestic Product (GDP) spent on health care has increased across OECD 
countries. For example, the Dutch share of GDP spent on health care increased from 
8.7%, to 11.2%, and 15.6% in 1972, 2000, and 2013, respectively.4
It is expected that health care expenditure will continue to rise globally due to ageing 
populations and the continual development of new medical technologies.5 Since the 
organisation of health care is mostly implemented at a national level, governments face 
major challenges to keep their health care system financially viable in the long term. The 
major challenge is to appropriately balance everyone’s legal right to health and access 
of health care (Article 25.1 Universal Declaration of Human Rights) given the increasing 
demand for and supply of health care with the financial sustainability of the system. 
Consequently, it is inevitable that priorities must be set to ensure efficient and equitable 
use of limited health care resources.
Scarcity of resources implies that choices must be made regarding access to health 
care. The health economic science is concerned with the question of how to allocate 
scarce resources given individual and social objectives. In the past decades, the health 
economic field of Health Technology Assessment (HTA) has received particular attention 
within health care policy making. HTA is a multidisciplinary field of policy analysis that 
entails the medical, social, ethical, legal, organisational, and economic implications of 
the development, diffusion, and use of a health technology,6 with the aim to facilitate 
informed social decision making regarding the application of the technology.7 Concerns 
about increasing costs of medical technologies as well as concerns about the non-
evaluated benefits of many technologies stimulated the development and use of HTA.8 
Since the 1990s, many European countries established formal HTA agencies to inform 
health care decision making.9,10
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Priority setting for pharmaceutical products
The pharmaceutical market is one of the most regulated sectors. Pharmaceutical 
expenditure accounted for a total of 800 billion USD across OECD countries in 2011, 
comprising on average 17% of total health care expenditure.2 Until 2009, the share of 
pharmaceutical expenditure increased faster than total health care expenditure, but 
due to the economic recession, annual growth rates decreased significantly. Interest-
ingly, there is a wide variation across OECD countries in pharmaceutical spending per 
capita (OECD average USD483 PPP; ranging from USD178 PPP in Chile to USD985 PPP 
in United States of America) as well as share of GDP (OECD average 1.50%; ranging from 
0.56% in Luxembourg to 2.63% in Hungary).2
A pharmaceutical product is only allowed to enter the market after the demonstration 
of its efficacy, quality and safety to the market licensing authority (e.g., the European 
Medicines Agency, and the United States Food and Drug Administration). However, in 
order to contain health care expenditure, many countries developed policies and deci-
sion structures to control the basic benefit package. Most of these policies have been 
directed at controlling pharmaceutical expenditure.11 This implies that, in order to justify 
public funding, many countries additionally require (HTA) evidence regarding the cost 
efficiency of a pharmaceutical product. This requirement is often perceived as an ad-
ditional barrier to market access and has therefore been labelled as ‘the fourth hurdle’.12 
Due to differences in health care organisation across countries there are differences 
in drug reimbursement systems and reimbursement policies. There is, however, little 
evidence on the efficiency and sustainability of these different reimbursement policies. 
A detailed comparison of various systems could help identifying systems’ strengths and 
weaknesses and could thus facilitate policy learning and provide lessons to improve 
system efficiency and sustainability. However, so far, most studies have been descriptive 
in nature; more analytically oriented studies could enhance understanding of decision-
making processes.13,14
This thesis focuses on decision making in drug reimbursement. It consists of a descrip-
tive part of European drug reimbursement systems’ procedures, processes, and their 
applied criteria, but also provides a detailed analysis of the actual use of reimbursement 
criteria in everyday decision making, evaluations of policy tools to handle uncertainty 
of the evidence, an evaluation of strengths of and challenges for the systems, as well as 
suggestions on how the decision-making process could be improved.
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Drug reimbursement decision making
Many countries institutionalised priority setting for pharmaceutical products at the 
national level; for instance, based on a ‘positive’ or a ‘negative’ list. In this thesis, the term 
drug reimbursement system is used for the established policy system that determines 
whether or not a drug is entitled for reimbursement (i.e., public funding). We distin-
guish four different phases in the reimbursement decision-making process (see Figure 
1.1). Firstly, the assessment phase entails the quantification of the clinical, pharmaco-
therapeutic and pharmacoeconomic value of a drug in comparison to other available 
drugs. The assessment can also include a description of other health care sector related 
arguments (e.g., ethical and organisational issues). Assessment is descriptive in terms 
of quality and uncertainty of evidence, thus, it does not include a value judgement. It 
provides a description of the available evidence, the level of quality of the evidence 
and the level of uncertainty related to the quantifications. Secondly, the appraisal 
phase entails the evaluation of the social value of a drug by weighing the assessment 
outcomes against other criteria related to the objectives of the health care system (e.g., 
necessity to pay out of public funding). Appraisal seeks to gauge societal willingness to 
pay for a specific drug out of public funding. A consequence of weighing criteria is that 
the appraisal includes a value judgement of the drug. Thirdly, the decision whether or 
Assessment
• Quantification of outcomes
• Health care sector related criteria
• No value judgement
• Weighing assessment outcomes against socially relevant health 
care sector related criteria
Appraisal
   
• Value judgement (advice)
Decision 
making
• Weighing appraisal outcomes against other socially relevant (non) 
health care sector related criteria  
• Social value judgement
• Ascertain the consequences of the decision
• Evaluate whether the decision is still appropriate
S i l l j dEvaluation • oc a  va ue u gement
Figure 1.1 Four phases in the drug reimbursement process*
* Adapted from Le Polain, Franken et al.15
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not to reimburse the drug is made in the decision-making phase. The decision is based 
on a value judgement from a broader social perspective. As such, the value judgement 
includes considerations of both health system objectives as well as non-health system 
objectives (e.g., employment in pharmaceutical industry). Finally, the last phase in the 
process is the evaluation phase. This phase entails ascertaining the consequences of the 
decision and evaluating whether the initial decision is still appropriate in case new evi-
dence becomes available (in which case the cycle of assessment, appraisal, and decision 
making will be reiterated).
Uncertainty of the evidence in the decision making
Reimbursement decisions are inherently made under uncertain conditions due to the 
absence of complete information.16,17 Evidence required for market access is mainly 
based on randomised clinical trials (RCT). These trials are conducted under ‘ideal cir-
cumstances’ and assure internal validity by randomly assigning patients to a treatment 
strategy. However, external validity may be hampered because patients treated in 
everyday practice may not be comparable to ‘ideal patients’ in an RCT setting. Moreover, 
RCTs often use intermediate efficacy estimates which may not be fully predictive of 
effectiveness endpoints such as improving quality of life and prolonging life in a real-
world setting. Consequently, uncertainty may arise on the actual clinical benefit, the 
adoption and diffusion, value for money, and the economic impact of the new drug.18
However, evidence from an RCT may be very promising and can thus put a high pres-
sure on policymakers to ensure early access to promising drugs for patients in need. For 
example, in the late 1990s the Dutch minister ensured early access to promising drugs 
for AIDS.19 More recently, various policies are implemented to guarantee access to new 
promising treatments for cancer20 (e.g., the Cancer Drugs Fund in the United Kingdom). 
Van Luijn et al.21 reported that between 1999 and 2005 only 48% of newly approved 
drugs had comparative efficacy data (i.e., compared with an active treatment) available 
at the moment of European market authorisation. Similarly, Goldberg et al.22 reported 
that between 2000 and 2010 only 51% of newly approved drugs had comparative ef-
ficacy data available for market authorisation in the United States. Consequently, policy-
makers face the challenge to strike an optimal balance between ensuring timely access 
and having sufficient evidence of drug’s comparative value. Policymakers could consider 
postponing the reimbursement decision until sufficient evidence becomes available.16 
This is, however, at the cost of delaying access. Another option would be to link the 
price paid for the drug not only to its actual value but also to the quality of the available 
evidence; this would incentivise manufactures to invest in good quality evidence.23 In 
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the last decade, many systems introduced policies to reduce the clinical and economic 
uncertainty of the performance of novel drugs by making reimbursement conditional 
on additional evidence collection.18,24-26 The gathered evidence should fill the gap be-
tween the evidence from RCTs and treatment in everyday practice. The policies address 
clinical and/or financial uncertainty; for example, by means of implementing patient 
access schemes,27 managed entry agreements,28 coverage with evidence development 
schemes,29-31 outcomes research requirements,32,33 and finance-based34,35 or outcomes-
based 35,36 risk sharing agreements. There is, however, little empirical evidence regarding 
the effectiveness of these different schemes.
Objectives
The overall aim is to describe, analyse and evaluate systems that make decisions on 
reimbursement of drugs. The thesis begins with exploring preferences for the objectives 
of a health system. To obtain insights into drug reimbursement decision-making pro-
cedures and processes, we describe and compare five European drug reimbursement 
systems. Based on this, a framework is presented to improve upon the legitimacy of the 
decision-making process. Subsequently, the use of two reimbursement criteria (cost-
effectiveness and disease severity) is assessed in actual decision making. Finally, one of 
the policy tools to handle uncertainty of evidence (coverage with evidence develop-
ment) is evaluated regarding its effectiveness, feasibility, and appropriateness.
The following research questions are addressed:
1. What are the objectives of a health care system?
2. What criteria are important in drug reimbursement decision making?
3. How do drug reimbursement decision-making systems handle uncertainty of evi-
dence?
4. To what extent do drug reimbursement systems satisfy the conditions of legitimate 
decision making?
5. What are the strengths of and challenges for drug reimbursement decision-making 
systems?
6. Based on the research findings, what suggestions can be put forward to improve 
decision making in drug reimbursement?
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Outline
This thesis is structured in three sections. Part A is a general explorative introduction 
into social preferences for the goals of health systems. Chapter two describes five main 
goals of a health system including their theoretical foundation, and presents a frame-
work, based on a multi-attribute choice technique, for measuring relative preferences 
for these goals. This chapter also presents goal valuations which were obtained in The 
Netherlands.
Part B focuses on drug reimbursement procedures, processes and criteria. Chapter 
three describes a comparative analysis of five European drug reimbursement systems 
(between Austria, Belgium, France, The Netherlands, and Sweden). The chapter pro-
vides insights into reimbursement procedures and processes, and identifies strengths 
and weaknesses of the five systems. Based on this comparative analysis, chapter four 
presents a framework for policymakers to improve upon the legitimacy of the decision-
making process. Chapter five to seven explore the actual importance of two reimburse-
ment criteria (the disease severity and cost-effectiveness criterion) in everyday decision 
making. Firstly, in chapter five, the role of the criterion disease severity is assessed in four 
European decision-making settings (in Belgium, France, The Netherlands, and Sweden). 
Secondly, chapter six provides a comparative analysis of the actual importance of the 
criterion cost-effectiveness in Dutch and Swedish drug reimbursement decision making. 
Chapter seven more specifically focuses on the actual impact of cost-effectiveness in 
The Netherlands.
Part C provides empirical evidence of the coverage with evidence development policy 
tool to handle uncertainty of evidence in drug reimbursement decision making. Chapter 
eight assesses whether the Dutch policy is effective towards reaching its objective. The 
next chapter provides insights into the practical feasibility of developing evidence on 
drug use and cost-effectiveness in everyday clinical practice. The last chapter shows 
whether this particular policy reduces policymaker uncertainty and debates whether 
other policy options could be appropriate to ensure sufficient value for money of ex-
pensive drugs.
Finally, chapter eleven reports the main findings and discusses the merits and limita-
tions of the research presented in thesis, and presents suggestions on how to improve 
decision making in drug reimbursement and explores challenges for future research.
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It should be noted that chapters two to ten are based on publications in, or intended for, 
scientific peer reviewed journals. These chapters can, therefore, be read independently, 
and some overlap may exist between these chapters.

A
Social preferences for  
health system objectives

2 
Health system goals: A discrete choice 
experiment to obtain societal valuations
With Xander Koolman
Health Policy 2013; 112(1-2):28-34
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Abstract
The aim of this study is to improve previous approaches to health system goals valua-
tion.
We reviewed literature on health system performance and previous comparative per-
formance assessments, and combined this with literature on process utility to create a 
theoretical foundation for health system goals. We used a discrete choice experiment to 
elicit goal weights. To obtain social justice weights respondents were placed behind a 
‘veil of ignorance’. To ensure that respondents understood their task, we instructed them 
in a classroom setting.
We identified five health system goals. All five goals significantly affected choice behav-
iour. An equitable distribution of health obtained the highest weight (0.34), followed by 
average level of health (0.29) and financial fairness (0.24). Both process outcomes (utility 
derived from the process and its distribution) received much lower weights (0.07 and 
0.06, respectively).
Our framework adds to that of the World Health Organization. We demonstrated the 
feasibility of measuring societal valuation of health system goals with a multi-attribute 
technique based on trade-offs. Our weights placed much greater emphasis on health 
and health inequality than on process outcomes. Our study improves the methodology 
of international health system performance comparison and thereby enhances global 
evidence-based health policy information.
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Introduction
Health systems around the world have contributed to better health and life expectancy 
with varying degrees of success. Even in countries with seemingly similar resources 
outcomes vary markedly.37 To date, policy effects on the performance of health systems 
remain largely unclear. Monitoring and evaluating performance can generate this vital 
policy information. Moreover, cross-country comparisons enable countries to learning 
from others.
The challenge, however, is how to assess health systems that are extremely complex and 
have multi-dimensional goals. This complex task has been explored by the World Health 
Organization (WHO) and the Organisation for Economic Co-operation and Development 
(OECD).
Our aim is to improve the valuation of health system goals. To do so, we first unify lit-
erature on health system goals, equity, and process utility to create the underpinnings 
of a theoretical framework for health system evaluation. Second, we review previous 
approaches to deriving relative weights for health system goals. Third, we suggest an 
enhanced methodology based on a multi-attribute choice technique to elicit goal valu-
ations using a ‘veil of ignorance’ perspective. Last, we present goal valuations for The 
Netherlands based on our proposed method.
Theoretical framework for health system goals
Until the 1990s health economics was dominated by the assumption that ‘health’ was 
the dominant outcome of health systems. This links with the consequentialism moral 
theory, which focuses solely on outcomes irrespective of the process that led to them, 
and Jeremy Bentham’s ‘act utilitarianism’, which states that the greatest amount of 
happiness for the greatest number of people determines choice behaviour. Although 
utility derived from health is an obvious outcome of a health system, research showed 
that people also care about the processes that precede health outcomes, irrespective 
whether they affect health.38-40 Therefore, processes are not just means to an end, not 
just instrumental to an intrinsic goal, but are an intrinsic goal of the health system.
This utility derived from processes, procedural utility, has a base in social sciences. 
Parsons’ social action theory (1937) already described the necessity of the subjective 
dimension of human action.41 Psychologists have developed a comprehensive notion of 
basic psychological needs for the human self, evident in the ‘self-determination theory of 
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intrinsic motivation’ by Deci and Ryan.42,43 The theory maintains that human motivation 
originates from three innate needs: autonomy, competence, and relatedness; individual 
well-being therefore depends on procedures that address them.42,43
The theory of procedural utility can be directly applied to health care. Consequently, 
both health outcomes and the process attributes of non-health outcomes are health 
system goals. Furthermore, it is widely recognised that health systems’ costs should 
be related to capacity to pay rather than the risk of illness.44 Therefore, health systems 
have three independent outcome-oriented objectives: health utility, process utility, and 
financial fairness.
Health utility
Health systems aim to improve health and strive for the highest possible health status of 
the entire population, taking both morbidity and mortality into account. Behind a ‘veil 
of ignorance’ the distribution of health also matters; empirical evidence indicates that 
the public is willing to trade efficiency for social objectives such as equity.45-47 Therefore, 
health utility consists of two goals: average level of health and the equitable distribution 
of health.
Process utility
Procedural utility can arise from two sources.48 First, interaction between people can 
generate utility since people evaluate actions by how they are treated by others. Sec-
ond, people have preferences for good institutions in addition to health outcomes (e.g., 
preferences on allocative and redistributive decisions) that address the innate needs of 
human motivation (autonomy, competence, and relatedness). Institutions also establish 
the fundamental rules for societal decision making. As a result, process attributes of 
health systems are twofold: utility derived from interaction between people and the 
health system (how people are treated by the health system), and utility obtained 
from living under institutions (how allocative and redistributive decisions are taken). 
Although distributional fairness of process utility is not well founded in moral theory, 
we followed the WHO framework and therefore included both process utility and its 
distribution in our framework.
Financial fairness
Murray et al.49 claim that a health system is fairly financed “if the ratio of total health 
system contribution of each household through all payment mechanisms to that house-
hold’s capacity to pay is identical for all households, independent of the household’s health 
status or use of health system.” This signifies two key challenges. First, households should 
not pay an excessive share of their income for health care or become impoverished.50 
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Second, wealthy households should contribute more than poor households reflecting 
vertical equity and an element of progressivity.
Existing international frameworks
Several countries, such as the USA, United Kingdom, The Netherlands, Australia, and 
Canada, have designed and implemented national schemes and indicators to measure 
health system performance.51 Cross-country comparison, however, requires a compre-
hensive international framework such as those of the OECD and WHO.
OECD framework. The three main goals of the OECD framework are (i) health improve-
ment and outcomes, (ii) responsiveness and access, and (iii) financial contribution and 
health expenditure.52 Without suggesting any relative importance of the system goals 
it provides a framework to measure performance in several dimensions that seem to 
be based on the historical development of health systems. A composite score requires, 
however, each goal to be independent. The OECD framework consists of input and 
output variables, and intermediate as well as end goals. Consequently, using the OECD 
framework gives rise to methodological problems when weighing goals.
WHO framework. The WHO framework for performance measurement consists of three 
intrinsic goals of health systems: health, responsiveness, and fairness in financing.37 
The first two are assessed on both level and fairness of the distribution. The framework 
satisfies the required conditions (i.e., a complete set of intrinsic goals) to facilitate global 
performance assessment.
WHO’s health system goals closely resemble those identified for our own theoretical 
framework. Health utility and its distribution are reasonably comparable to WHO’s level 
and the distribution of health. Our two sources of process utility can be described by 
WHO’s assessment of quality and equity of responsiveness. Last, one could suggest that 
financial fairness reflects WHO’s fairness in financing.
Valuing health system goals
Previous approach
WHO’s goal weights were acquired by measuring preferences of individuals with health 
system knowledge via an internet-based questionnaire, which included interactive, 
weight-assigning pie charts, descriptive multiple choice questions, and ranking tasks. 
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The final weights were rounded to the nearest one-eighth for the World Health Report 
2000 (WHR) to make the composite goal easier to understand.53 In 2000 and 2001, the 
WHO performed a follow up multi-country study to measure preferences from the pub-
lic.54 These questionnaires consisted of ranking tasks and pie charts. The Dutch sample 
included 1566 respondents: 1068 face-to-face and 498 postal interviews.54
Critiques on the WHO approach
Much critical attention and debate followed the publication of the WHO results. One of 
the major concerns was that WHO’s relative weights were highly subjective since they 
were derived from respondents who were far from representative.55-57 The WHO justified 
its method by stating: “the purpose of the first survey was not to describe preferences in 
a population, but rather empirically derive a set of weights reflecting normative choices.”58
Richardson et al.59 maintained that effective weights depend on variation in scores across 
countries as well as the nominal weights. Consequently, if there is no difference in, for 
example, health inequality then, regardless of the weight of 0.25, it would contribute 
nothing to the ranking scores. However, applying a standard set of weights appears to 
deny differences between countries’ ideologies and theories of social justice.
Moreover, the Oswaldo Cruz Foundation60 concluded that the composite index is very 
sensitive to modification in the relative weights and claimed that some countries can 
shift the scale by more than thirty points by small weight adjustments. On the contrary, 
Lauer et al.61 concluded that even large changes would have a small impact and that all 
rankings remained within the uncertainty intervals. Nevertheless, Lauer et al.62, in yet 
another publication, argued that the differences could be large for individual countries 
because of the impact of publication of the rankings.
The most essential critiques concern the valuation methodology. Smith57 argued that 
WHO’s methodology was highly questionable and that it is unlikely that it would elicit 
the required relative marginal valuation of an extra unit of performance. Moreover, Wil-
liams56 claimed that the main issue was the use of rankings, scores, and rating scales 
rather than facing respondents directly with trade-offs.
Making trade-offs is at the heart of economics. In a multi-attribute environment, such 
as a health system, individuals choose between attributes based on their relative im-
portance. The WHO limited their survey by using pie-charts, rankings, and descriptive 
multiple choice questions; their instrument did not allow for deliberation.
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Enhanced methodology
The Multi Attribute Utility Theory (MAUT) provides a foundation for valuing complex 
and multi-dimensional objectives. It has its roots in classical measurement theory and 
theories of economic choice behaviour. In the last decade, multi-attribute valuation 
methods and especially discrete choice experiments (DCEs) have become increasingly 
popular. DCE draws upon Lancaster’s economic theory of value63 and is firmly rooted in 
the random utility theory.64
Furthermore, Dolan et al.65 distinguish respondents’ perspectives in two dimensions: 
who the respondent should have in mind and at what point in time. The former dimen-
sion concerns oneself, other people, or all people; that is, preferences are personal, 
social, or socially inclusive, respectively. The time dimension relates to the context in 
which the valuation is obtained, that is, whether it is ex ante or ex post. The structure of a 
health system depends in large part on society’s choices concerning resource allocation; 
relatedly, a person’s societal position often reflects a feeling of social (un)fairness. There-
fore, it is essential to elicit ex ante socially inclusive personal preferences for social justice 
valuations. Valuations should therefore be obtained in a procedurally fair way reflecting 
a social justice perspective; i.e., respondents assume a Rawlsian ‘veil of ignorance’. The 
main characteristic of Rawls’s approach is that people make choices without knowing 
where their own position might be in a society.66 The ‘veil of ignorance’ ensures that the 
principles of justice are blind to age, health status or societal position.
An enhanced methodology should therefore be based on a multi-attribute choice 
technique such as a DCE. This technique applies direct trade-off questions, improves 
conscientious deliberation, and elicits marginal valuations. To ensure social justice valu-
ations, goal valuations should be obtained using an ex ante perspective.
Methods
We conducted a DCE to obtain goal valuations in The Netherlands. Our five-step proce-
dure, typical of a DCE, was to: (1) identify and describe the attributes for health systems; 
(2) assign attribute levels based on goal variation; (3) combine attribute levels and cre-
ate hypothetical scenarios; (4) establish goal valuations; and (5) analyse and interpret 
the data.
Attributes and levels
Our health system goals satisfy the attribute criteria by being complete, operational, 
decomposable, non-redundant and minimum-sized.67 For use in a questionnaire, at-
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tributes must be meaningful, relevant and easy to understand, and their levels should 
be plausible, actionable and tradable.68 Variation in their levels should mimic existing 
variation.
We pilot-tested attribute and level descriptions in 54 participants [data not shown]. They 
were interviewed face-to-face or by telephone and were asked to fill out a questionnaire 
while thinking aloud. Pilot questionnaires offered 30 questions comprising paired com-
parison of two attributes in which vignettes varied by one level. The interviewer could 
ask about the basis for respondents’ trade-offs and the extent to which they understood 
the descriptions. Answers provided insight into respondents’ ways of thinking and 
revealed any misinterpretation or misunderstanding of the notions of the attributes. Re-
spondents initially found it difficult to make a clear distinction between the intrinsic and 
instrumental contributions of process factors. The pilots also showed that respondents 
changed their behaviour when choosing from behind a veil of ignorance, some explic-
itly mentioning that equity was more of a concern. Preferences concerning solidarity 
versus individualism were partly balanced out. Table 2.1 shows the attributes and the 
final descriptions of the attributes and levels which were used in the DCE exercise.
Health outcome
Utility obtained from health outcome reflects the average level of health in a population 
expressed by life expectancy that takes both morbidity and mortality into account. The 
levels are actual Health Adjusted Life Expectancy (HALE) years in The Netherlands: 74, 
72, 70 and 68 years.
Table 2.1 Attributes and descriptions of attributes and levels used in the DCE exercise
Attribute Attribute description Level description
Average level of health Average health adjusted life expectancy 74, 72, 70 and 68 years
Distribution of health Differences in health adjusted life 
expectancy across social groups
3, 5, 7 and 9 years difference
Average level of process 
outcome
Patient experiences very good experiences, good 
experiences, rather good experiences, 
reasonable experiences
Distribution of process 
outcome
Differences in experiences between 
patients across social groups
no difference, small difference, some 
difference and fair difference
Financial fairness Persons in poverty because of health 
system payments
0, 1, 2 and 3 person(s) per 200 persons
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Distribution of health outcome
We assessed existing inequalities in HALE in The Netherlands. Inequality is present across 
social classes, educations groups, income levels, ethnic groups, gender and geographic 
areas. The differences across social groups in HALE were 3, 5, 7 and 9 years.
Process outcome from interactions
Because the pilots revealed that respondents experienced difficulties in understand-
ing the process-outcome concept, the concept and its implications were clarified and 
illustrated with recognisable examples from the Dutch health system during the DCE 
exercise. The levels in experience were very good, good, rather good, and reasonable. 
This variation mimics the actual variation in patient experiences in The Netherlands as 
measured by a population based study of the WHO (average responsiveness score of 
85.7 on a scale of 0 to 100).69
Distribution of process outcome
Although distributional fairness of process utility is not well founded in moral theory, 
we followed the WHO framework and allowed our empirical test to indicate the value 
respondents attached to an unequal distribution of process utility. This attribute thus 
indicates the inequality in the distribution of process outcome across groups. In The 
Netherlands options exist to bypass waiting lists and ‘buy’ quality but the majority of the 
population sees this as inequitable. The Health Insurance Act has since 2006 been mov-
ing towards managed competition in health care and it is thus likely that more options 
will become available to buy additional insurance or pay out-of-pocket for extra quality 
and other process attributes in the future. Therefore, our levels are actual differences in 
distribution and partly reflect potential future developments. The levels of difference 
offered were none, small, some, and fair. The differences in the levels were clarified and 
illustrated with recognisable examples from the Dutch health system.
Financial fairness. The last attribute describes financial protection against costs of illness. We 
explored national health insurance premiums and potential co-payments, and connected 
these financial flows with catastrophic payment and impoverishment. We selected a quasi-
relative poverty measure found to be recognisable and accurate for the core perception 
of poverty within the Dutch population.70 We expressed the levels as consequences of 
variations in (co-) payments. The levels offered were 0, 1, 2 and 3 extra person(s) per 200 
persons unable to satisfy basic needs because of health system payments.
Experimental design
A full factorial design would generate 1024 (45) scenarios. To reduce the DCE exercise to 
a manageable level, we applied a fractional factorial design. We obtained an orthogonal 
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array from the online Sloan library in order to assign 16 choice sets (http://www.research.
att.com/~njas/oadir). We applied an optimal design generator (12332, 21123 and 33211) 
based on strategies described by Street et al.71 Such a fold-over strategy provides an 
optimal design with a high efficiency for estimating main effects while satisfying the 
statistical properties of level balance, orthogonality, minimal overlap, and utility bal-
ance.68 Main effects usually account for 70–90% of explained variance.64 The order of 
vignettes was randomly varied for all three choice sets.
We did not include an opt-out option because (i) it can generate problems such as ap-
plying heuristics to prevent making difficult choices or preferring a status quo and (ii) 
it is impossible to opt-out by choosing not to have any health system. Our respondents 
were choosing from behind a veil of ignorance and thus we assumed that there was no 
default system, i.e., an opt-out option was non-existent.
Data collection
We selected 63 persons familiar with health systems to ensure that respondents under-
stood their task. Moreover, respondents were instructed by the principal investigator in 
a classroom setting via a PowerPoint presentation and a 20-minute interactive discus-
sion about the meaning of the attributes and their levels. In particular, the distinction 
between the intrinsic and instrumental contribution of both process attributes was 
explained and the levels were made operational by illustrative examples from the Dutch 
health system. Each respondent was provided with the information on paper to refer to 
if needed. Respondents had to choose in which country they would prefer to be born.
Data analysis
The software program STATA was used to perform data analysis. Given the exploratory char-
acter and aim of our study to investigate the feasibility to estimate health system goal valua-
tions using a multi-attribute technique based on trade-off questions, we used a conditional 
logit model to estimate the coefficients. The estimated function for the valuations of health 
system goals was: Ylatent = β0 + β1* average level of health + β2* distribution of health + β3* 
process outcome + β4* distribution of process outcome + β5* financial fairness + ε.
Results
Econometric model
All responses were included in our data analysis since all respondents correctly an-
swered the dominant question. Table 2.2 presents the results of the conditional logit 
model, which provides good insight into respondents’ trade-off behaviour because the 
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outcome probabilities are based only on the attributes and their levels. The summary 
statistics show that the model had a decent fit with a pseudo R2 of 0.35 and a statistically-
significant Chi-square test of 948.75.
The coefficients reflect the relative importance of the system goals. As expected, they 
revealed that respondents favour the best attainment in all five goals. The associated 
p-values indicated that all attributes have a statistically significant effect on choice 
behaviour. The table shows that health distribution received the highest importance 
followed by average level of health, financial fairness, average level of process outcome, 
and distribution of process outcome, respectively.
Marginal rate of substitution
The marginal rate of substitution (MRS) is computed by dividing the coefficients and 
demonstrates the trade-off between attributes. Table 2.3 shows that individuals are will-
ing to give up 0.848 level in health distribution to gain one level in average health (β1/
β2), meaning that individuals will trade 2 years of average health for 1.70 years of health 
inequality.
Valuation as percentage
To enable direct comparison between WHO’s relative weights and our valuations, our 
coefficients needed to be converted into percentages by dividing the coefficient of one 
attribute by the sum of all coefficients. This method is based on the same assumption 
as the MRS calculation, that is, linearity of the coefficients and a comparable realistic 
amount of variation between the levels for each of the attributes. Table 2.4 shows the 
results.
Table 2.2 Results conditional logit model
Attribute Coefficient Std. error z value P > |z| 95% Conf. interval
Average level of health -1.097 0.067 -16.31 0.000 -1.229; -0.966
Distribution of health -1.294 0.073 -17.84 0.000 -1.436; -1.152
Average level of process 
outcome
-0.277 0.058 -4.73 0.000 -0.391; -0.162
Distribution of process 
outcome
-0.236 0.061 -3.84 0.000 -0.356; -0.116
Financial fairness -0.927 0.063 -14.64 0.000 -1.051; -0.803
Log likelihood -880.674
Chi-Square test 948.75
Pseudo R2 0.350
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Although the sum of the quality (0.36 vs. 0.37) and equity (0.64 vs. 0.63) objectives are 
similar, their weights are derived differently. Specifically, our valuations place much 
greater emphasis on health (0.63 vs. 0.49) and far less on process outcomes (0.13 vs. 
0.29). Furthermore, our results show a greater weight for health distribution (0.34) com-
pared to the average level of health (0.29), whereas these weights were almost similar 
in WHO’s survey (0.25 and 0.24, respectively). Fairness in financing is roughly equally 
weighted in both methodologies.
Table 2.4 Comparison of goal valuations
WHO
1st 
surveya
WHR
applied 
weightsa
WHO 2nd survey 
(Netherlands)
(face-to-face/ 
postal)b
Discrete choice 
experiment 
valuations
Average level of health (1) 0.24 0.25 0.29
Distribution of health (2) 0.25 0.25 0.34
Average level of process outcome (3) 0.13 0.125 0.07
Distribution of process outcome (4) 0.16 0.125 0.06
Financial fairness (5) 0.22 0.25 0.24
Health outcomes (1+2) 0.49 0.5 0.415 0.63
Process outcomes (3+4) 0.29 0.25 0.309/ 0.306 0.13
Financial fairness (5) 0.22 0.25 0.277/ 0.279 0.24
Quality (1+3) 0.37 0.375 0.376/ 0.432 0.36
Equity (2+4+5) 0.63 0.625 0.624/ 0.569 0.64
a Gakidou et al. 200058
b Gakidou et al. 200354
Table 2.3 Marginal rate of substitution
Coefficients Attribute/ Attribute Observed MRS
β1/β2 average level of health/ distribution of health 0.848
β1/β3 average level of health/ average level of process outcome 3.968
β1/β4 average level of health/ distribution of process outcome 4.651
β1/β5 average level of health/ financial fairness 1.184
β2/β3 distribution of health / average level of process outcome 4.677
β2/β4 distribution of health / distribution of process outcome 5.482
β2/β5 distribution of health / financial fairness 1.396
β3/β4 average level of process outcome/ distribution of process outcome 1.172
β3/β5 average level of process outcome/ financial fairness 0.298
β4/β5 distribution of process outcome/ financial fairness 0.255
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Discussion
The focus of our research was twofold. First, we identified five health system goals 
and explored their theoretical foundation. We included the process of health care de-
livery in a utility framework supporting that the process of care giving is an end goal 
of health systems, irrespectively whether it affects health, and thus can be traded-off 
against health outcomes. Second, we obtained valuations for the goals using a multi-
attribute technique based on trade-offs. We used actual variation in goal attainment, 
elicited marginal weights from behind a ‘veil of ignorance’ reflecting the original posi-
tion, and created a setting to help respondents understand the concepts and their task. 
Consequently, we tested all five goals statistically significantly affect choice behaviour 
independently. An equitable health distribution has the highest valuation, followed by 
average level of health and financial fairness. Both attributes measuring process utility 
receive much lower weights.
By assuming a linear additive model for a latent preference variable, it was possible to 
compare our valuations with WHO’s weights. Some might argue that our DCE valuations 
only provide a rough estimate of actual percentages. Nevertheless, our results are quite 
different from WHO’s weights. Specifically, much weight of both process attributes shifts 
toward both health attributes. The shift may be due to the fact that we specifically made 
respondents aware that the intrinsic contribution of process attributes do not directly 
influence health. The extent to which WHO’s respondents were conscious of this distinc-
tion is unknown.
Several researchers have claimed that people are willing to sacrifice overall health to 
achieve a more equitable distribution of health45,47,62,72 Our results show this greater 
weight for health inequality whereas WHO’s weights are equal for both health attributes. 
First, an equitable health distribution attains a higher valuation compared to average 
level of health. Second, the computed MRS suggests that individuals are willing to trade 
2 years of average health for 1.7 years in health inequality. We believe that this might be 
attributable to our enhanced methodology to derive marginal valuations from behind 
a veil of ignorance.
The complexity of the attributes and levels forced us to make a trade-off between po-
tential interviewer bias caused by an interactive classroom setting and task simplicity. 
Furthermore, our respondents were well-educated and familiar with the Dutch health 
system. It is possible that we introduced selection bias and the goal valuations are not 
representative of the preferences of the Dutch population. Gakidou et al.,54 however, 
conclude that WHO’s valuations varied only slightly between informed respondents and 
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the population at large. We also obtained goal valuations from behind a veil of igno-
rance, although whether such a scheme guarantees societal preferences that are genu-
inely impartial is debatable. Two findings in favour of impartiality was that respondents’ 
equity concerns were altered by the ‘original position’ due to ‘the veil of ignorance’ and 
choice behaviour in the pilot study changed when respondents assumed an unknown 
position in society.
At the methodological level, economists are inclined to consider DCEs superior to rank-
ing and rating since they are based on the random utility theory. Therefore, we argue 
that the research resulting from our enhanced methodology can be seen as a follow-up 
to the WHO surveys. We do, however, acknowledge methodological issues of DCEs, most 
of which are related to human cognitive processes. For example, choice experiments as-
sume that people have stable preferences and are willing to trade between all attributes 
and a ‘veil of experience’ can influence decision making through status quo bias and the 
endowment effect.73 However, these issues have received much attention within health 
economics and should not be seen as ‘threats’ to economic methods of valuation.74
Conclusions
Our study demonstrates the feasibility of measuring health system goal valuations us-
ing a multi-attribute technique based on direct trade-off questions. We believe that our 
valuations improved on WHO’s derived weights because we applied a comprehensive 
enhanced methodology, used actual variation in goal attainment, elicited marginal 
weights from behind a veil of ignorance, and created a setting to help respondents un-
derstand the concepts and their task. And because new weights could affect countries’ 
rankings and comparisons over time, we advocate that appropriate weights be applied 
in future (international) comparisons of health system performance. Our study provides 
a promising and challenging basis on which to improve the methodology of global 
health system performance measurement. Advancing performance measurement is 
essential to cross-country comparison, which, in turn enhances global evidence-based 
health policy information.
Acknowledgments
This chapter has benefitted from the questions and suggestions of participants of a 
WHO-headquarters seminar. We also thank Marc Koopmanschap for providing valuable 
feedback on the manuscript.


B
Drug reimbursement procedures, 
processes and criteria

3 
Similarities and diff erences between fi ve 
European drug reimbursement systems
With Maïté le Polain, Irina Cleemput, and Marc Koopmanschap
International Journal of Technology Assessment in Health Care 2012; 28(4):349-357
38 Chapter 3
Abstract
The aim of our study is to compare five European drug reimbursement systems, describe 
similarities and differences, and obtain insight into their strengths and weaknesses and 
formulate policy recommendations.
We used the analytical Hutton Framework to assess in detail drug reimbursement sys-
tems in Austria, Belgium, France, The Netherlands and Sweden. We investigated policy 
documents, explored literature and conducted 57 interviews with relevant stakeholders.
All systems aim to balance three main objectives: system sustainability, equity and qual-
ity of care. System impact, however, is mainly assessed by drug expenditure. A national 
reimbursement agency evaluates reimbursement requests on a case-by-case basis. The 
minister has discretionary power to alter the reimbursement advice in Belgium, France 
and The Netherlands. All systems make efforts to increase transparency in the decision-
making process but none uses formal hierarchical reimbursement criteria nor applies a 
cost-effectiveness threshold value. Policies to deal with uncertainty vary: financial risk-
sharing by price/volume contracts (France, Belgium) versus coverage with evidence de-
velopment (Sweden, The Netherlands). Although case-by-case revisions are embedded 
in some systems for specific groups of drugs, systematic (group) revisions are limited.
As shared strengths, all systems have clear objectives reflected in reimbursement criteria 
and all are prepared to pay for drugs with sufficient added value. However, all systems 
could improve the transparency of the decision-making process; especially appraisal 
lacks transparency. Systems could increase the use of (systematic) revisions and could 
make better use of HTA (amongst others cost-effectiveness ) to obtain value for money 
and ensure system sustainability.
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Introduction
The sustainability of drug reimbursement systems is increasingly under pressure by 
continuously rising health care expenditures. A detailed comparison of various Euro-
pean drug reimbursement systems provides an overview of systems’ similarities and 
differences, and could help identify systems’ strengths and weaknesses and thus provide 
opportunities to improve their efficiency and sustainability.
Previous studies have investigated the use of health technology assessment (HTA) in 
coverage decision making,75-78 specific drug policies,79 or parts of drug reimbursement 
systems80-83 such as pricing and reimbursement,76,84 stakeholder involvement,85 and the 
role of reimbursement criteria.81,86-88 However, based on a literature review, Vuorenkoski 
et al.13 concluded that most studies are descriptive in nature. They suggest that more 
analytically oriented studies would enhance our understanding of how reimbursement 
decision-making processes perform against system objectives. Therefore, we compare 
five European drug reimbursement systems, providing a detailed and comprehensive 
comparative analysis between the systems’ objectives, institutions, processes, formal re-
imbursement criteria, and output and implementation in real life. In specific, the degree 
of detail in our analysis, the link with policy goals, and the breadth of our investigations 
improves upon previous research. We draw general conclusions with respect to systems’ 
similarities and differences, strengths and weaknesses and formulate policy recommen-
dations.
Methods
We used the analytical Hutton Framework89 to describe, analyse and compare the Bel-
gian, Austrian, Dutch, French and Swedish drug reimbursement systems. Although the 
country selection was partly arbitrary aiming to include our own countries, the selec-
tion of the other countries was based on observed important differences in systems’ 
structure, organisation and procedures. Our sample includes systems with (i) various 
historical contextual backgrounds such as having a Beveridge-type (Sweden), Bismarck-
type (Austria, Belgium, France, and The Netherlands), and managed competitive (The 
Netherlands) system; (ii) various types of final decision makers, i.e., the reimbursement 
agency (Austria and Sweden) or minister of health (Belgium, France and The Nether-
lands); and (iii) various implementation levels (national in Austria, Belgium, France and 
The Netherlands and regional in Sweden).
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We investigated policy documents, explored literature and conducted interviews. Ex-
perts in each country validated individual country reports. The aim of the interviews was 
to retrieve (up-to-date) information unavailable in policy documents and literature, and 
to obtain further insight into how the systems work in practice. The selection of inter-
viewees was based on their specific involvement in drug reimbursement. Interviewees 
were policymakers, representatives of the reimbursement agency/social insurance insti-
tution, expert committee members, patients, or representatives of the pharmaceutical 
industry. Interviews were performed by mail questionnaire (1), phone (2), or face-to-face 
(34), totalling 57 persons (3, 24, 5, 14 and 11 in Austria, Belgium, France, The Netherlands 
and Sweden, respectively). The number of interviewees was deliberately higher in our 
own countries in which we started; because of time restrictions, but mainly due to learn-
ing effects we could reduce the number of interviewees in the subsequent countries.
The descriptive Hutton framework provides a structure that comprehensively details re-
imbursement systems (including drug reimbursement systems), distinguishing between 
policy implementation and technology decision levels.89 The policy implementation level 
describes how the system is embedded in the broader political system. It encompasses 
the (legal) establishment, objectives, implementation, and accountability of the system. 
The technology decision level describes the process of an individual reimbursement 
request and its phases: assessment, decision making, and outputs and implementation. 
Based on the framework, information on the characteristics of reimbursement systems 
can be grouped into a four-area research matrix: constitution and governance, methods 
and processes, use of evidence, and accountability and transparency (see Table 3.1).
Table 3.1 Elements of the Hutton framework
Elements of the system
Policy 
implementation 
level
Establishment Objectives Implementation Accountability
Technology decision 
level
Constitution and 
governance
Methods and 
processes
Use of evidence Transparency, 
accountability
 a) Assessment Consultation and 
involvement of 
stakeholders
Methodology Evidence-base for 
assessment
Presentation and 
communication of 
assessment results
 b) Decision Who makes the 
decision
Decision-making 
process
Evidence-base 
and additional 
influences
Content and 
documentation of 
the decision
 c) Outputs and 
implementation
Appeal and dissent Implementation 
and communication
Monitoring and 
reappraisal
Evidence of the 
impact of the 
decision
Source: Hutton et al.12
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We added the concept of appraisal at the technology decision level. Assessment is the 
quantification of the clinical, pharmacotherapeutic and pharmacoeconomic value of a 
drug. It is descriptive in terms of quality and uncertainty of evidence. Appraisal seeks to 
gauge society’s willingness to pay for a drug by weighing assessment outcomes against 
other (societal) criteria which reflect health system objectives. Decision making is a 
value judgement from a broader societal perspective, considering health system objec-
tives as well as non-health care related objectives.
Results
Contextual background
All five countries have health care systems that cover more than 99 percent of their 
populations. The Swedish system originates from a Beveridge-type national health sys-
tem; the other four originate from a Bismarck-type social insurance system. The Dutch 
system uses managed competition between providers and insurers. Health policy is 
mainly developed and regulated at the national level, but implementation and financial 
responsibility can be regional or rely on external actors (e.g., insurers).
Based on OECD 2008 figures, health care expenditure varies from 9.4 to 9.9, 10.2, 10.5 
and 11.2 percent of GDP in Sweden, The Netherlands, Belgium, Austria and France, 
respectively.90 A larger variation is observed in pharmaceutical expenditure as a share of 
total health care expenditure: 11.0, 13.2, 13.3, 16.4, and 16.4 percent in The Netherlands, 
Sweden, Austria, Belgium, and France respectively.90
The countries share similar system objectives: system sustainability, equity, and quality 
of care. Countries can make different trade-offs to balance the objectives and obtain a 
socially acceptable equilibrium. All have an open-ended pharmaceutical budget moder-
ated by annual goals. Although pricing policies are not within the scope of this study, 
pricing and reimbursement are often strongly linked. All five countries use budget con-
trol mechanisms and supply/demand-side tools such as price regulations, international 
price referencing, internal reference pricing, financial risk-sharing agreements, (incentiv-
ised) prescription guidelines, and co-payments. The final price or reimbursement basis 
at least partially depends on the drug reimbursement evaluation.
Policy implementation level
All five drug reimbursement systems explicitly seek equitable and affordable access to 
high quality health care in a sustainable manner. Other shared objectives are transpar-
ency towards pharmaceutical companies and rewarding innovation and investments in 
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research and development (R&D). None of the systems is clear about the actual place of 
such ‘non-health’ objectives. In the past decade, all countries have reformed their reim-
bursement systems’ legal basis. The reforms aimed to improve efficient decision making 
in the context of increasing health care expenditure and were partly triggered by the 
EU Transparency Directive 89/105/EEC, requiring transparency of the decision-making 
process.
Except for expensive inpatient drugs in The Netherlands and ad-hoc procedures initiated 
by the reimbursement agency in Austria, the reimbursement process for a new product 
is initiated by the manufacturer. In all countries, outpatient drugs need to be assessed 
and enlisted to be eligible for reimbursement. Systems for inpatient drugs vary: they 
are part of the drug reimbursement system in Belgium, France and The Netherlands 
(expensive drugs only), the responsibility of county councils in Sweden, and hospitals, 
Länder, communities, and other hospital owners in Austria.
A shared characteristic is the existence of a national reimbursement agency: HVB in Aus-
tria, INAMI/RIZIV in Belgium, HAS in France, CVZ in The Netherlands and TLV in Sweden. 
In all countries, a technical department is responsible for compiling scientific evidence. 
The department prepares the assessment and drafts the preliminary summary report. 
An independent expert committee assesses and appraises the evidence and is respon-
sible for advising the final decision maker (i.e., the minister of health in Belgium, France 
and The Netherlands, HVB in Austria). In Sweden, the expert committee also makes the 
final decision. Expert committees are considered independent because members, who 
must disclose conflicts of interest, are appointed for their scientific skills and expertise 
as representatives of society’s prevailing interest. Only The Netherlands has, besides the 
expert committee (CFH), a separate appraisal (ACP) committee that also advises, based 
on societal considerations, the final decision maker. A closer look at the composition of 
the expert committees reveals divergences (see Table 3.2). Belgium has the largest ex-
pert committee (31 members, 23 of which have voting rights); Sweden has the smallest.
We distinguished two main differences in the composition of the committees. The 
Belgian and Austrian committees represent all relevant stakeholders. Sweden, The Neth-
erlands, and France rely heavily on academic and other scientific experts. Stakeholders 
can be consulted but are not entitled to deliberate or vote. In 2010, Sweden reduced the 
number of committee members, replacing scientific experts with health care planning 
experts. The Belgian and French committees include consultants from the pharmaceuti-
cal industry without voting rights. The Austrian committee has two representatives of 
employees and consumers. The Dutch appraisal committee and the Swedish expert 
committee have a patient representative. The reimbursement advice (or decision) is 
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based on majority voting or, in The Netherlands, consensus. Belgium is unique in that a 
two-thirds majority is required; without it no advice is formulated.
In all countries, the minister of health is responsible for defining the overall drug reim-
bursement policy and steering the system; the ministry is accountable to Parliament. All 
systems have a trend towards increasing the transparency of decision making, but all 
systematically assess the impact of the system by monitoring drug expenditure rather 
than other system objectives.
Table 3.2 Composition of the expert committees
Austria Belgium France The Netherlands Sweden
Expert 
committee
HEK CRM/CTG CT CFH (ACP) TLV Expert Board
Voting 
members
20 23 20 max 24 (9) 7
- 3 academics
- 10 sickness funds
- 2 physicians
- 1 pharmacist
- 2 employees/ 
consumers
- 2 pharmaceutical 
industry
- 1 chairperson
- 7 academics
- 8 sickness funds
- 4 physicians
- 3 pharmacists
- 1 chairperson 
(from HAS)
- 19 members 
with medical or 
pharmacological 
expertise
CFH:
- 1 chairperson 
(from CVZ)
- members have 
expertise in 
pharmacological, 
medical, health 
sciences and 
economics
ACP:
- 3 CVZ (board of 
directors)
- 6 members with 
societal expertise 
(e.g., patient, 
ethicist, economist)
- 1 chairperson 
(from TLV)
- 1 pharmacologist
- 1 (health) 
economist
- 1 patient
- 3 health care 
planners
Permanent 
consultative 
members
1 8 8 2 n/a
- federal government - 4 ministries
- 3 pharmaceutical 
industry
- 2 INAMI/ RIZIV
- 4 public 
institutions
- 1 pharmaceutical 
industry
- 3 sickness funds
- ministerial 
observers
ACP = Appraisal committee (Advies Commissie Pakket);
CFH = Expert Pharmaceutical Advisory Committee (Commissie Farmaceutische Hulp);
CRM/ CTG = Drug Reimbursement Committee (Commission de Remboursement des Médicaments/ Commissie voor 
Tegemoetkoming Geneesmiddelen);
CT = Transparency Committee (Commission de la Transparence);
CVZ = Health Care Insurance Board (College voor Zorgverzekeringen);
HAS = Natianal Authority for Health (Haute Autoritée Santé);
HEK = Pharmaceutical Evaluation Board (Heilmittel-Evaluierungskommission);
INAMI/ RIZIV =National Institute for Health and Disability Insurance (Institut National d’Assurance Maladie-Invalidité);
TLV = Dental and Pharmaceutical Benefits Agency (Tandvårds- och Läkemedelsförmånsverket)
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Technology decision level
Table 3.3 provides a summary of our findings regarding the technology decision level for 
individual drug reimbursement requests.
Assessment and appraisal
The authorities responsible for the final reimbursement decision rely on advice from 
the expert committees. Reimbursement advice results from the often-intertwined pro-
cesses of assessment and appraisal. The technical department starts the assessment and 
informs the expert committee, which appraises the reimbursement request and advises 
the final decision body. Even though The Netherlands has separate assessment and ap-
praisal committees, the processes are still intertwined.
Therapeutic value
A common key characteristic is the evaluation of the therapeutic value. All interviewees 
acknowledged that efficacy, effectiveness, safety, and adverse effects were the most 
important formal criteria. Although the criteria are related, they are subject to different 
interpretations and have various outcomes. In Austria and France, therapeutic value is 
rated in categories. Austria applies six categories ranging from ‘no added benefit’ to ‘im-
portant benefit for the majority of patients’. France distinguishes five levels of improve-
ment in the medical service rendered (ASMR) ranging from ‘no improvement’ to ‘major 
Table 3.3 Technology decision level
Austria Belgium France The Netherlands Sweden
Assessment
Main actor(s)
Preparation, processing 
& reporting
HVB INAMI/RIZIV HAS CVZ TLV
Expert committee HEK CRM/CTG CT CFH TLV Expert Board
Assessment criteria
- Efficacy Yes Yes Yes Yes Yes 
- Effectiveness Yes Yes Yes Yes Yes 
-  Safety & adverse 
effects 
Yes Yes Yes Yes Yes 
-  Ease of use/comfort Yes Yes Yes Yes Yes 
-  Added therapeutic 
value 
Yes Yes Yes‡ Yes Yes 
- Cost-effectiveness Yes* Yes No (new drugs†) Yes** Yes 
- Other(s): Extensive list of 
criteria
Therapeutic and 
social needs 
Public health, 
treatment 
properties, 
compliance
Applicability, 
feasibility, 
experience 
All effects on a 
person’s health 
and quality of life 
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Table 3.3 Technology decision level (continued)
Austria Belgium France The Netherlands Sweden
Appraisal
Main actor HEK CRM/CTG CT ACP (CVZ + CFH) TLV Expert Board
Explicit appraisal 
criteria
Yes Yes Yes Yes Yes
Appraisal criteria All assessment 
criteria judged 
in the light 
of system’s 
objectives.
Added 
therapeutic 
value, clinical 
effectiveness, 
budget 
impact, cost-
effectiveness 
and price/
reimbursement 
basis
SMR¥ criteria: 
efficacy, adverse 
effects, place 
of the drug 
with regard to 
alternatives, 
disease severity, 
treatment 
properties, 
public health 
benefit
Added 
therapeutic 
value, cost-
effectiveness, 
medical 
need, disease 
severity, rarity, 
public health, 
accessibility, 
own 
responsibility, 
societal 
affordability
Human value, 
need and 
solidarity, 
and cost-
effectiveness
Threshold (range) for 
cost/QALY
No No No No No
Expert committee 
report publicly 
available
No Yes Yes Yes Yes
No if applicant 
withdraws 
request
Expert committee 
advice binding
No No No No Yes
Decision
Decision-making body HVB Minister Minister Minister TLV
Discretionary power 
final decision maker
Yes,
deviation rarely 
occurs
Yes,
deviation 
sometimes 
occurs
Yes,
deviation rarely 
occurs
Yes,
deviation rarely 
occurs
n/a
Stakeholders 
involvement
No Yes Yes Yes n/a
Motivation publicly 
available
Yes Yes Yes Yes Yes
Reimbursement 
restrictions
(e.g., specific 
indications)
Yes (Yellow box) Yes (Chapter IV) Yes Yes (Annex 2) Yes
Temporary decision No Yes (Class 1) Yes (all drugs) Outpatient: No
Expensive 
inpatient: Yes
Yes (case-by-
case)
Risk sharing 
agreements
No Yes, financial 
based (Class 1 
with negative/
no proposal)
Yes, financial 
based (price-
volume 
agreements)
No No
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Table 3.3 Technology decision level (continued)
Austria Belgium France The Netherlands Sweden
Outputs and implementation
Appeal and dissent Yes Yes Yes Yes Yes
- Grounds for appeal Procedural and 
substantive 
grounds
Procedural 
grounds
Procedural 
grounds
Procedural 
grounds
Procedural 
grounds
- Initiator Applicant Any stakeholder Any stakeholder Any stakeholder Applicant
- Appeal options UHK State Council State Council Expert Review + 
Administrative 
Court
Administrative 
Court
Implementation
- Mechanisms National drug 
formulary
National drug 
formulary
National drug 
formulary
National drug 
formulary; 
Pharmaco-
therapeutic 
groups
County 
councils & Drug 
Therapeutic 
Committees
- Local variations No No No No Yes
Revisions
- Ad hoc Yes Yes Yes Yes Yes
- Systematic No Yes (Class 1) Yes (all drugs 
every 5 years)
Outpatient: No
Expensive 
inpatient: Yes
Yes (drugs 
enlisted < 2002)
-  Consequences 
revisions
Changes in 
conditions, 
delisting
Changes 
reimbursement 
modality; 
delisting (rarely)
Delisting Outpatient: 
delisting (rarely)
Inpatient: 
awaiting
Delisting
Impact assessment Drug 
expenditure
Drug 
expenditure
Drug 
expenditure
Drug 
expenditure
Drug 
expenditure
* quality and uncertainty of evidence            ** robustness of evidence
‡ New law (Article 14; Law No 2011-2012 December 29th, 2011): drug reimbursement applications are assessed relative 
to therapeutic strategies, where available, under conditions defined by decree in Conseil d’Etat –Council of State– 
(conditions not yet published at time of publication)
¥ HAS is currently drafting a proposal to replace the SMR and ASMR to one single criterion (Relative Therapeutic Benefit)
† HAS recently received an extended remit to assess methodological quality of economic assessments of new 
technologies (decree under review Conseil d’Etat –Council of State–)
ACP = Appraisal committee (Advies Commissie Pakket); CFH = Expert Pharmaceutical Advisory Committee 
(Commissie Farmaceutische Hulp);CRM/ CTG = Drug Reimbursement Committee (Commission de Remboursement 
des Médicaments/ Commissie voor Tegemoetkoming Geneesmiddelen); CT = Transparency Committee 
(Commission de la Transparence); CVZ = Health Care Insurance Board (College voor Zorgverzekeringen); HAS 
= Natianal Authority for Health (Haute Autoritée Santé); HEK = Pharmaceutical Evaluation Board (Heilmittel-
Evaluierungskommission); HVB = Main Association of Austrian Social Security Institutions (Hauptverband der 
Ősterreichischen Sozialverzicherungsträger); INAMI/ RIZIV =National Institute for Health and Disability Insurance 
(Institut National d’Assurance Maladie-Invalidité); TLV = Dental and Pharmaceutical Benefits Agency (Tandvårds- och 
Läkemedelsförmånsverket); UHK = Independent Pharmaceutical Commission (Unabhängige Heilmittelkommission)
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improvement’. It should be noted that the French agency is currently drafting a proposal 
to replace the SMR and ASMR to one single criterion (Relative Therapeutic Benefit). Swe-
den uses a sliding scale such that price depends on the drug’s cost-effectiveness. In 
contrast, the added therapeutic value is a binary yes/no decision in Belgium (class 1 or 
2) and The Netherlands (list 1A or 1B).
In all countries, only drugs with added therapeutic value can obtain a higher reimburse-
ment basis; in France, the added value also determines the level of patient cost share. 
For drugs with similar therapeutic value, the implications vary. In France, such drugs 
are reimbursed only if they realise savings. Dutch therapeutically-equivalent drugs are 
grouped and reimbursed equally. In Belgium, the reimbursement basis equals that of 
the comparator. Austria assigns such drugs a lower consumer price than the best thera-
peutic and reimbursable alternative.
Cost-effectiveness
All countries but France use cost-effectiveness as formal criterion. Although the French 
agency is explicitly encouraged to use cost-effectiveness, the expert committee has 
until now been reluctant to take it into account for assessing new drugs. France does 
consider cost-effectiveness in revision processes. Recently, the French agency received 
an extended remit to assess methodological quality of economic assessments of new 
technologies (decree under review Council of State –Conseil d’Etat–). In Belgium and 
The Netherlands, cost-effectiveness is taken into account only for drugs with recognised 
added therapeutic value. In Sweden and Austria, cost-effectiveness evidence require-
ments are most extensive for drugs claiming added therapeutic value.
Further exploration reveals divergence in countries’ assessment of cost-effectiveness. 
In Austria and The Netherlands, only the quality of evidence and its level of uncertainty 
are assessed. The Swedish and Belgian committees, in contrast, also consider the actual 
cost-effectiveness ratio.
Even though four countries have cost-effectiveness as a formal criterion, none applies 
a strictly defined or transparent cost-effectiveness threshold (range). Most interviewees 
indicated that if one existed, it would be an increasing threshold depending on factors 
such as disease severity and medical need. They also acknowledged being more lenient 
towards orphan drugs and drugs for severe and life-threatening diseases.
Appraisal
Appraisal criteria and the weighing process are far less transparent than assessment. 
Belgium uses five appraisal criteria: added therapeutic value, price, budget impact, 
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cost-effectiveness, and therapeutic importance in light of unmet medical and societal 
needs. Austria has an exhaustive list of assessment elements and uses system objectives 
as appraisal criteria. In France, the medical service rendered (SMR) evaluation includes 
the following criteria: level of efficacy relative to adverse effects, disease severity, treat-
ment properties (preventive, curative, symptomatic), the drug’s position in therapeutic 
strategy, and public health benefit. In The Netherlands, the appraisal committee has 
developed formal appraisal criteria such as medical need, disease severity and rarity, 
public health, accessibility, societal and patient affordability, and lifestyle. In Sweden, 
the three priority principles –human value, need and solidarity, and cost-effectiveness– 
set formal appraisal criteria. Sweden promotes a value for money system; budget impact 
is thus not a formal national level criterion.
All systems apply various reimbursement criteria without an explicit hierarchy. Although 
the appraisal criteria are often derived from system objectives, they remain somewhat 
implicit and are often not transparent.
Decision
All European countries are required to make a final reimbursement decision within 
180 days (excluding clock stops). Austria, France and Belgium apply strict timelines for 
advice (90, 90, and 150 days, respectively) and the reimbursement decision (180 days). 
For The Netherlands and Belgium, expert committee members’ limited time and limited 
technical staff were frequently mentioned as bottlenecks.
In Austria, Belgium, France, and The Netherlands, decision making occurs in two phases. 
First, the expert committee comes to reimbursement advice. Second, the minister of 
health (or in Austria the association of Austrian Social Security Institutions [HVB]) makes 
the final reimbursement decision based on the advice. The Swedish expert committee 
makes the final decision without an advice phase. Although the minister in Belgium, 
France and The Netherlands rarely deviates from the advice, in Austria and Sweden the 
minister has neither final decision right nor discretionary power with respect to indi-
vidual reimbursement decisions.
All countries but Austria publish their reimbursement advice (decision) reports although 
their extensiveness varies by country. (Additional) appraisal criteria especially are often 
not transparent and the weighing process is often not documented.
Outcomes of the decision-making process are similar: reimbursement, no reimburse-
ment, or conditional reimbursement. All countries can apply restrictions for specific indi-
cations, patient groups, access restrictions and the like. In Austria, drugs in the so-called 
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red box (i.e., newly launched drugs and drugs that have applied for reimbursement) can 
already be reimbursed on an individual basis conditional on an ex-ante approval of a 
sickness fund ‘head physician’ before the reimbursement decision has been made.
Use of temporary decisions varies by country. All positive decisions in France are re-
assessed after five years. No decisions in Austria are temporary. Only decisions on drugs 
with recognised added therapeutic value in Belgium and expensive inpatient drugs in 
The Netherlands are temporary. The Swedish reimbursement agency decides temporary 
reimbursement on a case-by-case basis which is based on uncertainty of the evidence.
Outputs and implementation
Applicants have formal opportunities in all countries to express their point of view or 
disagreement during the reimbursement process. They are also entitled on procedural 
grounds to appeal to the final decision at an administrative court.
All countries have mechanisms to support implementation by disseminating scientific 
evidence and improving appropriate drug use by means of national drug formularies 
and prescription guidelines. Only in Sweden every county council has its own guide-
lines. Impact assessment is often restricted to monitoring prescription volumes or drug 
expenditure.
We found substantially diverging policies regarding revision of enlisted drugs. The 
Austrian system has no systematic policy-enforcing revision process. In contrast, France 
systematically revises all decisions every five years, potentially changing reimbursement 
level or drug price. Sweden currently evaluates all drugs from the old reimbursement 
scheme (listed before 2002) according to therapeutic class. So far, this has resulted in 
guideline changes as well as delistings. In Belgium, all innovative drugs are systemati-
cally revised after 18 to 36 months. Changes in the reimbursement conditions occur but 
drugs are rarely delisted. Since 2006, expensive inpatient drugs in The Netherlands are 
revised after four years. No revision has been finalised thus far, hence its consequences 
are not clear. Recently, the Dutch minister announced that temporary decision making 
will be extended to outpatient drugs.
Discussion
We compared five European drug reimbursement systems and provided a detailed 
analysis of systems’ similarities and differences to obtain insight into their strengths and 
weaknesses and to formulate policy recommendations.
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Systems’ strengths
At the policy implementation level, all five countries have enforced a national system 
that evaluates the societal value of a drug and determines whether the drug is worth 
reimbursement. All systems share clear objectives: system sustainability, quality of care 
and equity. System performance is monitored in terms of pharmaceutical expenditure, 
addressing system sustainability.
At the technology decision level, all put forward formal criteria which reflect systems’ 
objectives. HTA is used at some phase in the decision-making process to trade-off be-
tween the objectives. All systems are prepared to pay for drugs with sufficient added 
therapeutic value. Stakeholder involvement is ensured either through consultation or 
direct representation in the expert committee. Mechanisms to support implementation 
are used by means of guidelines and drug formularies.
Systems’ weaknesses
At the policy implementation level, none of the systems systematically evaluates its 
performance regarding the quality of care and equity objective. All countries have a 
so-called supply driven system: the process starts with a manufacturer’s reimbursement 
request and proceeds on a case-by-case basis. In principle this might lead to ‘pragmatic 
incrementalism’,91 risking a low degree of consistency across decisions. Furthermore, 
most systems make limited use of tools to systematically (re-) evaluate drugs’ relative 
value for money throughout their life cycle.
At the technology decision level, assessment and appraisal are in practice often strongly 
intertwined. All systems seem to use similar reimbursement criteria. However, none 
of the systems applies a formal hierarchy and the actual role of each criterion in the 
decision-making process is often not transparent; especially appraisal criteria lack 
transparency. Although all countries recognise the importance of HTA, all experience 
difficulties in defining its role and weight in the decision-making process.
Study limitations
Our study only includes five countries. Nevertheless, we observed important differences 
in structure, organisation and procedures. The degree of detail in our analysis, the link 
with policy goals, and the breadth of our investigation contribute to previous studies 
and show opportunities to improve system efficiency and sustainability. Our analysis 
did not study individual reimbursement cases; such a case series analysis is part of our 
current work. This could produce additional insights.
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Implications for policy and recommendations
To increase legitimacy of societal decision making, all systems could improve trans-
parency, especially the use of appraisal criteria and their role in the decision-making 
process. Assessment and appraisal could be better disentangled. We believe it would 
be possible to develop standard European guidelines for the assessment of clinical, 
pharmacotherapeutic and pharmacoeconomic evidence; especially because countries 
already keep track of the evaluation in other countries which most likely influences 
their own evaluation of especially the clinical evidence. EUnetHTA has been exploring 
such activities for relative effectiveness assessment, though not for pharmacoeconomic 
evaluations.92 On the other hand, appraisal should remain country-specific because 
social values might vary across countries. Having the final reimbursement decision in 
the hands of the Ministry of Health (Belgium, France, and The Netherlands), might reflect 
central governments’ wish to keep discretionary power.
Drug reimbursement decisions are inevitably made under uncertainty. Although tools 
to reduce consequences of uncertainty, such as (financially-based) risk-sharing schemes 
and temporary reimbursements have been introduced and seem to gain more atten-
tion, not all systems are currently sufficiently equipped to systematically deal with 
uncertainty. Results from risk-sharing agreements in France are promising,93,94 as well 
as results from systematic revisions in France93,95 and Sweden.96. After reimbursement, 
evidence development using outcomes research and patient registries could improve 
monitoring real-world outcomes.97,98 Full package revisions might improve consistency 
of decision making over time and enhance overall value for money and thus ensure 
sustainability. Furthermore, countries could make better use of HTA to obtain value for 
money. HTA could play a more prominent role to systematically assess and determine 
the level of added societal value and set the price or reimbursement level accordingly.
Currently, the countries only evaluate performance of the system regarding sustainabil-
ity. We recommend developing tools to assess the impact of drug reimbursement on the 
other two objectives: quality of care and equity. Finally, policymakers could reconsider 
the current supply-driven system; they could also consider shifting towards a more 
demand-oriented system in which they state for which new drugs addressing unmet 
medical needs they are willing to pay.
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Abstract
In a democratic system, decision makers are accountable for the reasonableness of their 
decisions. This presumes (i) transparency, (ii) relevance of the decision criteria, (iii) revis-
ability of decisions, and (iv) enforcement/regulation. We aim to (i) evaluate the extent to 
which drug reimbursement decision-making processes in different contexts meet these 
conditions and (ii) develop, starting from these findings, a framework for improving the 
transparency and the relevance of used decision criteria.
We evaluated the Austrian, Belgian, French, Dutch and Swedish drug reimbursement 
systems. Based on this evaluation, we developed a framework for improving the trans-
parency of drug reimbursement decision-making processes. It makes explicit the ques-
tions often addressed implicitly during decision-making processes as well as criteria for 
answering each question.
Transparency of appraisal processes varies across systems. Justification with explicit 
criteria is generally limited. Although relevant criteria are similar across systems, their 
operationalization varies and their role in the appraisal process is not always clear. All 
systems seem to implicitly address five key questions, relating to (i) the medical, thera-
peutic and societal need for treatment; (ii) preparedness to pay for treating the condi-
tion as a principle; (iii) for using the treatment under consideration, (iv) preparedness 
to pay more compared with alternatives; and (v) actual willingness to pay from public 
resources.
Transparency of the appraisal process can be improved by using an explicit decision 
framework. Systematic use of such a framework enhances consistency across decisions, 
allows justification of value judgments, and thus enhances legitimacy of societal deci-
sion making.
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Introduction
In the context of continuously increasing public expenditure on pharmaceuticals, the 
efficiency and sustainability of drug reimbursement policies become increasingly im-
portant. While the health systems that shape such policies have the same primary objec-
tive (to increase and maintain health), constraints force policymakers to make choices 
toward system sustainability.99 Despite variations in the organisation and financing of 
health care between member states, the European Commission defined three common 
health system objectives: equity and accessibility, quality of care, and sustainability.100 
The US Department of Health and Human Services highlighted similar objectives in its 
strategic plan 2010-2015.101 Competition between these objectives often forces policy-
makers to make trade-offs. These trade-offs are primarily a matter of normative choice: 
countries will aim for a socially acceptable equilibrium between the different objectives. 
Judging drug reimbursement systems on this outcome is difficult but we can argue that 
a legitimate policy-making process that facilitates decisions in line with public values 
would optimally serve the stated objectives.
Key criteria for legitimacy or accountability for reasonableness according to Daniels and 
Sabin, are (i) transparency of the decision-making process, (ii) relevance of the decision 
criteria, (iii) revisability of decisions in light of new evidence and arguments, and (iv) 
enforcement/regulation of the previous criteria.102 This study evaluates to what extent 
these criteria are fulfilled in five European drug reimbursement systems with a different 
organisational and procedural context. The findings of this evaluation prompted for the 
development of a framework for improving the transparency of drug reimbursement 
decision-making processes and the relevance of drug reimbursement criteria. This study 
reports on both the evaluation and the decision framework.
Methods
We assessed legitimacy of drug reimbursement decision making in five European 
countries as follows. First, we performed an in-depth analysis of five different European 
drug reimbursement systems using the analytical Hutton Framework.12 Table 4.1 char-
acteristics of the five systems relevant for this study. Detailed methods and results of 
the analysis of the performance of these five systems are presented elsewhere.103 Using 
data triangulation, we investigated policy documents publicly available in English, 
French, German and Dutch at the Websites of the reimbursement agencies, explored 
(gray) literature and other relevant publications obtained by means of Medline and 
Cochrane Library searches and provided by our interviewees, and conducted interviews. 
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Table 4.1 Summary characteristics of five national reimbursement systems
Austria Belgium France The Netherlands Sweden
Regulation/ Enforcement
National reimbursement 
agency
HVB INAMI/ RIZIV HAS CVZ TLV
Expert advisory 
committee
HEK CRM/CTG CT CFH (and ACP) TLV Expert Board
Scope of national agency Outpatient drugs Inpatient and 
outpatient drugs
Inpatient and 
outpatient drugs
Expensive 
inpatient and 
outpatient drugs
Outpatient drugs
Final decision maker HVB Minister of 
Health
Minister of 
Health
Minister of 
Health
TLV
Implementation of the 
outcome
Positive list Positive list Positive list Positive list Positive list
Pharmaceutical budget Open-ended Open-ended Open-ended Open-ended Open-ended
Monitoring outcomes Drug 
expenditure
Drug 
expenditure
Drug 
expenditure
Drug 
expenditure
Drug 
expenditure
Appeal options Content and 
procedural 
grounds
Procedural 
grounds
Procedural 
grounds
Procedural 
grounds
Procedural 
grounds
Transparency
Reimbursement reports 
publicly available
No Yes Yes Yes Yes (not if case is 
withdrawn)
Relevance
Appraisal criteria (national level)
Medical, therapeutic and 
societal need
Yes Yes Yes Yes Yes
Added therapeutic value Yes Yes Yes Yes Yes
Cost-effectiveness Yes Yes No for first 
decision
Yes for revision
Yes Yes
Budget impact Yes Yes Yes Yes No
Threshold (range) for 
cost/ QALY
No No No No No
Revision
Ad hoc revision Yes Yes Yes Yes Yes
Systematic revision No Yes, all drugs 
with recognised 
added value
Yes, all drugs 
every 5 years
Yes, only 
expensive 
inpatient drugs
Case by case & 
all drugs enlisted 
before 2002
HVB= Main Association of Austrian Social Security Institutions [in German: Hauptverband der Österreichischen 
Sozialversicherungsträger]; HEK= Pharmaceutical Evaluation Board [in German: HeilmittelEvaluierungsKommission]; 
INAMI/ RIZIV = National Institute for Health and Disability Insurance [in French: Institut National d’Assurance 
Maladie-Invalidité; in Dutch: Rijksinstituut voor Ziekte- en Invaliditeitsverzekering]; CRM/ CTG = Drug Reimbursement 
Committee [in French: Commission de Remboursement des Médicaments; in Dutch: Commissie voor Tegemoetkoming 
Geneesmiddelen]; HAS = National Authority for Health [in French: Haute Autorité de Santé]; CT = Transparency 
Committee [in French: Commission de la Transparence]; CVZ = Health Care Insurance Board [in Dutch: College voor 
Zorgverzekeringen]; CFH = Expert Reimbursement Advisory Committee [in Dutch: Commissie Farmaceutische Hulp]; 
ACP = Appraisal committee [in Dutch: Advies Commissie Pakket]; TLV = Dental and Pharmaceutical Benefits Agency [in 
Swedish: Tandvårds- och läkemedelsförmånsverket]
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Interviewees were selected based on their involvement in the drug reimbursement pro-
cedure; they were policymakers from different organisations (n = 48), a patient represen-
tative (n = 1), or representatives of the pharmaceutical industry (n=8). Interviews were 
performed by mail questionnaire (1), phone (2), or face-to-face (34), totalling fifty-seven 
57 persons (3, 24, 5, 14, 11 in Austria, Belgium, France, The Netherlands and Sweden, 
respectively). The number of interviewees was deliberately higher in our own countries 
in which we started and in Sweden. Although the Swedish Website provides a great 
amount of information in English, we needed to ensure complete data on the Swedish 
system not limited by language restrictions, because of time restrictions, but mainly 
due to learning effects we could reduce the numbers of interviewees in the subsequent 
countries. The aim of each interview was to retrieve (up-to-date) information unavailable 
in policy documents and literature and to obtain further insight into how the systems 
work in practice. Experts in each country validated all our individual country reports. 
For this analysis, we selected five European countries: Austria, Belgium, France, The 
Netherlands and Sweden. Although this sample size is relatively small, we performed a 
detailed analysis requiring an intensive search for formal as well as informal information. 
In these five countries we observed important differences in structure, organisation and 
procedures of the systems. Our sample includes (i) health care systems with various 
historical contextual backgrounds: Beveridge-type (Sweden), Bismarck-type (Austria, 
Belgium, France, and The Netherlands), and managed competitive (The Netherlands) 
systems; (ii) various types of final decision makers: the reimbursement agency (Austria 
and Sweden) and minister of health (Belgium, France, and The Netherlands); and (iii) 
various implementation levels: national (Austria, Belgium, France, and The Netherlands) 
and regional (Sweden).
Second, based on the findings of the in-depth analysis, we evaluated the five systems’ 
organisation, structure, and procedures against the framework for accountability for 
reasonableness of Daniels and Sabin.102 This ethical-theoretical framework defines four 
conditions for achieving legitimate and fair coverage decisions for new treatments. The 
four legitimacy conditions are: (i) Transparency of the decision process: the process must 
be fully transparent about the grounds for/rationales behind a decision; (ii) Relevance of 
the decision criteria: the decision must rest on reasons that all stakeholders can accept 
as relevant to meeting health needs fairly given the resource constraints; (iii) Revisability 
of decisions: decisions should be revisable in light of new evidence and arguments; and 
(iv) Enforcement/regulation: there must be some kind of regulation guaranteeing the 
previous three conditions.
Although this framework has been criticized,104,105 empirical evidence suggests that 
priority-setting processes that fulfil the conditions for accountability for reasonableness 
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are perceived as being legitimate and fair.101,106-108 Without making any value judgements, 
we evaluated each country’s achievement regarding these legitimacy conditions. There 
is a conceptual distinction between assessment, appraisal and decision.78 Our evalua-
tion mainly focuses on appraisal.
Third, based on our legitimacy evaluation, we developed a policy tool that can improve 
transparency and relevance of the drug reimbursement decision-making process in all 
countries. We unravelled the decision-making process in smaller pieces and identified 
questions that all systems seem to address to a certain extent, more or less explicitly. 
After that, we assigned appraisal criteria currently used either explicitly or implicitly to 
each of the defined questions. This process led to a five-question decision framework, in-
cluding a set of relevant criteria for each question. Our developed framework provides a 
tool to structure the decision process, allows reconstruction of the decision process, can 
improve consistency across decisions, and provides a tool to increase transparency of 
the appraisal process. Finally, to illustrate the application of our framework, we described 
how each country addresses the questions and uses the criteria of our framework.
Results
Evaluation of the four conditions for accountability for reasonableness
Condition 1. Transparency
Although all five systems seem to use similar criteria, the actual role of the criteria in the 
decision-making process is often not transparent. Assessment reports are usually made 
public, except in Austria, where evaluation reports (for outpatient drugs) are not pub-
lished. However, the appraisal process, which leads to an advice or a decision, is rarely 
made public, although variations exist. The minutes of the French expert committee’s 
meeting are published, including the main points of discussion, the voting results, and a 
motivated advice. The Belgian system publishes the initial assessment report, applicant 
responses, and the committee reactions to these responses, whereas the eventual (pro-
visional) advice is withheld. Both countries conceal confidential information upon ap-
plicants’ request if deemed justifiable by the expert committee. Dutch assessment and 
appraisal reports are available online and include main points of discussion. Appraisal 
committee meetings are open to the public. Sweden publishes the final reports online 
after deliberation with the manufacturer; confidentiality issues stated by the latter are 
concealed. Noteworthy is that in Sweden pharmaceutical companies can withdraw their 
case before the final reimbursement decision has been made, in which case no report is 
published, a guarantee of confidentiality at the cost of transparency.
Legitimacy of European drug reimbursement systems 61
Ch
ap
te
r 4
Condition 2. Relevance of the decision criteria and rationales
Involvement of all stakeholders affected by a decision is thought to facilitate account-
ability for reasonableness because it increases the likelihood that the rationales adopted 
will be relevant and acceptable.107,109 This presumes, though, that all stakeholders under-
stand the decision problem and recognise the choices that have to be made to meet the 
different health care system objectives; that is, they must be aware that resources are 
limited and fair choices have to be made within such a resource-constrained context.109 
All systems ensure stakeholder involvement either through direct representation of 
stakeholders in the expert committee (Belgium and Austria) or through consultation of 
stakeholders by the expert committee in cases where this committee consists of scien-
tific experts (Sweden, The Netherlands, and France). Only the Swedish expert committee 
has a patient representative as committee member.
Condition 3. Revisability
Revisability is most important in case of (high) uncertainty about the estimates of ef-
ficacy, effectiveness, cost-effectiveness, or budget impact, or if relevant evidence is still 
being developed. Austria is the only country that has no system of systematic revisions, 
although ad hoc revisions can be initiated. Belgium and The Netherlands have a revision 
procedure for specific drug classes, which can occur only once after the initial decision 
and within a window of 1.5 to 3 years (Belgium) or 4 years (The Netherlands). France 
revises all positive decisions every 5 years. In addition to an ongoing revision of all 
enlisted drugs before 2002, Sweden decides on a case-by-case basis whether a decision 
requires revision after a certain number of years. In all countries, depending on the re-
assessment results revisions can have consequences, such as delisting or a change in the 
level of reimbursement or the level of restrictiveness of the reimbursement condition. 
After revision, reimbursement conditions might become more or less restrictive than 
during the period of temporary reimbursement, depending on the reassessment results. 
In The Netherlands, the first revisions of expensive inpatient drugs that were condition-
ally reimbursed for a period of 4 years, are discussed now. Yet, their consequences are 
still unknown.
Condition 4. Enforcement
All countries legally instituted a designated national reimbursement agency. These 
agencies fall under ministerial responsibility and are audited or certified by external 
(parliamentary) committees. However, in all countries, little self-evaluation of the sys-
tem is performed on the process and outcomes. (Parts of ) reimbursement processes are 
monitored only on an ad hoc basis. The outcome is mainly monitored on pharmaceutical 
expenditure. All countries have formal appeal procedures for reimbursement decisions, 
although there is a variety in how and for what reasons appeal is possible. All countries 
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but Austria allow applicants to appeal against a decision on procedural grounds to an 
administrative court. In Austria, the Independent Pharmaceutical Commission acts as an 
appeal court for both procedural and content issues.
Decision framework for the transparent use of relevant decision criteria
The results of our in-depth analysis of drug reimbursement systems showed that all 
countries use similar criteria in their decision-making process, including severity of 
disease, added therapeutic value, cost-effectiveness, budget impact, and uncertainty 
of evidence. However, systems lack transparency about how they deal with each of 
Table 4.2 Key Questions and relevant criteria for increasing the transparency of drug reimbursement ap-
praisal processes
Decision Question Relevant criteria
Medical, therapeutic 
and/or societal need
Does the product target a medical, 
therapeutic and/or societal need?
Medical need:
- Life-threatening condition
- Severe symptoms
Therapeutic need:
- Effective alternative treatment available
Societal need:
- High prevalence
- Disease leads to health inequalities
-  Distance from an acceptable baseline 
health level
Preparedness to pay for 
a particular indication
Are we, as a society, prepared to 
use public resources to pay for a 
treatment to improve this particular 
indication?
- Personal responsibility
- Affordable out-of-pocket
Preparedness to pay for 
a particular treatment
Are we, as a society, prepared to 
use public resources to pay for this 
particular treatment, given that we 
are prepared to pay for a treatment 
to improve this indication?
-  Safety and efficacy of the treatment 
compared to alternative treatment(s)
-  Quality and uncertainty of the evidence 
regarding safety and efficacy
- Curative, symptomatic, or preventive
- Therapeutic value
- Significance of health gains
Preparedness to 
pay more than an 
alternative
Given that we are prepared to pay 
for this treatment using public 
resources, are we prepared to pay 
more than the best alternative 
treatment?
- Added therapeutic value
- Potential savings elsewhere
-  Quality and uncertainty of the evidence 
regarding effectiveness
- Acceptability of co-payments
- Rarity of disease
Willingness to pay: price 
and reimbursement 
basis
How much more are we willing to 
pay out of public resources for this 
particular treatment?
- Added therapeutic value
- Incremental costs
- Budget impact / ability to pay
- Cost-effectiveness ratio
- Medical, therapeutic and societal need
- Limits to cost sharing
- Quality and uncertainty of evidence
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the criteria in their appraisal process and how their relative importance was judged. By 
unravelling the decision-making process, we were able to identify five key questions 
that all systems seem to address to some extent more or less explicitly. We assigned 
appraisal criteria currently used without much transparency or even implicitly to each of 
the defined questions. Table 4.2 displays our developed decision framework.
Five key questions in decision making
Question 1: Is there a medical, therapeutic and/or societal need for this indication?
A pharmaceutical is valuable in as far as it meets a specific need, be it medical, therapeu-
tic, and/or societal.110 The evaluation of ‘need’ in a specific disease is essentially relative, 
that is, compared with other indications that need treatment. Medical and therapeutic 
needs are functions of disease severity and treatment necessity, respectively. The more 
severe a disease and the less effective alternative treatments or the fewer the available 
alternatives, the higher the medical and therapeutic need.111 Need also relates to soci-
etal objectives, such as reducing health inequalities. Medical, therapeutic, and societal 
need can collectively refer to the societal objective of equitably maximising health or 
well-being.112-114
In the literature, suggestions to operationalize need criteria have mostly been in terms 
of disease severity. Examples of approaches include ‘fair innings’,115 ‘severity of illness’,116 
‘proportional shortfall’,117 and ‘rule of rescue’.118 By taking available treatment alterna-
tives into account when determining disease severity (i.e., disease severity given cur-
rent treatment options), medical and therapeutic need are addressed simultaneously. 
Measures to draw conclusions about societal needs, however, remain necessary.
All countries in our study have operationalized need during some phase of their 
decision-making process. Austria considers societal need when assessing added thera-
peutic value: drugs benefitting the majority of patients are classified higher in the added 
therapeutic value classification than those benefiting a subgroup. France defines need 
in a particular disease area relative to other needs in the health care sector through the 
assessment of the ‘medical service rendered’ (SMR), which is determined by disease se-
verity, level of efficacy relative to adverse effects, the drug’s place in therapeutic strategy 
(particularly with regard to treatment alternatives), treatment properties (preventive, 
curative, or symptomatic) and public health benefit. As such the SMR addresses medical, 
therapeutic and societal need. An insufficient SMR leads to a negative reimbursement 
advice.
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Other countries only appear to operationalize medical need, The Netherlands formally 
do so during the appraisal process using disease severity based on the proportional 
shortfall definition.119,120 Sweden uses medical need and solidarity as one of the three 
main principles for priority-setting in health care, which is further defined by various 
levels of disease severity: life-threatening diseases, disease prevention, and less severe 
acute and chronic diseases.107 Belgium uses necessity of treatment to determine the level 
of reimbursement, ranging from necessary for life-threatening diseases to symptomatic 
treatment. The relative weight of medical need vis-à-vis other needs is in all countries 
unclear.
Although rarity of a disease was also mentioned by interviewees from all countries as 
important to decision making, whether rarity as such determines need, or the fact that 
often no alternative treatment exists for a severe disease that happens to be rare, is 
unknown.121
Question 2: Is society prepared to pay with public resources for a treatment that will improve 
the indication in question?
Preparedness to pay is independent of ability to pay and product price, a feature that 
differentiates ‘preparedness’ from ‘willingness’. Before discussing preparedness to pay, 
policymakers should determine whether society is prepared to pay for anything that 
would improve the indication of the treatment under consideration. Preparedness to 
pay is independent of a particular treatment’s need, cost, or effectiveness but might de-
pend on the causes of the disease (e.g., unhealthy or risky behaviour), the characteristics 
of the population groups affected by the disease (e.g., their socioeconomic status) or 
the nature of the outcome (e.g., relief of a headache). The answer might be “Yes, if…”, in 
which case preparedness to pay is subject to conditions.
Although the preparedness to pay out of public resources is not necessarily strictly 
linked to the medical, therapeutic and societal need, we found that both judgements 
are in practice frequently considered equal. This indicates that society believes that 
treatments for high needs should be able to rely on public funding, regardless of, for 
instance, personal responsibility. Therefore, countries operationalise this question simi-
larly to the needs question, meaning they are in principle prepared to pay for treatments 
for high medical, societal, or therapeutic needs.
Question 3: Do we want to pay for this product out of public resources?
Societal willingness to pay for the treatment under consideration, given its character-
istics, may depend on the effectiveness and therapeutic value of the treatment com-
pared with alternative treatments and whether it concerns a curative, symptomatic, or 
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preventive treatment. It can also depend on the burden of the costs of a treatment, for 
example, for a relatively cheap treatment such as paracetamol, the administration costs 
of reimbursement would be higher than the treatment itself.
All countries evaluate the therapeutic value of each individual drug to evaluate whether 
the drug should be reimbursed and thus paid for by society. This question is often con-
sidered in combination with preparedness to pay (i.e., question 2).
Question 4: Do we want to pay more for the drug compared with the comparator?
Whether society wants to pay more for a drug than its comparator depends on the 
product’s added societal value, which depends on its added therapeutic value, potential 
savings effected elsewhere in the health care sector, and the quality and certainty of the 
evidence on these two criteria.
All countries but Austria use internal reference pricing to determine the reimbursed 
price for products with equivalent therapeutic value, meaning society is not willing to 
pay more for the drug than other products with equivalent therapeutic value. Added 
therapeutic value can be decomposed in several elements; increased efficacy and/or 
effectiveness and safety get the highest weight in all countries. A drug judged to have 
added therapeutic value is likely to be reimbursed at a higher price. Although improve-
ment in comfort, ease of use and applicability are mentioned as determinants of added 
therapeutic value, they are in practice rarely sufficient for a product to be reimbursed at 
a higher price.
Question 5: How much more is society willing to pay with public resources for this treatment?
Societal willingness to pay depends on societal value. This value is determined by all 
previous criteria and is independent of price. In practice, it is difficult to measure societal 
value in monetary terms. Therefore, in a supply-driven context, where pharmaceutical 
companies decide what, when, and at what price to launch a drug, policymakers will in 
practice have to consider whether the price requested by the company is reasonable 
given its societal value.
For this purpose, cost-effectiveness and budget impact are used as decision criteria, 
strongly depending on the previously described value-criteria. While cost-effectiveness 
is traditionally seen as a criterion for assessing efficiency, it only does so when health 
maximisation is the main objective and a threshold value for the incremental cost-
effectiveness ratio (ICER) is defined. All our countries deny using an ICER threshold value 
or a threshold range, thus confirming the observation of previous studies that the ICER 
has limited weight in the appraisal process.122,123 Instead of being a criterion for technical 
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efficiency, the ICER can also be used as an instrument or measure to judge the accept-
ability of an intervention’s cost, given its societal value. This requires the weighing of all 
value-criteria against each other. In this respect, all five countries appear to be willing to 
pay more for a unit of health gained in case of more severe diseases.
It is difficult to define a priori the relative weight of each criterion because decision 
makers and stakeholders might want to give different weights in different situations. 
For example, therapeutic value may get more weight when no alternative treatment is 
available. Interviewees from all countries reported a higher willingness to pay for drugs 
for rare diseases for which no alternative treatment exists (therapeutic need). This may 
then suggest the acceptability of a higher cost-effectiveness ratio. The Netherlands also 
reports a higher willingness to pay for more severe diseases and France and Belgium 
apply a lower level of cost sharing to drugs for more severe diseases. Table 4.3 illustrates 
examples how our countries operationalize the relationship between separate value-
criteria and the (additional) willingness to pay.
Additional criteria helping policymakers to assess the acceptability of a requested 
price are budget impact and mechanisms for cost sharing. Although these criteria are 
not value-criteria, they cannot be considered independently. Table 4.4 illustrates how 
budget impact and cost sharing can modulate decisions and give incentives to install 
measures to stimulate value-based medicine.
Table 4.3 Illustrations of the relationship between value-criteria and societal willingness to pay
Value criterion How the value criterion influences willingness to pay
Medical, therapeutic, 
and societal need
In Sweden priority-setting principles state that persons in greatest medical and 
therapeutic need should get the highest priority. The Swedish expert committee refers 
to “marginal utility”, which is further defined as “if no alternative treatment exists, cost 
should be reasonable”; “reasonable”, however, remains undefined.124
In the Netherlands, the reimbursement agency recently suggested a threshold range for 
the incremental cost-effectiveness ratio (ICER), where willingness to pay varies within 
that range depending on disease severity (medical need).120 The Dutch minister has 
neither confirmed the range nor endorsed an ICER threshold.
In Austria, medical need is implicitly considered in the evaluation of the therapeutic 
benefit, which in turn is strongly related to the price.
Added therapeutic 
value
Belgium and the Netherlands apply a binary outcome (i.e., yes or no) for added 
therapeutic value, thereby not relating societal willingness to pay to the degree of 
added therapeutic value.
France and Austria classify the degree of added therapeutic value in five and six 
categories, respectively. Societal willingness to pay is defined in function of the added 
value category.
Sweden uses the ICER to determine an acceptable price of a product, thereby directly 
relating societal willingness to pay to the degree of added therapeutic value.
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Finally, uncertainty of evidence may impact upon the appraisal of the value-criteria as 
well as on the societal willingness to pay. For example, uncertainty about the added 
therapeutic value in daily clinical practice might lead expert committees to lower their 
estimate of the added therapeutic value, advise restricted reimbursement, or deny 
reimbursement altogether. They could also make a temporary reimbursement decision 
or negotiate a lower price.23 Our five countries deal with uncertainty in budget estimates 
by the implementation of one or more of the following measures: financial risk sharing 
agreements, price negotiations, cost sharing, and conditional reimbursement.
Discussion
An in-depth analysis of five European drug reimbursement systems showed that these 
systems use similar criteria in their drug reimbursement decision processes. The relative 
importance attached to each of the criteria may vary, but the implicit questions posed 
during a decision-making process are similar. Our study shows that there is room for im-
proving the transparency and relevance of decision criteria, two legitimacy conditions. 
Table 4.4 Illustrations of how criteria for judging the acceptability of a requested price take value-criteria 
into account and can shape drug reimbursement decisions
Criteria for appraising the 
acceptability of a requested 
price
Relation with value criteria
Budget impact Budget impact is a decision criterion in all countries but Sweden. In Sweden 
regional county councils are responsible for the financing and implementation 
of decisions. The same county councils are also responsible for clinical 
guidelines, which include financial incentives that stimulate the usage of 
preferred drugs.
France and Belgium use price-volume agreements (financial risks-sharing 
agreements).
For statins, Belgium has defined a “first choice treatment” (reimbursed without 
conditions) and a “second choice treatment” (subject to the condition that the 
first choice failed to benefit a patient).
All countries use financial incentives to influence utilisation (co-payments, co-
insurance, deductibles).
Cost sharing Belgium uses “necessity of treatment” (medical need) to define the level of cost 
sharing. A negative correlation has been observed between the level of cost-
sharing and the added therapeutic value of drugs,123 indicating that products 
for more severe diseases are more likely to be considered of added therapeutic 
value.
In France, medical need is one of the criteria determining the SMR rating 
(Service médical rendu), which determines the level of cost-sharing.
Both France and Belgium use the medical needs criterion to define the level 
of co-insurance or co-payment, which increases affordability of the most 
necessary treatments.
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Empirical evidence suggests that the four legitimacy conditions defined by the Daniels 
and Sabin framework actually improve perceived legitimacy, fairness, and quality of 
decision-making, but should be used flexibly.101,106-108,125,126
The public payer is continuously faced with the dilemma of simultaneously ensuring 
equitable access to high quality health care and sustainability of the health care system. 
The challenge for policymakers is therefore to find a publicly acceptable balance be-
tween the objectives. This is pursued by considering and weighing several criteria in the 
decision-making process. Added therapeutic value, being the most prominent criterion 
in decision making in all countries, addresses the quality of care objective. Disease 
severity, also important in decision making in all countries, reflects the equity objective. 
Cost-effectiveness addresses the objective of efficiency (maximising health with a given 
amount of resources). It is a reimbursement criterion in all countries, be it only for revi-
sions in France. No country, however, uses a fixed ICER threshold value; even threshold 
value ranges seem unacceptable. Budget impact, which also reflects the sustainability 
objective, is considered in all countries either at the national or at the regional decision 
level. Although all countries have a more or less open-ended pharmaceutical budget, 
reimbursement can still be denied for budgetary reasons. Disease rarity, a frequently 
mentioned decision criterion, reflects the equity objective of systems: patients with rare 
diseases should have equal chances of affordable treatment. It gives companies the op-
portunity to set high prices and remain somewhat inflexible in price negotiations.
While all these criteria are relevant, their relative importance and how they shape the 
final decision often remains unclear. This can result in differences in accountability of 
the systems: the lower the transparency of both formal and informal criteria, the less 
accountable the system.
Our relatively small sample of countries, not necessarily representative for Europe, could 
be seen as a limitation to our study. However, important differences were observed in 
structure, organisation and procedures of the drug reimbursement systems, supporting 
the external validity of our study. A thorough understanding of the explicit and implicit 
processes taking place during a drug reimbursement decision process required an in-
tensive search for formal as well as informal information. Such an analysis was therefore 
only feasible in a small number of countries within a reasonable period of time.
Our conclusions could be extended by reviewing actual reimbursement dossiers in these 
countries. For example, judging the consistency of decision making requires detailed 
comparison of reimbursement dossiers. Furthermore, different appraisal processes and 
reimbursement criteria can still produce comparable results in terms of drug expendi-
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tures, health gains and equity. It would be worthwhile to further investigate to what ex-
tent these crucial outcomes are sensitive to country differences in reimbursement policy.
We believe, however, that transparency of the drug reimbursement decision process can 
be improved in all countries by using an explicit decision framework. Our developed 
framework provides a first provisional tool to structure the decision-making process, 
it can support the justification of decisions, and is a tool for defining and making ex-
plicit the societal choices which currently often remain implicit. Crucial is the societal 
acceptability of the decision criteria. Proper justification of the reimbursement advice 
or decision, with a sufficiently differentiated reflection on the multiple considerations 
taken into account during the appraisal and decision-making processes and with a clear 
statement on the final position taken on each key question, ensures transparency and 
enhances trust in the system. No system can define a general rule applicable to deci-
sions in all situations,122 but the decision process can be reconstructed by providing an 
explicit answer to each crucial question.
Conclusions
To reach accountability for reasonableness and thus ensure a legitimate drug reimburse-
ment process, any democratic political system has the obligation to be transparent, use 
societally-relevant rationales in decision making, allow revisability of decisions in the light 
of new evidence, and enforce the three previous conditions. Many systems currently lack 
transparency, especially in the use of appraisal criteria. The appraisal process could ben-
efit from using an explicit decision framework specifying the social choices and decisions 
made during the appraisal process as well as the criteria on which the choices and deci-
sions are based. This would improve accountability and coherence between decisions, 
and, in turn, enhance legitimacy of societal decision making on drug reimbursement.
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Abstract
Considerations beyond (cost-) effectiveness are important in reimbursement decision 
making. We assessed the importance of disease severity in drug reimbursement deci-
sion making in Belgium, France, The Netherlands and Sweden.
We investigated scientific literature and policy documents and conducted three inter-
views in each country (four in The Netherlands) with persons involved in drug reim-
bursement.
Disease severity, as part of the ‘need principle’, is an important consideration; espe-
cially in case of high severity. The Netherlands operationalised disease severity using 
the proportional shortfall approach. Sweden uses categories to give an indication of 
the severity. In The Netherlands and Sweden, severity only implicitly plays a role in the 
decision whether to reimburse a drug, whereas in Belgium and France it also explicitly 
plays a role in determining the willingness to pay out of public sources. Interviewees 
acknowledged that quantitative information, besides a qualitative description of the 
disease, may provide additional information. None of them, however, considered such 
information to be of decisive importance.
Although disease severity is important in drug reimbursement decision making in all 
four countries, all seem to struggle in making its actual role explicit. Belgium and France 
are most explicit by using severity in setting reimbursement levels; all four countries 
could, however, improve the transparency of its actual importance relatively to the 
other criteria in the decision making.
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Introduction
Considerations beyond (cost-) effectiveness and safety are important in reimbursement 
decision making.103,127-131 One such consideration is disease severity or any other op-
erationalization of ‘medical need’. Valesco-Garrido et al.132 found the ‘need’ aspect to be 
one of the most considered criteria in nine European countries. It seems that drugs that 
target more severe diseases more easily obtain reimbursement; this reflects the equity 
objective of most health care systems. On the other hand, health care interventions 
may not be reimbursed for diseases of low severity as it indicates a limited ‘need’. Many 
stakeholders and analysts seem to agree on the fact that the severity of the disease may 
play a role in reimbursement decision making. However, the way disease severity is used 
is often not transparent and may differ across countries.15,130
Previous studies investigated the importance of societal concerns, for example, by 
eliciting policymakers’ preferences,133,134 or by eliciting public preferences regarding 
the social value of the Quality Adjusted Life Year (QALY),135-137 preferences for severity 
of illness,138-140 for end-of-life treatment,141,142 or for the rule-of-rescue.143 These studies 
provided insights into the importance of the severity of the disease. Most studies are, 
however, mainly theoretically based. Consequently, there are still many unsolved issues 
regarding the implementation in actual practice. A comparison across countries on the 
role of disease severity in reimbursement decision making may provide insights into ac-
tual policymaking. It may, therefore, facilitate learning probabilities how to incorporate 
this criterion in health care resource allocation as many countries seem to experience 
difficulties in doing so.
We investigated the role of disease severity and its operationalization in drug reimburse-
ment decision making in four European countries: Belgium, France, The Netherlands and 
Sweden. We explored concepts of disease severity and assessed how information on 
disease severity is used in everyday drug reimbursement decision making. This paper 
addresses the following questions: (i) is disease severity considered in drug reimburse-
ment decision making; (ii) if considered, how or by which method or indicator is it 
presented; and (iii) in what way is this information used in practice and how does it 
affect decision making.
Context
All four countries have a national drug reimbursement agency. Within the agency, a 
technical department prepares the assessment and preliminary reports. An independent 
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pharmaceutical expert advisory committee assesses and appraises the evidence and is 
responsible for advising the final decision maker (i.e., the minister of health). Notably, 
the ministers hardly ever deviate from the advice.103 In Sweden, the expert advisory 
committee also makes the final decision. Only The Netherlands has a separate appraisal 
committee, which has an advisory function. All four countries use drug effectiveness 
and cost-effectiveness (in France only recently -2012- for new drugs) as reimbursement 
criteria. This paper focuses on the role of disease severity in decision making. For more 
detailed information on the four systems regarding their (other) reimbursement criteria, 
reimbursement process, and their Health Technology Assessment (HTA) models, we 
refer to Franken et al.103 and Le Polain et al.15 Table 5.1 provides an overview of the four 
drug reimbursement systems.
Table 5.1 Summary characteristics of the four drug reimbursement systems
Belgium France The Netherlands Sweden
System characteristics
National reimbursement agency INAMI/RIZIV HAS CVZ TLV
Pharmaceutical expert advisory 
committee
CTG/CRM CT WAR-CG PBB
Appraisal committee n/a n/a ACP n/a
Final decision maker Minister Minister Minister PBB
Expert committee report 
publicly available
Yes Yes Yes Yes (No, if 
applicant 
withdraws 
request)
Assessment and appraisal criteria
Medical, therapeutic and 
societal need
Yes Yes Yes Yes
Added therapeutic value Yes Yes Yes Yes
Cost-effectiveness Yes Yes (for new drugs 
since 2012)
Yes Yes
Explicit threshold for cost/ QALY No No No No
Budget impact Yes Yes Yes No
Other Price and 
reimbursement basis
Public health, 
treatment 
properties, disease 
severity
Disease severity 
and rarity, own 
responsibility, 
accessibility, societal 
affordability, public 
health
All effects on a 
person’s health 
and quality 
of life, human 
value, need and 
solidarity
ACP = AdviesCommissie Pakket; CRM = Commission de Remboursement des Médicaments; CT = Commission de la 
Transparence; CTG = Commissie voor Tegemoetkoming Geneesmiddelen; CVZ = College voor Zorgverzekeringen; 
HAS = Haute Autoritée Santé; INAMI =Institut National d’Assurance Maladie-Invalidité; n/a = not applicable; PBB 
= Nämnden för läkemedelsförmåner; QALY = Quality Adjusted Life Year; RIZIV = Rijksinstituut voor Ziekte- en 
Invaliditeitsverzekering; TLV = Tandvårds- och läkemedelsförmånsverket; WAR-G = Wetenschappelijke AdviesRaad 
Geneesmiddelen
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Concepts of disease severity
Need principles are commonly discussed in academic literature concerning health care 
rationing decisions.112 A drug is valuable when it fills a specific need; this may be a medi-
cal, therapeutic, or societal need.110 These needs depend on factors such as treatment 
necessity and disease severity (medical need), the availability and the effectiveness 
of alternative treatments (therapeutic need), and the prevalence of the disease and 
inequalities in health (societal need).15 As such, disease severity is part of the ‘need 
principle’; the more severe a disease, the higher the (medical) need.
A large number of empirical studies acknowledge the concept of ‘severity’ as prioritising 
principle.140 Several approaches to determine ‘who are the worst off’ are described in 
the literature to operationalize the concept of severity. According to the ‘fair innings’ 
approach, everyone is entitled to some ‘normal’ span of health achievement.115 This 
implies that treatments for patients who did not yet had their fair innings are valued 
higher than treatments for patients who have had their fair share. The latter ones are, ac-
cording to Williams,115 ‘living on borrowed time’. This approach considers life time health 
achievement including the quality as well as the length of a life, thus also including past 
health (losses). The ‘severity-of-illness’ approach prioritises persons with the worse off 
initial condition based on the severity of the initial health state as well as the expected 
(prospective) health in case no treatment is available.144,145 This approach emphasises 
the need to rescue persons with a severe condition (e.g., facing immediate death); the 
approach does not consider past health. In contrast to the previous two ‘absolute’ worse 
off approaches, the ‘proportional shortfall’ approach, considers the worse off in relative 
terms. This approach bases the need on the proportion of health lost due to the disease 
as compared to the expected health (i.e., level of health and remaining life expectancy) 
without the disease.146 Finally, the rule of rescue’ approach prioritises identifiable indi-
viduals facing avoidable death, regardless of the costs.118 It should be noted that, if used 
for priority setting, all approaches can identify a group of persons (or an individual) who 
are the worst off. The last approach, however, deviates because it concerns identifiable 
individuals who are worst off no matter what disease, whereas the others identify the 
worst off per disease and concern a measure of loss. Therefore, only the first three ap-
proaches facilitate a numerical expression of the severity of a specific disease that could 
be used in reimbursement decision making at the national level.
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Methods
We compared the role of disease severity and its operationalization in drug reimburse-
ment decision making in Belgium, France, The Netherlands and Sweden. The selection of 
these countries was based on our previous research on European drug reimbursement 
systems.15,103,130,147 All four countries have established HTA agencies using reasonably 
comparable reimbursement processes.
To obtain insight in the role of disease severity in actual decision making, we first evalu-
ated the reimbursement processes and criteria. Second, we explored scientific literature 
describing concepts of disease severity. Third, we conducted face-to-face interviews; 
three in each country (four in The Netherlands because of the existence of the appraisal 
committee). Fourth, using data triangulation we combined the information from the 
literature, policy documents and the interviews to assess the role of disease severity and 
its operationalization in drug reimbursement decision making.
All interviews were tape-recorded. Citations were reported anonymously and were 
translated by the authors if the interview was not in English (i.e., interviews in The Neth-
erlands and Belgium were in Dutch, interviews in France and Sweden were in English). 
The selection of interviewees was based on their specific involvement in drug reim-
bursement. They were either a representative of the reimbursement agency or an expert 
from the pharmaceutical expert (advisory) committee or the appraisal committee. In 
each country, we interviewed at least one person with an economic background and 
one person with a medical or pharmacy background. Interviews were semi-structured; 
questions addressed topics such as explicit versus implicit use of disease severity, 
operationalization(s) of disease severity, reimbursement levels, qualitative versus quan-
titative information on disease severity, published versus not published reimbursement 
information, and assessment and appraisal considerations that might be related to or 
interact with disease severity (e.g., age, child vs. adult, fair innings, past health, future 
health, absolute vs. relative health status, health gain, quality of life, rarity of the disease, 
availability of alternative treatments, end-of-life treatment, rule of rescue, medical need, 
life-style, own responsibility, necessity to insure, and personal vs. societal affordability).
All interviewees had the opportunity to comment on the final draft of the paper. Al-
though the reflections made are based upon information from the interviews, it should 
be noted that the reflections are strictly ours and do not necessarily reflect the views of 
the interviewees.
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Results
Is disease severity considered in drug reimbursement decision making?
All interviewees acknowledged considering the severity of the disease in drug reim-
bursement decision making, especially in case of high severity. An interviewee replied 
“yes definitively, oh yes” to the question whether disease severity played a role.
How or by which method or indicator is disease severity presented?
In all four countries reimbursement information contains a qualitative description of 
the disease and, besides that, most often contains information on survival, progression 
free survival, and sometimes on quality of life. This information is prepared by the reim-
bursement agency and presented to the pharmaceutical expert committee, and in The 
Netherlands to the appraisal committee. Also published reimbursement information 
most often contains a qualitative description of the disease.
The Swedish agency indicates whether the disease is ‘highly’, ‘moderately’ or ‘less’ severe. 
This information is always available for the pharmaceutical expert committee, but not 
always available in the published memorandum. In The Netherlands, the proportional 
shortfall approach is presented to operationalize the concept of disease severity in 
policy documents.120 However, numerical outcomes based on the proportional shortfall 
approach were until now not available for the pharmaceutical expert committee, and 
only recently a few times available for the appraisal committee as well as in published re-
imbursement information (i.e., for the first reassessments of expensive inpatient drugs). 
Moreover, members of the appraisal committee have indicated that they preferred to 
be informed with more information than only the proportion shortfall calculations, for 
example, also information based on the fair innings approach.
In France, disease severity is one of the five Service Médical Rendu (SMR) criteria; the 
other SMR criteria are efficacy and adverse events, place of the drug, availability of 
alternative treatment, treatment properties and public health benefit. Disease severity 
is, however, no criterion of the new proposed French Relative Therapeutic Benefit (RTB) 
criterion, which is proposed to replace the SMR and the Amélioration du Service Medical 
Rendu (ASMR) criterion (both the price and reimbursement decision will be based on the 
RTB criterion). Furthermore, France has special regulations for thirty serious and chronic 
diseases (i.e., the Affections de Longue Durée (ALD) List), certain irreplaceable and costly 
drugs (e.g., cancer or AIDS), costly drugs for diseases that constitute a progressive or dis-
abling disorder with a previous treatment period over six months (i.e., the so-called ‘31st 
disease’), and multiple diseases of over six months (i.e., the so-called ‘32nd disease’).15
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Belgium uses reimbursement categories which reflect the necessity of the drug, and 
thus partly reflect disease severity. The categories are category A (and Fa) for vital drugs 
for life-threatening diseases (e.g., diabetes and cancer), category B (and Fb) for thera-
peutic significant drugs for non-life threatening diseases (e.g., antibiotics), category C 
for therapeutic less significant drugs for systemic treatment –symptomatic treatments–, 
category Cs for chronic illnesses, and category Cx for contraceptives and antispasmod-
ics.148
In what way is information on disease severity used in practice and how does it 
affect decision making?
All interviewees acknowledged that disease severity affects drug reimbursement deci-
sion making. An interviewee stated “if you talk about disease severity, you have of course 
the implicit as well as the explicit weighing.” Interviews revealed that disease severity 
often plays an implicit role and sometimes an explicit role in the consideration whether 
or not society is willing to pay for a treatment.
The role of disease severity in decsion making whether or not to reimburse a drug
Disease severity or, overarching, the need principle can be found in all four countries’ 
policies as prioritising principle. All share similar system objectives: equitable access, 
quality of care and system sustainability.103 For example, the Swedish Health and Medical 
Service Act (1982:763) emphasises equal access to health services on the basis of need 
and a vision of equal health for all. Accordingly, the three Swedish prioritising principles 
are human value, need and solidarity (i.e., those in greatest need of health care should 
be given priority access to care), and cost-effectiveness.107 Article R163–1.6.3 of the 
French Code de la Se´curite´ Sociale’ states that drugs should not be reimbursed in case 
of absence of severity of the disease they address.149 In The Netherlands, necessity (i.e., 
whether the severity of the illness or the care needed justifies solidarity) is one of the 
four criteria for determining the basic benefit package (including drugs).120 In Belgium, it 
is obliged by law to position new technologies relatively to other available technologies 
in medical practice.
Effectiveness, safety, and cost-effectiveness are formal and explicit reimbursement 
criteria. All interviewees, however, agreed that, implicitly, the more severe a disease, the 
higher the chance to obtain reimbursement and/or a higher level of reimbursement. As 
indicated by interviewees “the severity of the disease balances the benefit risk ratio” and 
“it is an issue for discussion for drugs that just go with the narrowest of margins.” Although 
disease severity is a formal appraisal criterion in The Netherlands, drugs are not often 
discussed in the appraisal committee, so far only reassessments of expensive inpatients 
drugs have been discussed in the appraisal committee. Even though the French SMR 
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classification seems straightforward, interviewees acknowledged being more lenient in 
case of high(er) severity. A French interviewee stated “The importance of severity might 
be very high, you have the same type of evaluation, assessment of the efficacy and effective-
ness, but since in one case it is a very severe disease and you want to give something to 
the patient, it is reimbursed, and it has a level of SMR that opens reimbursement and in the 
other case, I can tell the patient is not happy about that.“ Regarding the effect of the list of 
diseases for full reimbursement, another French interviewee stated “When a new drug 
is about one of these diseases so, we are authorised to be very rigorous …… our thinking 
is only about the level of efficacy …… we are sure that when you give 15% the patient will 
be full reimbursement, but if we give a bad score the pricing will be difficult.” This seems 
to imply that the French committee not only aims to ensure reimbursement for severe 
diseases, but also, simultaneously, aims to influence the price to ensure value for money.
Seven out of thirteen interviewees (i.e., four Dutch, two Swedish and one Belgian 
interviewee(s)) were familiar with at least one of the disease severity concepts. Con-
fronting interviewees with elements from these concepts revealed that interviewees 
did not consider age as criterion in the decision making. Some even mentioned that it 
would be illegal to use age as criterion. However, all acknowledged being more lenient 
towards drugs for children. Past health was also not seen as criterion. Consequently, 
the ‘fair innings’ approach does not seem to fit well in actual practice. Also ‘the rule of 
rescue’ approach does not fit in actual practice because the agencies make national 
decisions and, therefore, cannot consider identifiable individuals. However, media at-
tention in specific (individual) cases may lead to (ad-hoc) decisions based on ‘the rule 
of rescue’ when policymakers are under societal pressure. Moreover, decisions on (ultra) 
orphan drugs can also be influenced by ‘the rule of rescue’ considerations. Interviewees 
stated that the absolute gain in health or quality of life (future health effects) is most 
important, and also the current (absolute) health status is important. This reasonably 
fits with Nord’s ‘severity-of-illness’ approach. Even though it is Dutch policy to use the 
‘proportional shortfall’ approach, interviewees stated “The proportional shortfall is one 
way of doing it, but this may not be appropriate in all cases, that depends on the type of 
disease, sometimes it can be better to use other methods to quantify the severity, or use more 
methods at the same time and discuss what is most relevant for the specific case,” and “but 
the description of the disease next to it also remains important.”
All interviewees indicated that they would like to have, at least, a qualitative descrip-
tion of the disease. Only six out of thirteen stated to appreciate the availability of 
numerical expressions of disease severity. However, such figures were only appreciated 
if presented additional to a qualitative description of the disease, and, if appropriate, 
additional to an incremental cost-effectiveness ratio. An interviewee explained “if you 
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compute all information including disease severity into one cost-effectiveness estimate, 
then it will become very opaque, something we will not do so quickly, it is more that we 
come to a decision by putting cost-effectiveness, disease severity and other arguments 
side by side.” Other interviewees expressed concerns regarding the use of quantitative 
information on disease severity in decision making: “you think is it possible, is it easy to 
do it in a reliable way?” and “cost-effectiveness, now it is accepted in principle, but still, …… 
medical people are still suspicious about it, …… the speed in these developments goes too 
fast, the rest of the society is not there” and “using numbers between one and zero is at odds 
with the complexity of the reality,” and “they (i.e., expert committee members) would prefer 
more qualitative and not too formal information, with possibility of discussing, …… they 
would prefer to feel more free.”
Although all interviewees agreed that the severity of the disease affects the decision 
whether or not to reimburse a drug, none of them could indicate its relative importance 
compared to other decision criteria. All interviewees agreed that it remains a balancing 
exercise. One interviewee explained “Another discussion is our willingness to pay, at the 
moment, we maybe sometimes; I personally do think that we are willing to pay more for 
severe disease compared to for example an erectile dysfunction.” Although formally using 
the proportional shortfall approach in The Netherlands, the relative importance of 
disease severity remains unclear. Similarly, the classification used in Sweden (i.e., low, 
moderate, high severe) does not explicate how important disease severity is relatively 
to other criteria in the decision making. A Swedish interviewee stated “in some dossiers it 
is (i.e., published severity scoring), we probably could and should publish it more frequently 
those statements, but it is available in some, …… if it is relevant …… you still have a balanc-
ing there (i.e., in the public memorandum), but it is not as clear.” Nevertheless, previous 
research (i.e., a comparative study of Dutch and Swedish published reimbursement 
information147) found that in four out of eleven cases disease severity was explicitly 
mentioned. Although the relative importance of disease severity was not stated, all four 
drugs obtained reimbursement, three of them concerned indications in cancer.
Regarding other decision criteria, a Belgian interviewee indicated that budgetary impact 
may even be more important than disease severity. Interviewees acknowledged that the 
‘end-of-life’ criterion is mostly visible in treatments in cancer, thus concerning treatments 
that most often obtain reimbursement. Nevertheless, all agreed that even in such cases 
a minimal absolute gain, without clearly indicating what kind of minimum would still 
be acceptable, was still important. Interviewees did not consider the fact whether the 
treated disease was self-inflicted or someone’s ‘own fault.’ On the other hand, especially 
in case of low disease severity and low treatment costs, interviewees agreed consider-
ing the necessity to reimburse a treatment and/or whether treatment costs could be a 
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person’s own responsibility. Furthermore, most interviewees agreed that rarity as such is 
not (that) important; most also indicated a correlation between severity, rarity and the 
availability of alternative treatments. As explained by an interviewee “that is difficult, I 
think if all three elements are there, in case it concerns a rare disease, which is also severe and 
no other alternative treatment is available, that scores high, we are more lenient in such a 
situation.” Another interviewee stated “disease severity was number one …… now we are 
not thinking the same way, it is very rare, it is not a frequent situation that there is no other 
drug …… we are reluctant to give favourable opinion when the drug is not very very, they 
are all efficacious because they have market authorisation of course, but the level is some-
times very very thin.” This shows that disease severity correlates with the ‘need principle’, 
in this case a relation between the medical need and the therapeutic and societal need.
The role of disease severity in determining the level of reimbursement
Once drugs are granted reimbursement, they are fully reimbursed in The Netherlands 
and Sweden. In contrast, Belgium and France use levels of reimbursement which are 
partly based on disease severity (see Table 5.2). All Belgian and French interviewees 
agreed that the reimbursement levels partly reflect the severity of the disease. In France, 
the reimbursement levels (i.e., 65%, 30% and 15%150) depend on the SMR level. Besides 
that, drugs are fully reimbursed for patients with a disease included on the ALD list, 
31st and 32nd diseases, or drugs classified as being irreplaceable and costly. Interestingly, 
disease severity is no criterion of the new proposed RTB criterion, whereas it was for 
the SMR, implying that, in the future, the reimbursement level will not (partly) reflect 
disease severity anymore. Nevertheless, a French interviewee stated “if you have a severe 
Table 5.2 Levels of reimbursement and cost sharing mechanisms
Belgium France The Netherlands Sweden
Reimbursement level
Level of 
reimbursement
100%; 75%; 50%; 
40%; 20%
100% (ALD, 31st and 
32nd diseases);
65%; 30%; 15%; 0% 
(SMR level)
100% 100%
Basis for the level of 
reimbursement
Category of treatment 
necessity: A (Fa), B 
(Fb), C, Cx and Cs
SMR level: Important, 
Moderate, Weak, 
Insufficient
n/a n/a
Cost sharing Product specific co-
insurance
Product specific co-
insurance; prescription 
fees
General health care 
deductible
Drug specific 
co-payment
Category A (and Fa): vital drugs for life-threatening diseases (e.g., diabetes and cancer); B (and Fb): therapeutic 
significant drugs for non-life threatening diseases (e.g,. antibiotics); C: therapeutic less significant drugs for systemic 
treatment –symptomatic treatments-; Cs: chronic illnesses; Cx: contraceptives and antispasmodics;
ALD: Affections de Longue Durée; SMR: Service Médical Rendu
n/a : not applicable
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disease you might admit a less important difference than in a non-severe disease” and “for a 
non-severe disease it is not justified to have a high level of reimbursement.”
Belgium’ms reimbursement levels (i.e., 100%, 75%, 50%, 40%, and 20%) depend on the 
reimbursement categories (i.e., the therapeutic necessity of the drug category)148 which 
partly reflect the severity of the disease. Category B contains by far the largest group of 
drugs followed by Category A (i.e., 78.3% and 19.3% in 2009, respectively151). The decision 
base for the reimbursement level hardly ever gives rationale for discussion. As a Belgian 
interviewee stated: “the category is usually not a discussion because the companies know 
very well, by analogy, where to place their product.”
Discussion
We investigated the role of disease severity and its operationalization in drug reimburse-
ment decision making in Belgium, France, The Netherlands and Sweden. As expected, 
the severity of the targeted disease is an important, but often implicit, consideration 
in drug reimbursement decision making; the more severe the disease the higher the 
chance to get the treatment reimbursed (and at a higher reimbursement rate). In The 
Netherlands and Sweden disease severity only implicitly plays a role in the decision 
whether or not to reimburse a drug, whereas in Belgium and France it also explicitly 
plays a role in determining the percentage of costs society is willing to pay out of public 
sources for a specific treatment targeting a more or less severe condition. About halve 
of the interviewees (7 out of 13) were known with at least one of the concepts of disease 
severity. However, all four countries seem to struggle in operationalizing the concept 
and making the actual role of disease severity explicit.
A limitation of our study is that we only conducted thirteen face-to-face interviews 
in four countries. Expert committee meetings are, however, not public; therefore it is 
impossible to attend such meetings and observe the deliberation in actual practice. 
Nevertheless, we conducted interviews with persons involved in everyday decision 
making and observed many similarities across the four countries. We therefore believe 
that saturation was achieved and that our study provides important insights into the 
role of disease severity in actual drug reimbursement decision making in Belgium, 
France, The Netherlands and Sweden and yields valuable lessons for policymakers and 
Health Technology Assessment (HTA) researchers.
National reimbursement agencies are responsible for appraising whether a drug is 
worth paying for by society and are thus accountable to society. According to Daniels 
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and Sabin,102 a fair and legitimate prioritising procedure must satisfy four conditions: (i) 
transparency of the decision-making process; (ii) relevance of the decision criteria; (iii) 
revisability of the decision in light of new evidence and arguments; and (iv) enforce-
ment of the existing criteria. Our study shows that disease severity is a relevant decision 
criterion. However, our study also shows that policymakers experience difficulties in 
employing the concept of disease severity explicitly, and also the importance of disease 
severity relatively to other decision criteria is not transparent.
The governance structure to safeguard legitimacy of reimbursement decision mak-
ing may differ in our four countries. The Swedish, Dutch and French system are more 
information –assessment– driven compared to a more deliberation –process– driven 
system in Belgium in which stakeholders are part of the discussion.15 However, our study 
illustrates that all four countries struggle in making the role of disease severity explicit. 
Even though The Netherlands has a separate appraisal committee and formally uses 
the proportional shortfall approach and Sweden classifies the severity in categories, 
it remains unclear how important disease severity is relatively to other criteria in the 
decision making.
Using levels of reimbursement, which depend on the severity of the disease, as in 
Belgium and France, can be a legitimate way of incorporating disease severity into the 
decision how much society is willing to pay out of public sources for treating a specific 
condition. However, other countries may be averse against the use of co-payments, and 
using levels of reimbursement may therefore be seen as inappropriate or inequitable. In 
such cases, the severity of the disease can only play a role in the decision whether or not 
to reimburse the health care intervention as in The Netherlands and Sweden.
Interestingly, other studies129,142,152 found strong support for ‘fair innings’ arguments in 
the general public. In contrast, our study revealed that age is not important for policy-
makers and that using age as criterion as advocated by ‘fair innings’ arguments may even 
be against the law in some countries. Nevertheless, interviewees indicated to be more 
lenient in case of treatments targeting children. Our study also revealed that past health 
is not important, but that absolute future health gains as well as the current health status 
are important in decision making. This fits with ‘severity of illness’ arguments. Although 
identifiable individuals cannot be considered in national decision making, media at-
tention and societal pressure may appeal to ‘the rule of rescue’ arguments. Cookson153 
analysed eleven potentially relevant justifications for the NICE ‘end-of-life’ premium; he 
concluded that none of them provides sufficient ethical justification. Interestingly, our 
interviewees indicated that even in case of end-of-life treatment a minimal absolute 
gain is still important. Such findings have been previously advocated by Kvamme et al.154
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Another important finding of our study is that policymakers prefer to have, at least, 
qualitative information on the severity of the disease and, above all, prefer to maintain 
their discretionary decision power and implicitly weigh all decision criteria. It remains 
the question why policymakers experience such difficulties in explicating their deci-
sion base. It could be that using an explicit criterion and instrument not only leads to 
favourable decisions at one end of the scale (i.e., high severity leads to reimbursement), 
but also may enforce making and/or explicating unfavourable decisions at the other 
end of the scale (i.e., low severity leads to no reimbursement). The latter one may be a 
less comfortable position. Nevertheless, we believe that policymakers could enhance 
the transparency of the actual role of disease severity and/or underlying considerations 
(e.g., future health, past health, age, end-of-life considerations and medical, therapeutic 
and societal needs) in their decision making. This can be achieved by using classifica-
tions (as in Sweden) or numerical expressions of disease severity (as in The Netherlands), 
but, more importantly, more information on the weighing exercise of the criteria could 
be published. For example, published information can describe that because of the high 
severity of the disease (e.g., remaining life expectancy of 6 months), the absolute gain 
of two months in life expectancy is acceptable. Policymakers may (re)consider the use of 
additional HTA evidence; for example, evidence derived from the disease severity con-
cepts, and/or evidence from multi criteria decision analysis (MCDA) including evidence 
from obtained (public) preferences (e.g., social value of the QALY,135-137 preferences for 
severity of illness,138-140 end-of-life treatment141,142). This may help to improve consistency 
in the deliberation and increase the legitimacy of their decision making.
On the other hand, it is important that academic and HTA researchers realise that HTA 
and/or MCDA evidence will most likely not be decisive and only be informative to poli-
cymakers. Our study reveals that policymakers may not be interested in explicitly weigh-
ing QALYs. Many policymakers do not prefer to use quantitative information on disease 
severity and prefer to implicitly weigh all criteria and, above all, prefer to maintain 
discretionary decision power. To further advance evidence based and legitimate deci-
sion making, it is, however, important to continue developing the theoretical concepts 
of disease severity and investigating different ways of operationalization. Information 
on and the use of (operationalization of the) disease severity approaches may provide 
additional quantitative information on the severity of the disease in a more structured 
way. Therefore, (HTA) researchers and policymakers should closely work alongside each 
other, and make use of each other’s expertise to fine tune the most useful way to opera-
tionalize disease severity in order to enhance the legitimacy of societal decision making.
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Conclusions
Our study showed that the severity of the disease is an important consideration in drug 
reimbursement decision making, especially in case of high severity. However, all four 
countries seem to struggle in making its actual role compared to other criteria explicit. 
Belgium and France are explicit by using the severity of the disease in setting reimburse-
ment levels. However, all four countries could improve the transparency of the actual 
importance of disease severity relatively to other criteria in the decision making.
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Abstract
To sustainably manage equitable access to effective drugs, many developed countries have 
established a national system to determine whether drugs should be reimbursed. Our objec-
tives were (i) to investigate the role of pharmacoeconomic evidence in Dutch and Swedish 
drug reimbursement decision-making; and (ii) to determine the extent to which appraising 
the importance of full economic evaluations relative to other evidence is a transparent process.
We investigated all Dutch and Swedish drug reimbursement information published in 
the period January 2005 to July 2011. After categorising all the reimbursement applica-
tions and decisions in published data sources, we selected all dossiers –in both coun-
tries– that included a full economic evaluation (i.e., cost-effectiveness and/or cost-utility 
analysis) and then investigated how the evidence was appraised for its societal value.
In The Netherlands, only 35% of the 118 applications on List 1B (i.e., claiming added therapeutic 
value) were found to include pharmacoeconomic evidence. In all cases where drugs received 
a ‘no’ decision, combined with an evaluation that they were of similar (n = 7) or added (n = 5) 
therapeutic value, we found that the pharmacoeconomic evidence had been judged insuf-
ficiently robust. We also found that in 21% of the ‘yes’ decisions, combined with an evaluation 
of similar (n = 2) or added (n = 2) therapeutic value, the pharmacoeconomic evidence had 
been judged insufficiently robust. In Sweden, we found that drugs that received a ‘no’ deci-
sion (n = 39) had been judged either not cost effective (74%) or not supported by sufficiently 
credible data (26%). Nearly all drugs that received a ‘yes’ decision (n = 252) had been judged 
cost effective (92%). However, of all these judgements 53% were based on a price comparison 
and 10% on a cost-minimisation analysis; only 33% were based on a full economic evaluation. 
More economic evaluations were available in Sweden than in The Netherlands (97 vs. 31, 
respectively), mainly due to the numerous exemptions from pharmacoeconomic evidence 
in The Netherlands (65%). Dossiers for only 11 drugs included a full economic evaluation in 
both countries; of these, the reimbursement decisions differed for four drugs. Appraisal ele-
ments were reported only descriptively; their actual influence on the final decision remained 
unclear. In four dossiers, the (high) severity of the treatable disease was explicitly mentioned 
in both countries; three of these were identical and related to indications in cancer.
Both countries publish drug reimbursement information. Therapeutic value appears 
to be the most decisive criterion; the relative importance of full economic evaluations 
is more modest than would generally be expected, especially in The Netherlands. Al-
though the assessment process is reasonably transparent, both countries could make 
the appraisal process more transparent by more explicitly showing the actual role of 
each different (societal) criterion in their decision making.
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Introduction
Globally, increasing expenditures are placing health care systems under continual pres-
sure. In the past two decades, in order to manage equitable access to effective drugs 
while controlling expenditure, many developed countries have established agencies 
to determine whether the costs of new drugs should be reimbursed. For each new 
drug, these agencies are responsible for assessing the evidence (i.e., quantification of 
evidence) of its therapeutic value and appraising (i.e., the process of valuing assessment 
outcomes and weighing them against other criteria) whether it warrants being paid for 
by society.
Previous publications in this area have provided a global overview of the various re-
imbursement criteria used in different countries;81,86,87,155,156 compared reimbursement 
outcomes for specific groups of drugs;157-159 compared health technology assessment 
(HTA) recommendations in England, Scotland, Sweden, Canada and Australia;160 com-
pared the contribution of economic analysis in the French and Scottish systems;161 and 
quantitatively analysed reimbursement outcomes (for example, UK National Institute 
for Health and Clinical Excellence [NICE]162,163 or Australian Pharmaceutical Benefits 
Advisory Committee [PBAC]164 decision making). However, reimbursement assessment 
and appraisal processes and their outcomes have seldom been subjected to in-depth 
cross-country comparison combined with analysis of countries’ evidence bases and 
consideration of potential differences between their reimbursement policies.
A recent study described five European drug reimbursement systems and comparatively 
analysed their objectives, institutions, processes, formal reimbursement criteria, and 
output and real-life outcomes.15,103,130 To further investigate the extent to which policy 
differences result in differences in reimbursement outcomes and, more specifically, to 
determine the role of pharmacoeconomic evidence in decision making, this present 
research compares Dutch and Swedish drug reimbursement decisions in the period 
January 2005 to July 2011. We used a two-pronged approach. First, we retrospectively 
analysed all reimbursement dossiers published during that period in the two countries, 
thereby investigating the reimbursement decisions and the assessment of the underly-
ing evidence. Second, for all dossiers that included a full economic evaluation in both 
countries, we determined the extent to which the decision-making process was trans-
parent, by exploratively analysing the evidence base, the assessment, the appraisal, and 
the relative importance of the reported decision criteria.
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Context
Drug reimbursement in The Netherlands
In The Netherlands, The Health Care Insurance Board (College voor Zorgverzekeringen 
[CVZ]) is legally responsible for managing entitlements in the basic benefit package, 
including drugs. A technical department prepares assessment reports, which are then 
evaluated by the Scientific Pharmaceutical Advisory Commission (Wetenschappelijke 
Adviesraad Geneesmiddelen [WAR]; formerly Commissie Farmaceutische Hulp [CFH]). 
On the request of the CVZ Board of Directors, reimbursement applications may also be 
evaluated by the Appraisal Commission (Adviescommissie pakket [ACP]), though this 
seldom occurred in the first few years following the commission’s establishment in 2008. 
In appraising the reimbursement request, this commission considers a broader societal 
perspective before advising the CVZ Board. The Board then forwards the definitive re-
imbursement advice to the Minister of Health, who makes the final decision. Regarding 
pharmacoeconomic evidence, the CVZ and the WAR formally advise only on its robust-
ness. The advisory reports are published online in Dutch and include the assessment, 
summaries of the evidence, and reasons for the advice.
Application requirements differ depending on the type of drug. Applications for expen-
sive inpatient drugs require information on therapeutic value, a cost prognosis and a 
research plan for outcomes research. Outpatient drugs fall under the drug reimburse-
ment system (Geneesmiddelen Vergoedingssysteem [GVS]), which consists of List 1A 
(i.e., groups of therapeutically interchangeable drugs), List 1B (i.e., non-interchangeable 
drugs and/or drugs with added therapeutic value), and List 2 (i.e., drugs restricted in 
reimbursement). For drugs on List 1A, the reimbursement level is limited to the group’s 
historically determined average product price. Drugs on List 1B are fully reimbursed. 
Applications for List 1A only require pharmacotherapeutic evidence; applications for 
List 1B also require a budgetary impact estimation and, since 2005, pharmacoeconomic 
evidence.
Drug reimbursement in Sweden
Sweden’s Dental and Pharmaceutical Benefits Agency (Tandvårds- och läkemedelsför-
månsverket [TLV]) is legally responsible for deciding, by means of a value-based pricing 
approach as well as taking a societal perspective, whether outpatient drugs are to be 
included in the pharmaceutical benefits scheme. County councils are responsible for 
procurement and reimbursement of inpatient drugs. The Agency’s Reimbursement 
Application Unit prepares assessment reports; these are evaluated by the Agency’s Phar-
maceutical Benefits Board (PBB), which makes the final reimbursement decision. The 
Agency’s Director-General makes decisions, without consulting the PBB, on requests for 
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price changes, new strengths, generic drugs, new package sizes, and parallel-imported 
drugs. Decisions are published online in Swedish and include summaries of the evidence 
and reasons for the decisions.
Application requirements differ depending on the type of application. The two main 
application categories are (i) generics, and (ii) new pharmaceuticals (including impor-
tant new indications). The requirements are most extensive for new pharmaceuticals; 
the procedure for generics is simpler. If a drug is judged to be clinically similar to the 
comparator, a cost-minimisation analysis or price comparison may suffice. If the manu-
Table 6.1 Summary of characteristics of the Dutch and Swedish drug reimbursement system
The Netherlands Sweden
System characteristics
National reimbursement agency CVZ TLV
Pharmaceutical committee WAR (and ACP) PBB
Scope of national agency Outpatient and expensive 
inpatient drugs
Outpatient drugs
Final decision maker Minister of Health PBB
Implementation of the outcome Positive list Positive list
Reimbursement reports publicly available Yes, CVZ’s advisory report to 
minister
Yes, TLV’s decision including 
summary of evidence and 
motivation of decision
Assessment and appraisal criteria (national level)
Medical, therapeutic and societal need Yes Yes
Added therapeutic value Yes Yes
Cost-effectiveness Yes Yes
Budget impact Yes No
Explicit threshold for cost/ QALY No No
Other Disease severity and rarity, own 
responsibility, accessibility, 
societal affordability, public health
All effects on a person’s health 
and quality of life, human 
value, need and solidarity
Re-evaluation/ revision
Re-evaluation/ revision of previous 
decision
Yes, expensive inpatient drugs 
after 4 years
Yes, decided case-by-case
Outpatient drugs only ad-hoc 
(from 2013 case-by-case)
Therapeutic areas in which 
drugs do not appear to be 
used in a cost-efficient way
CVZ = Health Care Insurance Board [in Dutch: College voor Zorgverzekeringen]
WAR = Scientific Pharmaceutical Advisory committee [in Dutch: Wetenschappelijke Adviesraad Geneesmiddelen]
ACP = Appraisal committee [in Dutch: Adviescommissie Pakket]
TLV = Dental and Pharmaceutical Benefits Agency [in Swedish: Tandvårds- och läkemedelsförmånsverket]
PBB = Pharmaceutical Benefits Board [in Swedish: Nämnden för läkemedelsförmåner]
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facturer claims an added therapeutic value, evidence is required on that value, as well 
as on cost-effectiveness.
County councils are responsible for implementing national (compulsory) reimburse-
ment decisions; each county can establish its own drug therapeutic committee and 
own therapeutic guideline. Outpatient drugs are fully reimbursed after a maximum co-
payment level has been reached. Table 6.1 provides an overview of the characteristics 
of the Dutch and Swedish drug reimbursement systems. It should be noted that the 
requirements that both countries place on pharmacoeconomic evidence are similar, as 
is their adoption of a societal perspective (e.g., inclusion of productivity costs) in the 
decision making. For more detailed information on these two systems and their HTA 
models, see Franken et al.103 and Le Polain et al.15
Methods
We investigated whether and how the Dutch and Swedish national agencies respon-
sible for deciding on reimbursement of new drugs actually used pharmacoeconomic 
evidence in their decision making. We also assessed the extent to which the process of 
establishing its importance relative to other criteria was transparent. These two coun-
tries were selected because, in both cases, their responsible agencies formally use drug 
effectiveness and cost-effectiveness as reimbursement criteria. For both countries, we 
investigated all reimbursement dossiers published in the period January 2005 to July 
2011. It is important to emphasise that we only used published documentation. Our 
analysis started in 2005 because that was the first year in which pharmacoeconomic 
evidence was required for reimbursement decision making in The Netherlands.
Reimbursement decisions and the reasons given for these decisions were investigated 
as follows. First, for new drugs, we compared all the reimbursement applications and de-
cisions and sorted them into categories. For those categories in which it was reasonable 
to expect that pharmacoeconomic evidence had been used (i.e., outpatient drugs with 
an added therapeutic value claim in The Netherlands, and all new pharmaceuticals in 
Sweden), we investigated the reimbursement decisions to determine whether pharma-
coeconomic evidence had been included, and if so, we identified the type of evidence. If 
no pharmacoeconomic evidence had been included, we retrieved any reported underly-
ing reasons.
Second, to determine the extent to which establishing the importance of full economic 
evaluations –relative to other criteria considered in the decision making– was a trans-
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parent process, for a group of selected drugs we exploratively analysed the evidence-
base, the assessment, the appraisal, and the reported relative importance of the decisive 
criteria. We selected those dossiers that, in both countries, provided a full economic 
evaluation (i.e., cost-effectiveness, cost-benefit and/or cost-utility analysis165); dossiers 
including only a price comparison or cost-minimisation analysis were not selected. Dos-
siers on vaccines were also excluded.
To analyse the assessment, we compared the Dutch and Swedish evaluations of the 
pharmacotherapeutic and pharmacoeconomic evidence and retrieved other factors 
that may have influenced the decision. Regarding pharmacotherapeutic evidence, we 
extracted data on therapeutic value, comparator, efficacy, adverse effects, other clinical 
effects, and pharmacotherapeutic uncertainty, as well as information on underlying 
studies. Regarding pharmacoeconomic evidence, we extracted data on the type of 
economic evaluation, incremental effects, incremental costs, type of comparison (i.e., 
indirect vs. direct), costs per intermediate outcome, costs per life-year gained (LYG), 
costs per quality-adjusted life-year (QALY), and pharmacoeconomic uncertainty, as well 
as information about the economic evaluation (e.g., applied model). To allow easy com-
parison, Swedish kronor (SEK) were converted to Euros (€) using the European Central 
Bank’s average exchange rate over the period January 2005 until July 2011 (€1.00 = 
SEK9.5379).
Finally, as both countries adopt a societal perspective in their decision making, in order 
to analyse the appraisal of a drug’s societal value, we extracted reported information 
on consultation with stakeholders, product price, expected number of eligible patients, 
budgetary impact, added therapeutic value, cost-effectiveness, medical and therapeutic 
need, as well as any other reported societal criteria (e.g., disease severity, human value, 
public health, accessibility, affordability, solidarity, rarity, alternative treatments, and 
incentive for innovation).
Results
Reimbursement applications and decisions in The Netherlands
Between January 2005 and July 2011, The Netherlands published 311 advisory reports 
for new drugs: 58 expensive inpatient and 253 outpatient drugs (see Figure 6.1). For 
general outpatient drugs (n = 186), 68 were List 1A and 118 were List 1B applications. Of 
the List 1A applications (n = 68), four were subsequently placed on List 1B, 60 on List 1A, 
and four were rejected for reimbursement. Of the List 1B applications (n = 118), 63 were 
subsequently placed on List 1B, 29 on List 1A, and 26 were rejected for reimbursement.
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Public reimbursement dossiers in The Netherlands
From 2005 to July 2011
N=311
Outpatient drugs Expensive inpatient drugs
n=253 n=58
Enlisted
Outpatient drugs Non-registered Extension expensive drug list
general indication indication/ n=49
change in
conditions Not enlisted
n=186 n=43 n=23 expensive drug list
n=9
No 
reimbursement
n=4
Claim manufacturer
Similar
therapeutic value
Added Similar n=60 (List 1A)
therapeutic value therapeutic value
(List 1B) (List 1A) Added
n=118 n=68 therapeutic value
n=4 (List 1B)
Reimbursement advice
Added therapeutic Similar therapeutic No reimbursement                  
value (List 1B) value (List 1A)
n=63 n=29 n=26
evidence evidence
Pharmacoeconomic Pharmacoeconomic
* available: n=19 * available: n=12
* not available: n=44 * not available: n=14
 
Figure 6.1 Overview of reimbursement applications and outcomes in The Netherlands
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Table 6.2 Pharmacoeconomic evidence and its evaluation in The Netherlands
Application List 1B List 1B
Reimbursement advice no listing List 1B
Total number of reimbursement dossiers 26 63
No pharmacoeconomic evidence available 14 (54%) 44 (70%)
Exemption due to orphan status a 1 24
Exemption due to being a HIV drug a 7
Exemption due to estimated budget impact < €500,000 a 4
Small number of expected eligible patients a 1 1
Similar/ lower therapeutic value and higher costs b 12
Similar therapeutic value, no higher costs b 1
Added therapeutic value and budget neutral or lower costs b 3
Application before 01-01-2005 (evaluated in 2005) 4
Pharmacoeconomic evidence available 12 (46%) 19 (30%)
Type of pharmacoeconomic evidence
Cost-minimisation analysis 1 3
Cost-effectiveness analysis 3 3
Cost-utility analysis 4 4
Cost-effectiveness & cost-minimisation analysis 1
Cost-effectiveness & cost-utility analysis 4 8
CE plane and acceptability curve available 3 9
Either CE plane or acceptability curve available 3 2
Evaluation pharmacotherapeutic and economic evidence
Similar therapeutic value 7 4
Pharmacoeconomic evidence
Sufficiently robust 2
Insufficiently robust 7 2
Added therapeutic value 5 15
Pharmacoeconomic evidence
Sufficiently robust 7
Reasonably robust 4
Moderately robust 2
Insufficiently robust 5 2
List 1B: not interchangeable within a cluster/ added value
CE plane: Cost-Effectiveness plane; HIV: Human Immunodeficiency Virus
a Exempted as described by Borst 2000, Cheung 2011 and van der Meijden 2011
b Exempted as described by documentation of the Dutch Health Care Insurance Board (not publicly available)
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In The Netherlands, pharmacoeconomic evidence is only evaluated and published if 
a drug is judged to have added therapeutic value and is placed on List 1B. Therefore, 
none of the original List 1B applications that were placed on List 1A (n = 29) included 
pharmacoeconomic evidence. Interestingly, such evidence was included in only 19 of 
the 63 ‘yes’ (30%) and 12 of the 26 ‘no’ (46%) decisions (List 1B applications). The relevant 
regulations19,166,167 formally exempted certain drugs, such as orphan drugs (n = 25), and 
HIV drugs (n = 7) (see Table 6.2). Available pharmacoeconomic evidence was presented 
as a cost-minimisation analysis (n = 5), a cost-effectiveness analysis (n = 19) and/or a 
cost-utility analysis (n = 20).
With regards to all 12 ‘no’ decisions that included pharmacoeconomic evidence, that 
evidence had been evaluated as insufficiently robust and the judgement was that intro-
duction of the drug would increase the pharmaceutical budget. Five of these drugs had 
been judged to be of added therapeutic value and seven to be of similar therapeutic 
value, yet they received a ‘no’ decision, for reasons that were not explicitly stated. Three 
applications concerned two vaccines; their dossiers discussed an inconsistency with 
policy, as vaccines should be part of the national vaccination programme (i.e., a separate 
financial budget). Notably, one drug (i.e., ivabradine) received a ‘yes’ decision a year later 
on the basis of new pharmacoeconomic evidence.
Of the 19 ‘yes’ decisions that included pharmacoeconomic evidence, 15 of the drugs 
had been judged to be of added therapeutic value, and introduction of the drug would 
increase the pharmaceutical budget. Interestingly, in the case of four dossiers (two 
indicating added and two indicating similar therapeutic value), the drugs obtained a 
‘yes’ decision (21%) even though the pharmacoeconomic evidence had been judged to 
be insufficiently robust.
Table 6.2 provides an overview of the publication of this pharmacoeconomic evidence 
and its evaluation in The Netherlands.
Reimbursement applications and decisions in Sweden
Between January 2005 and July 2011, Sweden’s TLV made 291 decisions on new phar-
maceuticals: of these, 39 were rejected for reimbursement and 252 were accepted for 
reimbursement (see Figure 6.2). Of the accepted applications, 46 were restricted in 
reimbursement (e.g., in most cases to a subgroup of patients); of these 46 applications, 
15 dossiers also included either conditions on evidence development (n = 9) or time 
restrictions (n = 6). A total of 22 were granted ‘general’ reimbursement conditional on 
evidence development.
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Public reimbursement dossiers in Sweden
From 2005 to July 2011
Applications for price changes, 
new strenghts, new package size, 
New pharmaceutical
parallel import, and genericsn=291
 
Reimbursement decision
No 
reimbursement Reimbursement
n=39 n= 252
General Restricted Conditional on
reimbursement reimbursement evidence
development
n=183 n=47 n=22
General Time
restriction restriction
(subgroep of patients)
n=46 n=1
Including evidence OtherIncluding
development time
condition restriction
n=9 n=6
restriction
n=31
Economic evaluation
No decisions (n=39):
Economic evaluation
Yes decisions (n=252):
* available: n=18 * available: n=79
* not available: n=173* not available: n=21
 
Figure 6.2 Overview of reimbursement applications and outcomes in Sweden
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Nearly two thirds of all these decisions relied on price comparisons (53%) or cost minimi-
sation analyses (10%); only 33% were based on a full economic evaluation. In ten cases, 
the decision was not based on any economic evidence and was therefore classified as 
‘other’; most of these decisions referred to high disease severity or lack of alternative 
treatments.
Regarding the underlying reasons for the ‘yes’ decisions (n = 252), 60% of the drugs had 
been judged to be similar in clinical effect to the comparator and to be cost effective 
(i.e., having similar or lower costs); 31% were accepted for reimbursement on the basis of 
a full economic evaluation. A total of 91% of the full economic evaluations were part of 
judgements in the ‘better’ clinical effects category, 4% in the ‘similar’ category, and 3% in 
the ‘worse’ category. Three drugs were judged to be ‘worse’ in effect than the compara-
tor but cost effective due to a sufficiently lower price. Interestingly, eight ‘yes’ decisions 
were not based on any pharmacoeconomic analysis, though the drugs were accepted 
for reimbursement because the costs were judged to be reasonable. The 11 decisions 
classified as ‘other’ refer to a high disease severity combined with a lack of alternative 
treatments; one decision was based on a health economic evaluation developed for 
British conditions.
Regarding the underlying reasons for the ‘no’ decisions (n = 39), 51% of the drugs were 
judged similar in clinical effect to the comparator but not cost effective (i.e., higher price 
or costs); 46% were rejected as not cost effective based on a full economic evaluation. 
Thirty-three percent of the full economic evaluations were part of judgements in the 
‘better’ clinical effects category, 11% in the ‘worse’ and 6% in the ‘similar’ category. In ten 
decisions (26%), either the clinical or the economic evidence was judged as lacking in 
credibility. Table 6.3 provides an overview of the reimbursement outcomes and type of 
pharmacoeconomic evidence in Sweden.
Comparative analysis of a selection of drugs
We found that the reimbursement dossiers for only 11 drugs included a full economic 
evaluation (i.e., cost-effectiveness and/or cost-utility analysis165) in both countries. In 
seven of these cases, the reimbursement decision was similar, whereas in four cases it 
differed. Notably, all four differing decisions were restricted or conditional in at least 
one of the countries. Table 6.4 provides an overview of the results of this comparative 
analysis.
Pharmacotherapeutic evidence (11 cases)
All the dossiers that we investigated included information on pharmacotherapeutic 
evidence, and all but one (Sweden: inhaled insulin) included a description of the under-
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Table 6.3 Reimbursement outcomes and type of pharmacoeconomic evidence in Sweden
Total number of applications (new pharmaceuticals) 291
Type of pharmacoeconomic evidence available
Economic evaluation 97 (33%)
Cost minimisation analysis 29 (10%)
Price comparison 155 (53%)
Other 10 (3%)
Yes reimbursement decision 252 (87%)
General reimbursement 183 (73%)
Type of pharmacoeconomic evidence
Economic evaluation 42
Cost minimisation analysis 16
Price comparison 120
Other 5
Restricted reimbursement 46 (18%)
Including time restrictions 6
Including evidence development conditions 9
Type of pharmacoeconomic evidence
Economic evaluation 23
Cost minimisation analysis 8
Price comparison 11
Other 4
Time restricted reimbursement 1 (0.4%)
Type of pharmacoeconomic evidence
Economic evaluation 1
Conditional on evidence development 22 (9%)
Type of pharmacoeconomic evidence
Economic evaluation 13
Cost minimisation analysis 3
Price comparison 5
Other 1
No reimbursement decision 39 (13%)
Type of pharmacoeconomic evidence
Economic evaluation 18
Cost minimisation analysis 2
Price comparison 19
TLV judgement
Judgement based on a 
full economic evaluation
Yes reimbursement decision 252 79 (31%)
Similar clinical effects and cost effective 152 3
Better clinical effects and cost effective 78 72
Worse clinical effects but cost effective 3 2
No economic analysis but reasonable costs 8
Other 11 2
No reimbursement decision 39 18 (46%)
Similar clinical effects but not cost effective 20 1
Better clinical effects but not cost effective 7 6
Worse clinical effects and not cost effective 2 2
No credible economic evidence nor clinical effects 10 9
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lying studies. All the Dutch dossiers included detailed information on underlying studies 
(stating, at least, name of study, patient numbers, follow-up, and literature references), 
whereas only three Swedish dossiers included such detailed information. Comparators 
were always reported and, in eight cases, at least one was the same. Regarding the best 
therapeutic value judgement, irrespective of comparator, Sweden reported nine added, 
one similar and one lower; The Netherlands reported eight added and three similar in 
this respect. In three cases (i.e., varenicline, inhaled insulin, sitagliptin) using similar 
comparators, the therapeutic value judgement differed. First, varenicline received a ‘no’ 
decision in The Netherlands, based on similar therapeutic value and insufficiently robust 
economic evidence. In contrast, it received a ‘yes’ decision in Sweden, based on added 
therapeutic value and cost-effectiveness of treatment, though the decision was condi-
tional on additional data collection. Second, inhaled insulin obtained a ‘yes’ decision in 
both countries based on similar therapeutic value and cost-effectiveness of treatment 
in Sweden, but based on added therapeutic value and insufficiently robust economic 
evidence in The Netherlands. Both countries restricted reimbursement to a subgroup of 
patients; in addition, Sweden made the decision temporary, requiring additional data. 
Third, sitagliptin received a ‘yes’ decision in both countries, based on added therapeutic 
value and cost-effectiveness of treatment in Sweden, but based on similar therapeutic 
value and insufficiently robust economic evidence in The Netherlands. The Dutch agency 
restricted reimbursement to a subgroup of patients, whereas the Swedish agency made 
the decision conditional on data collection.
Pharmacoeconomic evidence (11 cases)
All the dossiers that we investigated included pharmacoeconomic evidence and 
information on input variables. In all dossiers, the comparators were similar. In Swe-
den, incremental effects and costs were separately reported in six and four dossiers, 
respectively. Costs per QALY were reported  for nine drugs; one dossier only reported 
“similar cost-effectiveness”. Cost savings were reported in two cases. In The Netherlands, 
all dossiers included information on incremental effects and costs. Costs per LYG and per 
QALY were reported in six and seven dossiers, respectively. Five did not report costs per 
QALY or LYG due to ‘dominance’.
Both countries require uncertainty analysis using, for example, cost-effectiveness planes 
and acceptability curves. In Sweden, uncertainty was only descriptively reported (e.g., 
specification of uncertain items; judgement: high or low uncertainty). In contrast, all 
Dutch dossiers included detailed information on uncertainty, such as sensitivity analyses 
outcomes (all dossiers), cost-effectiveness planes (ten dossiers) and acceptability curves 
(eight dossiers).
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In Sweden, ten drugs that received ‘yes’ decisions had been judged cost effective (in-
cremental cost-effectiveness ratios [ICERs] ranged from €6,836 to €40,890/QALY, and 
“similar” to the comparator, having “very low” incremental costs, one case reported a 
range from cost-saving to an additional cost of €62,906/QALY). One drug that received a 
‘no’ decision had been judged not cost effective, with savings of €26,211 to €57,665 per 
QALY lost (i.e., south-west quadrant of the cost-effectiveness plane).
In The Netherlands, of the nine drugs that received ‘yes’ decisions, in three cases the 
pharmacoeconomic evidence had been judged to be sufficiently robust (ICERs ranged 
from €5,231 to €33,464/QALY), in one reasonably robust (ICER: ‘dominant’), in two 
moderately robust (ICERs: ‘dominant’ and €34,267/QALY), and in three insufficiently 
robust (ICERs: ‘dominant’ [n = 2] and €44,596/QALY). Of the four drugs that received ‘no’ 
decisions, in each case the pharmacoeconomic evidence had been judged insufficiently 
robust (ICERs ranged from ‘ dominant’ to €20,926/QALY). Due to the limited number of 
dossiers investigated, it was not possible to establish a relationship between the quality 
of economic evidence and the final decision.
Appraisal elements (11 cases)
All Swedish dossiers included information on consultations with county councils. Al-
though it is Dutch policy to obtain the opinions of various stakeholders (e.g., patient, 
professional, and health insurer associations), these were only reported for six drugs. 
None of the Dutch dossiers were evaluated by the appraisal committee (ACP).
Budgetary consequences including the expected number of eligible patients were 
reported in all Dutch dossiers. Although all Swedish dossiers included the product price, 
none included information on budgetary consequences (budgetary impact is not a 
decision criterion in Sweden).
Appraisal elements were only descriptively reported; their actual influence on the final 
decision was not clarified. Most dossiers (10 of the 11 drugs in both countries) included 
a description of the disease. Although no quantifications of disease severity were incor-
porated, the fact that the disease in question was (highly) severe was reported in four 
cases in both countries. In three cases, the drug was identical, and all three concerned 
‘yes’ decisions for indications in cancer. Other reported appraisal elements were public 
health reasons, new treatment mechanism, medical need for additional treatment op-
tions, limited treatment possibilities, fatality of disease, comparators not reimbursed, 
reduced risk factors of severe diseases, and necessity to insure (i.e., whether the illness 
or the care needed justified solidarity).
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Similar decision (seven cases)
Seven drugs received a ‘yes’ decision in both countries. The therapeutic value judgement 
(added value) was the same in four cases even though three used different comparators. 
In Sweden, all four were judged to be cost effective treatments, whereas in The Nether-
lands the pharmacoeconomic evidence was judged sufficiently (n = 2), moderately (n = 
1), or insufficiently (n = 1) robust. The other three decisions, while using similar compara-
tors, differed in therapeutic value judgement (i.e., similar vs. added value). In Sweden, all 
three were judged cost effective, whereas in The Netherlands the pharmacoeconomic 
evidence was judged reasonably (n = 1) or insufficiently (n = 2) robust. In all economic 
evaluations, at least one of the comparators was the same.
Diverging decision (four cases)
For four drugs, the reimbursement decision differed.
First, in The Netherlands in 2007, rimonabant received a ‘no’ decision based on similar 
therapeutic value, insufficiently robust pharmacoeconomic evidence (€20,926/QALY), 
and increase of the pharmaceutical budget. The Dutch dossier reports that two com-
parators (sibutramine and orlistat) for the same indication (i.e., overweight and obesity) 
are also not reimbursed. In Sweden in 2006, using similar comparators, rimonabant 
obtained a ‘yes’ decision based on added therapeutic value (comparator 2), as well as 
on similar (comparator 1) and reasonable (comparator 2) cost-effectiveness (no val-
ues reported). However, reimbursement was restricted not only in time but also to a 
subgroup of patients and was made conditional on obligatory collection of additional 
data and provision of marketing information. It should be noted that, at the time of the 
rimonabant decision, the two comparators (sibutramine and orlistat) were reimbursed 
in Sweden. In 2009, European Medicines Agency (EMA) market authorisation was with-
drawn; the drug was subsequently delisted.
Second, in The Netherlands in 2007, exenatide first received an initial ‘no’ decision for 
the entire diabetic population, based on similar therapeutic value, insufficiently robust 
pharmacoeconomic evidence (€17,979/QALY), and increase of the pharmaceutical bud-
get. In 2009, it received a ‘yes’ decision, with reimbursement restricted to a subgroup 
of patients (i.e., patients for whom –a combination of– other diabetic treatments were 
inappropriate or had insufficient effects, and who had a body mass index [BMI] ≥ 35 
kg/m2), sufficiently robust pharmacoeconomic evidence (€5,231/QALY), and increase of 
the pharmaceutical budget. In Sweden in 2007, using similar comparators, exenatide 
received a ‘yes’ decision conditional on additional data collection. It had been judged 
to be of added therapeutic value and to be cost effective (€13,315/QALY). Having been 
incorporated in a 2009 review of the diabetic therapeutic class, it is still reimbursed, 
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though with restrictions similar to those placed on other diabetic products (i.e., patients 
for whom –a combination of– other diabetic treatments were inappropriate or had 
insufficient effects). Re-evaluation of the requested additional data has been put on 
a prioritisation list. It should be noted that, due to the additional BMI restriction, the 
Dutch decision is more restrictive.
Third, in The Netherlands in 2007, varenicline received a ‘no’ decision, based on similar 
therapeutic value, insufficiently robust pharmacoeconomic evidence (€1,520/QALY), 
and increase of the pharmaceutical budget. The dossier reports that the comparator 
(bupropion) is also not reimbursed for the indication of smoking cessation; it also 
indicates the costs of varenicline treatment compared with smoking, explicitly stating 
that ‘own responsibility’ and ‘co-payments’ in smoking cessation are to be discussed in 
a follow-up report. It should be noted that the manufacturer subsequently initiated 
a court case, though this did not alter the decision. In Sweden in 2007, using similar 
comparators, varenicline received a ‘yes’ decision based on added therapeutic value 
and cost-effectiveness (€10,484/QALY). Reimbursement was restricted to second-line 
treatment combined with motivational therapy and was made conditional on obliga-
tory marketing information. It should be noted that the comparator bupropion is also 
reimbursed in Sweden.
Fourth, in The Netherlands in 2006, ivabradine for the indication of stable angina pectoris 
received an initial ‘no’ decision, based on added therapeutic value, insufficiently robust 
pharmacoeconomic evidence (‘dominant’), and increase of the pharmaceutical budget. 
In 2007, it received a ‘yes’ decision based on the same pharmacotherapeutic evidence 
combined with new pharmacoeconomic evidence (using a different comparator), which 
was judged to be moderately robust (‘dominant’). Reimbursement was restricted to a 
subgroup of patients. In 2011, the manufacturer’s request to loosen this restriction was 
denied. In Sweden, first in 2007 and then in 2008, ivabradine received two ‘no’ decisions. 
Both were based on lower therapeutic value (using a different comparator than in the 
Dutch dossiers); the first was also based on an actual lack of cost-effectiveness, the 
second on insufficient evidence of cost-effectiveness (saving of €26,211- €57,665/QALY 
lost; comparator in 2007 similar to that used in the Dutch economic evaluation).
Discussion
Using official information on drug reimbursement decisions that were published in The 
Netherlands and Sweden in the period January 2005 to July 2011, we investigated the 
role of pharmacoeconomic evidence in reimbursement decision making. We also deter-
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mined the extent to which the decision-making process was transparent, by comparing 
the evidence base, the quantitative assessment, the comparative appraisal, and the 
reported decision criteria.
As expected, we observed differences in processes and outcomes due to reimburse-
ment policies. First, whereas the Dutch agency evaluates both outpatient and expensive 
inpatient drugs, the Swedish agency only evaluates outpatient drugs. Second, because 
information on budgetary impact is not a criterion at the national level in Sweden, 
none of the Swedish dossiers that we investigated included such information. Third, the 
Swedish agency judges whether a drug is cost effective and incorporates that judge-
ment in its final reimbursement decision, whereas the Dutch agency only evaluates the 
pharmacoeconomic evidence for its robustness and accordingly advises the Minister of 
Health, who makes the final decision. Fourth, in Sweden, consultation with stakeholders 
is limited to county councils, whereas the Dutch policy is to obtain the opinions of a 
wide range of stakeholders. Finally, Swedish decisions may be made conditional on the 
obligatory provision of additional data where outcomes are uncertain, whereas in The 
Netherlands this practice did not occur for outpatient drugs during the period of our 
analysis. It should be noted that, at the time of writing, The Netherlands is planning 
to expand reimbursement conditional on evidence development to specific groups of 
outpatient drugs in 2013.168
We also expected to observe less use of pharmacoeconomic evidence in The Nether-
lands than in Sweden, partly because, in the former, new drugs on List 1A (i.e., groups 
with therapeutically interchangeable drugs) are reimbursed similarly to therapeutically 
equivalent existing drugs and are therefore not evaluated for cost-effectiveness. Howev-
er, surprisingly, only 35% of the dossiers for Dutch List 1B drugs (i.e., non-interchangeable 
drugs and/or drugs with added therapeutic value: ‘no’ decision 46%; ‘yes’ decision 30%) 
included pharmacoeconomic evidence. In contrast, Sweden requires that all new drugs 
be evaluated for cost-effectiveness. Only 3% of the 291 Swedish applications included 
no economic evidence. However, only 33% included a full economic evaluation. Eighty 
percent of the Swedish economic evaluations were part of judgements in the category 
‘better’ clinical effects. It should be noted that Sweden’s system of comparing the prices 
of drugs is similar in its impact on the reimbursement costs to the Dutch clustering 
system of grouping therapeutically equivalent drugs on List 1A.
Regarding the role of pharmacoeconomic evidence in decision making in everyday prac-
tice, the Swedish ‘no’ decisions were based on a judgement that either cost-effectiveness 
(74%) or credible economic evidence (26%) was lacking; 92% of the ‘yes’ decisions were 
based on a judgement of cost-effectiveness. Even though, in principle, the Swedish 
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agency explicitly judges whether a drug is cost effective, it is important to realise that, 
in practice, most of these judgements were merely based on price comparisons (53%). 
Forty-six percent of the ‘no’ and 31% of the ‘yes’ decisions were based on a full economic 
evaluation. In one of the dossiers, cost saving at the expense of QALYs lost was judged 
cost-ineffective. Strikingly, most of the Swedish decisions that were not based on any 
economic evidence were made in 2005 or 2006.
In The Netherlands, all ‘no’ decisions were based on a judgement that the pharmacoeco-
nomic evidence was insufficiently robust, combined with a judgement of either similar 
(n = 7) or added (n = 5) therapeutic value. More surprisingly, the same was true for 21% 
of ‘yes’ decisions. Of the drugs that received a ‘yes’ decision, 79% had been judged of 
added therapeutic value, whereas 21% had been judged of similar therapeutic value to 
the comparator. It should be noted that most of the unfavourable judgements regarding 
the robustness of pharmacoeconomic evidence in The Netherlands occurred in the early 
years of this requirement (2005-2007). All but one of the Dutch ‘yes’ decisions (nine of 
ten) made in the period 2008-2011 were based on a judgement that such evidence was 
sufficiently robust.
We found the agencies in both countries to be insufficiently transparent in two senses: 
(i) in not explaining how they determined the importance –for the decision– of full 
economic evaluations relative to other evidence; (ii) in not stipulating a threshold range 
of cost-effectiveness. Furthermore, when dossiers only report that a drug is ‘dominant’, 
as in The Netherlands and Sweden, or ‘similarly cost effective’, as in Sweden, the actual 
and relative differences in effects and costs are unclear.
As so few of the investigated dossiers published during a 6.5-year period actually in-
cluded full economic evaluations (i.e., 31 in The Netherlands and 97 in Sweden) that 
were comparable, we could only include 11 drugs in our in-depth comparative analysis. 
This is the main limitation of our research, and the conclusions we draw from this 
analysis should therefore be regarded as tentative rather than definitive. Whereas 
economic evaluations play a more important role in Sweden (i.e., 80% of drugs with an 
added therapeutic value claim –combined with a premium price– included an economic 
evaluation) than they do in The Netherlands (i.e., 35% of list 1B applications), our results 
suggest that therapeutic value is the most decisive criterion, which is consistent with 
the findings of previous studies.15,103,162,163
Another limitation of our study is that we were only able to investigate published infor-
mation, which may not necessarily reveal all arguments and reasoning that led to a par-
ticular decision. Both agencies are responsible for appraising whether a drug warrants 
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society paying for it and are thus accountable to society. That is why we investigated 
the transparency of their societal decision making and the reported underlying reim-
bursement criteria. According to Daniels and Sabin102, a fair and legitimate prioritising 
procedure must satisfy four conditions: (i) transparency of the decision-making process; 
(ii) relevance of the decisive criteria; (iii) revisability of the decision in light of new 
evidence and arguments; and (iv) enforcement of the existing criteria. Our data show 
that both The Netherlands and Sweden generally report –albeit in varying detail– their 
assessment of the pharmacotherapeutic and pharmacoeconomic evidence, including 
references to underlying studies. However, in Sweden, drug manufacturers can with-
draw their application, in which case no data are published. This practice guarantees 
confidentiality at the cost of transparency.103,130
At first glance, Sweden, in only reporting a single cost-effectiveness estimate, may 
appear to be less transparent than The Netherlands regarding decision-makers’ un-
certainty. However, the large number of such estimates in The Netherlands may not 
necessarily improve decision-makers’ understanding of the impact of uncertainty nor 
reduce its consequences. The Sweden agency’s practice of requesting additional data 
on specific items where there is (high) uncertainty contributes to the legitimacy of its 
decision-making process by fulfilling both the transparency and the revision require-
ment as defined by Daniels and Sabin. Even though the Swedish agency makes the final 
reimbursement decision, whereas its Dutch counterpart merely advises the Minister of 
Health, the former agency could consider publishing a greater amount of standardised 
and/or quantified information on uncertainty in order to enhance its transparency to 
the general public. For example, it could achieve this by publishing outcomes of sen-
sitivity analyses or (descriptions of ) cost-effectiveness planes or acceptability curves. 
The Swedish agency could also consider the advantages of more frequently reporting 
incremental effects and costs separately. In accordance with research results on the lim-
ited utility of small increases in life expectancy reported by Kvamme et al.,154 we assert 
that, even when a drug is judged to be cost effective, it is still important to consider 
whether the actual health gain is significant; for example three months of survival rather 
than just one week.
Although the Dutch system currently does not yet fulfil Daniels and Sabin’s revision 
requirement, it may do so if temporary decision making (including requirements on out-
comes research) is extended to specific groups of outpatient drugs in 2013, as planned. 
Irrespective of this possible improvement, Dutch decision makers could consider emu-
lating their Swedish counterparts in requesting additional data on specific uncertain 
items, rather than requiring general ‘outcomes research’. Recently, Dutch decision mak-
ers (i.e., CVZ, ACP and the Minister of Health) experienced difficulties in enforcing the 
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consequences of first revisions for expensive inpatient drugs (i.e., omalizumab, inflix-
imab, and ranibizumab). After four years of data collection, the revisions were judged to 
include insufficient data. If the reimbursement of drugs were to be made conditional on 
evidence development, the consequences of evaluating new evidence (e.g., delisting, or 
altering the reimbursement price or reimbursement restrictions) would be enforceable. 
The Swedish policy option of revising a decision increases the probability of a ‘yes’ deci-
sion. In this sense, that system can be regarded as being more lenient than the Dutch 
system, in which decisions on outpatient drugs are rarely revised.
Surprisingly, although the contrary is often held to be true,169,170 pharmacoeconomic evi-
dence does not seem to play an important role in The Netherlands. Dutch policymakers 
could reconsider the rationale behind the exemptions for pharmacoeconomic evidence 
(65%). Swedish dossiers show that, for example, in the case of drugs that have orphan 
status, manufacturers still seem to be able to provide information on value for money. 
Similarly, other European agencies (e.g., in Scotland, England and Wales) do not exempt 
pharmacoeconomic evidence on the sole grounds that a drug has orphan status or is 
indicated for HIV treatment.
Although both countries reported on consultation with stakeholders, it was not clear 
whether, and if so, how this influenced the decision making. Regarding the role of other 
appraisal criteria, in both countries, dossiers for three drugs (i.e., dasatinib, erlotinib, 
bortezomib) reported that the drug in question was indicated for a disease of (high) 
severity (i.e., cancer); all three received a ‘yes’ decision for reimbursement. Interestingly, 
while in three out of 11 cases (i.e., varenicline, inhaled insulin, sitagliptin) similar com-
parators were used, the therapeutic value judgement differed. All three drugs received 
a ‘yes’ decision in Sweden, whereas one (i.e., varenicline) received a ‘no’ decision in The 
Netherlands. Regarding varenicline, other arguments that may have played a role are 
‘life-style’, ‘own responsibility’, and/or budgetary impact. In all these ‘yes’ decisions, re-
imbursement was restricted to a subgroup of patients and/or was made conditional on 
additional data collection. This may indicate that both countries were uncertain about 
the drug’s actual value, or that, in The Netherlands, budgetary impact was a concern. It 
should be noted that the published dossiers did not reveal whether, and if so, how these 
or other arguments were decisive in the decision-making process.
Furthermore, two of the four different decisions (i.e., rimonabant and varenicline) 
concerned drugs for which life-style arguments may have played a role in the decision-
making. If the Dutch agency’s restrictiveness was due to such arguments, that may 
have reflected their ‘necessity to insure’ criterion (i.e., whether the illness or the care 
needed justifies solidarity). Other possible explanations are that the Swedish agency, 
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on the grounds of value-based pricing, considered the drugs to be cost effective, or 
that considerations of budgetary impact led to the ‘no’ decision in The Netherlands. 
Budgetary impact may also have played a role in the Dutch agency’s decision to place a 
BMI restriction on a third drug, exenatide. It is important to realise that, for rimonabant 
and varenicline, the decision-making context differed: comparator drugs with the same 
indications were reimbursed in Sweden and not in The Netherlands. The reimbursement 
decision may have differed because agencies chose to be consistent with previous deci-
sions.
Finally, the Swedish value-based pricing system may provide pharmaceutical companies 
with a better incentive for appropriate price setting than the Dutch system, in which 
prices are determined independently of reimbursement decisions.
Conclusion
Both The Netherlands and Sweden publish information relating to their decisions on 
drug reimbursement. Their assessment processes are reasonably transparent: both 
report –albeit in varying detail– information on underlying studies, therapeutic value 
and cost-effectiveness. However, both could improve transparency of the appraisal. 
Therapeutic value appears to be the most decisive criterion; the relative importance of 
full economic evaluations is more modest than would generally be expected, especially 
in The Netherlands. The actual role of other (societal) criteria is more or less implicit and 
thus not sufficiently transparent. Therefore, both countries could improve legitimacy of 
their decision-making process by more explicitly showing the actual role of each differ-
ent (societal) criterion in the appraisal process.
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Abstract
Health technology assessment already informed Dutch policymaking in the early 1980s. 
Evidence of health economic evaluations is, however, only systematically used in drug 
reimbursement decision making. Outpatient drugs with an added therapeutic value 
and expensive specialist drugs require evidence from an economic evaluation. Due to 
many exemptions, however, the availability of evidence of health economic evaluations 
remains rather low.
The Dutch reimbursement agency suggested a cost-effectiveness threshold range 
depending on the severity of the disease (i.e., €10,000–80,000 per Quality Adjusted Life 
Year), but it was never confirmed nor endorsed by the Ministry of Health. It is highly 
questionable whether health economic evaluations currently play a role in actual Dutch 
reimbursement decision making.
Although the requirements exist in policy procedures, recent cases show that Dutch 
policymakers experience great difficulties in putting restrictions on reimbursement 
based on evidence from health economic evaluations. The near future will show whether 
the need increases to base decisions on societal value for money, and whether Dutch 
policymakers show the courage to take health economic evaluations seriously.
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Introduction
Health Technology Assessment (HTA) became a policy tool in The Netherlands in the 
early 1980s.171 Although the contrary is often held to be true,172 we believe, however, that 
the role and impact of evidence from a health economic evaluation (HEE) still remains 
limited in actual health care decision making. To arrive to this conclusion, this article 
firstly describes the Dutch reimbursement system and the applied priority setting prin-
ciples. Since HEEs are mainly used in drug reimbursement decision making, we focus on 
the drug reimbursement process, the applied criteria and the requirements regarding 
HEEs. After that, we assess HEE evidence regarding its availability and quality. Finally, we 
evaluate the impact of HEE in actual decision-making practice.
Health care reimbursement and priority setting in The Netherlands
The Dutch health care system is based on a social health insurance system, funded by 
public and private sources. Since 2006, all residents are obliged to enrol to universal 
basic health insurance which is provided by competing health insurers. Adults pay a flat 
rate premium, a subsidy scheme relieves financial burden for lower incomes. Supple-
mentary health insurance is privately offered on a voluntary basis. The Health Insurance 
Act (Zorgverzekeringswet, Art. 63–66), Health Insurance Ordinance (Besluit Zorgverzeker-
ing, Art. 2.8) and the Health Insurance Decree (Regeling Zorgverzekering) establish the 
legal basis of the reimbursement system.
Since the early 1980s, Health Technology Assessment (HTA) became a policy tool in The 
Netherlands, mainly due to the increasing numbers of new expensive technologies.171 
HTA-studies already informed policy making in the 1980s, for example on liver and heart 
transplantation, and screening for breast cancer.173,174 In 1991, the Dutch Committee on 
Choices in Health Care explicated HTA as a priority setting tool by suggesting a funnel, 
the funnel of Dunning, to determine the basic benefit package. The Dunning funnel has 
four decision criteria: the technology should be necessary, effective, cost effective, and 
affordable (i.e., individuals cannot bear the responsibility for the actual costs).175 Ever 
since, the Dutch government continued to express the potential importance of the role 
of HTA in reimbursement decision making.
The Health Care Insurance Board (College voor Zorgverzekeringen; CVZ; from April 2014 
Zorginstituut Nederland), an independent government funded agency, has the respon-
sibility to advise the minister of Health care, Welfare and Sports regarding the entitle-
ments of the basic benefit package. It is CVZ’s mission to “safeguard and develop the 
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public preconditions for the health care insurance system, so that Dutch citizens can obtain 
their right to health care.”176 To ensure this mission, CVZ’s guiding principles regarding the 
entitlements of the basic benefit package are: quality, accessibility and affordability.177 
As inspired by the Dunning funnel, CVZ uses four priority setting principles, namely 
necessity, effectiveness, cost-effectiveness, and feasibility.177
Consequently, cost-effectiveness is one of the four formal priority setting principles for 
the basic benefit package. This criterion is, however, not systematically used across the 
entire benefit package, but mainly used for decision making concerning drugs. Regard-
ing non-pharmaceuticals, only in a few cases considerations of cost-effectiveness may 
have been taken into account (e.g., smoking cessation programs, and severe dyslexia in 
children).178 Therefore, the next part of the article will only focus on decision making for 
drugs.
Drug reimbursement and health economic evidence requirements
The aim of the Dutch drug reimbursement system is to guarantee safe and efficient phar-
maceutical care according to individual patient’s need in concurrence with scientific stan-
dards.179 The CVZ has the legal responsibility to advise the minister whether or not a drug 
should be included in the basic benefit package and thus funded from public sources.
Briefly, the reimbursement procedure is as follows (see Figure 7.1). The applicant sub-
mits a reimbursement request. Based on the application file, CVZ’s secretariat prepares 
an assessment report. This report is then, at least once, evaluated by the Scientific 
Pharmaceutical Advisory Commission (Wetenschappelijke Adviesraad Commissie Genees-
middelen, WAR-CG; formerly Commissie Farmaceutische Hulp, CFH). Members of the 
WAR-CG have expertise in various medical disciplines, pharmacology, health sciences, 
and (health) economics; two representatives of the ministry attend WAR-CG meetings 
as observers. During this procedure, CVZ sends preliminary reports to the manufacturer 
and relevant stakeholders such as physicians, physician associations, patient associa-
tions, health care insurers, and hospital associations. Stakeholders have maximally two 
weeks to put forward their comments. Reimbursement files may, in case of perceived 
societal aspects, also be evaluated by the Appraisal Committee (Adviescommissie pakket, 
ACP), but this seldom occurred since the committee’s establishment in 2008. Besides 
three CVZ directors, the ACP consists of experts in social security, health care, health 
insurance, medical ethics, HTA, and one patient representative. Finally, CVZ’s Board of 
Directors forwards the reimbursement advice to the minister of health, who makes the 
final decision.
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The CVZ applies, without a formal hierarchy, the following assessment and appraisal 
criteria: medical need, (added) therapeutic value (including effectiveness and adverse 
effects), cost-effectiveness, feasibility, necessity to insure, budget impact, disease sever-
ity, rarity of the disease, own responsibility, accessibility, social affordability, and public 
health benefit.120 The reimbursement pathway and the requirements differ for outpatient 
and (expensive) specialist drugs (before 2013 called expensive inpatient drugs). Outpa-
 Applicant submits reimbursement request to the Minister of Health 
Outpatient drugs (Expensive) Specialist drugs 
Therapeutic 
equivalent (List 1A) 
Therapeutic  added 
value (List 1B) 
 Pharmacotherapeutic 
evidence 
 Pharmacotherapeutic 
evidence 
 Pharmacoeconomic 
evidence 
 Pharmacotherapeutic evidence 
 Pharmacoeconomic evidence 
 Cost prognosis 
 Study plan for outcomes research 
Secretariat Health Care Insurance Board (CVZ): prepares reimbursement report 
Applicant submits reimbursem nt request to the Minist r 
Scientific Pharmaceutical Advisory Committee (WAR-CG): deliberation on draft report 
Consultation of stakeholders 
Secretariat CVZ: adjustment of the reimbursement report 
WAR-CG: consensus final reimbursement report 
Board of Directors CVZ: final reimbursement advice 
Appraisal committee (ACP): advice from societal perspective 
Minister: final reimbursement decision 
Outpatient drugs: reimbursement yes/no Specialist drugs: conditional funding yes/no 
(4 years) 
Figure 7.1 Flowchart of the drug reimbursement procedure in The Netherlands
118 Chapter 7
tient drugs either belong to List 1A (i.e., groups of therapeutically interchangeable drugs 
for which the reimbursed price is based on the average price of the group) or List 1B (i.e., 
drugs with added therapeutic value for which the reimbursed price is not subject to 
a referenced limit). Besides evidence on pharmacotherapeutic value, only applications 
for List 1B require pharmacoeconomic evidence. Specialist drugs (i.e., provided through 
hospitals and an estimated budgetary impact ≥ €2.5 million180) fall under a conditional 
funding policy if uncertainty exists about cost-effectiveness and appropriate use in 
everyday clinical practice; initial applications require, besides pharmacotherapeutic and 
pharmacoeconomic evidence, a cost prognosis, and a study plan for outcomes research. 
After four years of temporary funding, a reassessment is performed based on additional 
collected data. Since 2012, several groups of expensive outpatient drugs (e.g., TNF alpha 
blockers) have been transferred to the specialist drug list. The ministry expects that 
(groups of ) hospitals can successfully negotiate for lower prices of these drugs, and that 
these drugs will be used appropriately if prescribed by medical specialists.
Information on cost-effectiveness through a HEE is thus only required for applications 
for List 1B and specialist drugs, and, for the latter, reassessments after four years. Since 
2002, CVZ encouraged submitting HEE evidence for List 1B applications; in January 
2005, it became a mandatory requirement. Since the introduction of the coverage 
with evidence development policy in 2006, outcomes research including HEE evidence 
requirements became mandatory for specialist drugs.
Regarding outpatient drugs, the manufacturer is responsible for the application and 
thus for submitting HEE evidence. Although the manufacturer is not the applicant party 
for specialist drugs, the manufacturer is in most cases involved in the execution of HEEs. 
CVZ does not conduct its own HEE as in some other countries (e.g., the United Kingdom); 
they base their reimbursement advice on the submitted evidence in combination with 
other available information. The manufacturer is free to conduct their own HEE, or can 
outsource this to, for example, a HTA organisation or consultancy firm.
Table 7.1 provides an overview of the Dutch method guidelines for pharmacoeconomic 
research.181 For more detailed information on the Dutch system, we refer to Franken et 
al.103 and Le Polain et al.15
The availability of health economic evidence
The Dutch system seems straightforward; namely, an internal price referencing system 
determines the reimbursed price in case a drug is therapeutically comparable to other 
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drugs (List 1A), and HEE evidence is considered in case a drug has added therapeutic 
value (List 1B). In practice, however, manufacturers are often exempted from submitting 
pharmacoeconomic evidence. Formal regulations exempt drugs with an orphan sta-
tus,182 drugs with an estimated budgetary impact lower than €500,000 per year,182 and 
HIV drugs.19 As a consequence, between January 2005 and July 2011, 65% of List 1B ap-
plications were exempted from conducting a HEE;147 HEE evidence was only available for 
35% of List 1B applications. The available HEE evidence consisted of cost-minimisation 
analyses (n = 5), cost-effectiveness analyses (i.e., costs per life-year gained; n = 19), and 
cost-utility analyses (i.e., costs per QALY; n = 20).147 Moreover, 55% of the published 
dossiers included a description of a cost-effectiveness plane and/or an acceptability 
curve.147 Regarding specialist drugs, so far, many initial applications do not include HEE 
Table 7.1 Dutch guidelines for pharmacoeconomic research a
Guideline item Explanation of the requirements for pharmacoeconomic research
Study perspective The economic evaluation should be conducted using a societal perspective.
Comparator The drug should be compared to the standard treatment for the indication in 
question, or, if not possible, compared to usual care. The comparator treatment can 
be a pharmaceutical as well as a non-pharmaceutical.
Analysis technique The following techniques should be used in case of added therapeutic value:
• Improvement of quality of life: a cost-utility analysis
• No improvement of quality of life: a cost-effectiveness analysis
And in case of similar therapeutic value:
• Cost-minimisation analysis
Time horizon A time horizon is sufficient when it enables a valid and reliable judgement of the 
effects and costs (modelling techniques can be used).
Costing methods All (direct, indirect, medical, and non-medical) costs should be included; volume 
and unit costs need to be transparent.
Quality of life methods Quality Adjusted Life Years should be transparently reported using survival data 
and utilities (by means of patient reported outcomes EQ-5D, HUI, or by direct utility 
valuation techniques such as TTO, SG, VAS).
Modelling techniques The pharmacoeconomic model should be transparently reported (including model 
structure, input parameters, assumptions etc.), and preferably based on peer 
reviewed public publications.
Incremental methods Incremental differences in effects and costs should be separately reported in detail.
Discounting Costs should be discounted at a 4% rate, and effects at a 1.5% rate.
Sensitivity analysis Sensitivity analysis should be conducted using deterministic, probabilistic, and 
scenario analysis.
Expert panels In case of lack of input parameters, expert panels can be used. A detailed 
description should be provided regarding the composition of the expert panel and 
how consensus was reached.
a Based on Dutch guidelines for pharmacoeconomic research181
EQ-5D= EuroQol 5 Dimensions; HUI= Health Utility Index; TTO= Time Trade-Off; SG= Standard Gamble; VAS= Visual 
Analogue Scale
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evidence. Consequently, HEE evidence is often only available for the reassessment after 
four years of conditional funding.
Furthermore, even if available, the methodological quality of the performed HEEs is 
often insufficient. Hoomans et al.169 reported that, between January 2005 and October 
2008, only eight out of twenty-one HEEs were consistent with CVZ’s guidelines. Franken 
et al.,147 however, reported that most of CVZ’s unfavourable judgements on the robust-
ness of the HEE evidence for List 1B applications occurred in the earlier years of the HEE 
requirement (i.e., 2005 to 2007).
The impact of health economic evidence in actual decision making
Above all, it should be noted that CVZ only advises the minister regarding the robust-
ness of the pharmacoeconomic evidence, thus CVZ does not advise on the actual 
cost-effectiveness estimate. In The Netherlands, there is no formal threshold value for 
the incremental cost-effectiveness ratio. Although CVZ suggested a threshold range 
depending on the severity of the disease (i.e., €10,000–80,000 per QALY); CVZ also 
stated that this range is only indicative and not predictive because their advice is always 
based on a balance of different considerations.120 One could consider that the ACP (i.e., 
CVZ’s committee that evaluates the entitlements of the benefit package from a broader 
societal perspective) is responsible for advising regarding cost-effectiveness. How-
ever, members of the ACP have indicated that the actual implementation of the cost-
effectiveness criterion requires further exploration.178 Importantly, the Dutch minister 
has never confirmed nor endorsed a cost-effectiveness threshold (range). An important 
step forward, however, may be that, in 2012, the two governing political parties formally 
stated their intention to give the cost-effectiveness criterion a statutory basis.183 So far, 
no changes have been made in official documents.
Regarding outpatient drugs with HEE evidence, Franken et al.147 found that, for all List 
1B applications that were rejected for reimbursement between January 2005 and July 
2011, the HEE evidence had been judged insufficiently robust. Of these twelve drugs, 
five were considered to have an added therapeutic value. Although unknown, HEE 
evidence can have played a role in these decisions to reject reimbursement. Interest-
ingly, however, the HEE evidence of 21% of drugs that obtained reimbursement was 
also judged insufficiently robust.147 Of these four drugs, two were considered to be of 
similar therapeutic value and two of added therapeutic value. It is highly questionable 
if HEE evidence played a role in these decisions to grant reimbursement. Most decisions 
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that were granted reimbursement concerned drugs with an added therapeutic value 
judgement (15 out of 19).147
The picture of the impact of HEE evidence in actual decision making becomes more 
complete when scrutinising decisions regarding specialist drugs. Since 2006, outcomes 
research including HEE evidence became mandatory in the coverage with evidence de-
velopment policy. Initially, reassessments were scheduled after three years of temporary 
funding. Within a short time period, this was revised to four years due to expected fea-
sibility issues. Consequently, one could expect that from 2010 onwards reassessments 
would take place on a regular basis.
However, only a few reassessments have been finalised; most reassessments, even from 
initial assessments in the years 2006, 2007 and 2008, are still queued up at CVZ. Remark-
able, until a reassessment is finalised, funding from public sources continues for these 
expensive drugs. It seems that Dutch policymakers experience serious difficulties in en-
forcing the consequences of reassessments. Even after a time period for data collection 
in everyday practice, decision makers seemed to be embarrassed by the lack of sufficient 
evidence for the first reassessments. This, however, did not result in delisting of drugs.
In 2012, CVZ concluded that omalizumab for severe asthma had an added therapeutic 
value compared to other available treatment, but it remained highly uncertain at what 
costs (i.e., cost-effectiveness uncertainty range: €36,000 to 87,000 per QALY gained).184 
The minister followed CVZ’s advice and arranged a pay-for-performance agreement.184 It 
is to be evaluated in the near future whether this agreement contributes to cost effective 
usage of this drug. Experiences from other countries, however, show mixed results.185,186 
For expensive specialist drugs, CVZ currently often advises to set up public-private 
financed patient registries to lower uncertainty on the (cost) effectiveness in everyday 
practice. The minister even made reimbursement conditional on the set up of such a 
registry for an expensive treatment for melanoma.187
Furthermore in 2012, reassessments of three specialist orphan drugs for Pompe and 
Fabry disease resulted in a turbulent episode. Preliminary draft reports were leaked to 
the press. CVZ considered a negative advice for these drugs because they were con-
sidered too expensive relatively to their effectiveness (e.g., Myozyme for classic Pompe 
disease was estimated to cost 300,000 to 900,000 € per QALY188). The opinions of the 
ACP members were divided in a very well attended public ACP meeting. One absent 
ACP member put forward his point of view in writing by questioning the sustainability 
of reimbursing such expensive drugs in the long term and questioning the fairness of 
disproportionately prioritising orphan diseases.189 After a considerable amount of public 
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debate and political pressure, CVZ modified its advice, recommending continuation of 
funding because of the high severity of the disease in combination with high costs per 
patient but a relatively low budgetary impact.188 Remarkably, CVZ did not have any new 
scientific HTA evidence. It appears, therefore, that CVZ modified its advice only based on 
an undecided ACP advice and public and political influence. The minister accepted CVZ’s 
advice and made, in 2013, a (confidential) price agreement with the manufacturer.190 It is, 
however, debatable whether HEE evidence influenced the price agreement. Due to the 
extreme high costs per QALY, it must have been impossible agreeing on a price which 
ensures societal value for money. Consequently, the Dutch society continues paying an 
extreme high price for an uncertain and probably limited health gain. Because more 
expensive (ultra) orphan drugs are to be expected in the near future, it is debatable if 
such decisions are sustainable in the long term.
Consequently, the only conclusion that we can draw is that, so far, HEE evidence does 
not play a major role in actual Dutch decision making. Although HEE requirements are 
implemented in reimbursement policy procedures and the technical quality of HEE has 
increased, it seems that policymakers experience great difficulties putting restrictions 
on reimbursement based on value for money considerations. It is of course easier for 
policymakers to make ‘happy’ decisions that satisfy all stakeholders and do not attract 
any media attention.
Because a formal cost-effectiveness threshold (range) is absent, it cannot be expected 
that the CVZ, only having an advisory role, takes the lead in determining the Dutch 
threshold and advices the minister accordingly, for which they will get blamed for by 
society and subsequently overruled by the minister. A threshold range for society’s 
willingness to pay for a QALY gained, potentially with orphan drugs at the upper range, 
could also act as a gatekeeper for conditional funding. If an expensive drug costs, for ex-
ample, more than 100,000 euro per patient per year, it will, even in case of optimistically 
estimated health gains, inevitably fail to meet the maximum of any realistic threshold 
range. Policymakers could make better use of this knowledge at the initial decision and 
thus deny conditional funding for a too high priced drug in the first place. Moreover, 
being more stringent at the initial decision may limit the impression that access to that 
drug is an acquired right. It should be noted that CVZ does not decide on pricing, and 
has, therefore, no capacity for negotiations on the price. An alternative approach such 
as value based pricing is therefore not possible for CVZ; only the minister can arrange, 
since recently, a price agreement.
Besides a threshold range, other criteria may complement sustainable decision making. 
Importantly for example, the Dutch Commission for the Assessment of Oncological Re-
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sources (Commission BOM) suggested a minimal gain of 2 months in life expectancy.191 
This links closely to pleas for only reimbursing interventions that produce at least a 
non-negligible health gain.154
Reimbursement decision making involves balancing different goals, namely access to 
high quality products in a sustainable manner. The perceived need to make ‘unhappy’ 
decisions, especially related to identifiable victims,118 may not be very high in The 
Netherlands because pharmaceutical expenditures as percentage of total health care 
expenditure remained relatively stable over the previous years, mainly as result of other 
policies (e.g., tendering policy by health insurers). However, it is questionable if this is 
sustainable in the long-term. There is no incentive to appropriately price drugs accord-
ing to their actual value; will there be any limit for prices and cost-effectiveness in the 
future? Moreover, if evidence from HEEs is hardly considered in decision making, the 
question may arise why HEE evidence requirements exist in the first place. Until now, it 
seems that access to (potentially) effective drugs is most important in decision making, 
no matter at what costs. Besides actual using HEE evidence in decision making, explicat-
ing a minimal health gain and a cost-effectiveness threshold (range) may be two of the 
most difficult political aspects. It is debatable, however, what the value is of a statutory 
basis of the cost-effectiveness criterion if not applied in actual decision making. The 
near future will show whether the need increases to base actual decision making on 
societal value for money, and whether Dutch policymakers show the courage to take 
HEE seriously.

C
Handling uncertainty in drug 
reimbursement decision making

8 
Access to expensive cancer drugs in Dutch 
daily practice: Should we be concerned?
With Hedwig Blommestein, Silvia Verelst, Michel van Agthoven, Peter Huijgens, 
Carin Uyl-de Groot
The Netherlands Journal of Medicine 2014; 72(4):235-241
128 Chapter 8
Abstract
The aim of this study was to investigate whether equal access to bortezomib has been 
achieved under Dutch policy regulations that guarantee equal access to expensive 
inpatient drugs.
We investigated accessibility to bortezomib treatment at national and regional levels by 
(i) conducting interviews with stakeholders in the Dutch health care system to explore 
prescription barriers and (ii) tabulating sales data from 2004–2009 and trial participation 
rates.
Interviews revealed awareness of the high treatment costs although prescription bar-
riers were not encountered. National use of bortezomib increased slowly (treating 2% 
of patients in 2004 to 17% in 2009), indicating a long adjustment period. Furthermore, 
use remains below the rate estimated by the professional association of haematologists 
(27%). Regional differences were found for both daily practice use (e.g., ranging from 
13–27% in 2009) and clinical trial participation (e.g., ranging from 1–12% in 2006).
Our results were somewhat conflicting: interviews did not reveal any prescription bar-
riers, but quantitative methods showed regional differences, signs of underutilisation, 
and access inequality. Investigating use and accessibility, based on data triangulation, 
provides valuable feedback which can enhance evidence-based decision making for 
both physicians and policymakers. This could improve appropriate and efficient use and 
ensure equal access to expensive drugs.
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Introduction
Increasing health care expenditures may result in limited and unequal access, par-
ticularly with regard to new and innovative cancer drugs with high acquisition costs. 
Policymakers have to make reimbursement decisions considering both rapid and equal 
accessibility to promising drugs as well as the scarcity of resources. Usually, guarantee-
ing rapid access means making decisions while available evidence on clinical and cost-
effectiveness is limited.26 One way of dealing with the need for rapid access and limited 
evidence is the ‘coverage with evidence development’ policy; reimbursement under the 
condition that additional research will be conducted.26
Such policies have been implemented in several countries for surgical procedures, 
medical devices and pharmaceuticals.31 Over the last decade, a coverage with evidence 
development policy was also initiated in The Netherlands, partly triggered by signs of 
underutilisation and ‘zip code prescribing’ of trastuzumab.192 Early access to expensive 
inpatient drugs is linked with the obligation to gather data on appropriate drug use and 
cost-effectiveness in daily practice.193 Drugs meeting the criteria of added therapeutic 
value and expected budget impact of at least 2.5 million were temporarily included 
in the policy of 2006–2012. Four years after inclusion, a reassessment will determine 
whether or not additional financing should continue to exist. At the time we conducted 
our study, hospitals received 80% of its acquisition costs if a drug was included.
Currently more than 30, mostly cancer, drugs are included in this policy. One of these 
drugs is bortezomib, used for treating multiple myeloma (MM). MM is the second most 
common haematological cancer. The five-year prevalence in Western Europe is 31,056 
while the annual age-standardised incidence rate is 3.2 per 100,000 (IARC GLOBOCAN 
2008). Bortezomib obtained EMA approval in 2004 by demonstrating superior efficacy 
compared with chemotherapy for the treatment of advanced MM;194-196 it was included 
on the Dutch expensive drug list in 2006. Advances in MM treatment in the past decade 
significantly increased overall survival (44.8 vs. 29.9 months197), which was largely due to 
the introduction of autologous stem cell transplantation and new therapeutic agents in-
cluding thalidomide, lenalidomide, and bortezomib.197,198 While thalidomide is relatively 
inexpensive, bortezomib and lenalidomide are expensive drugs. Both are incorporated 
in professional guidelines.199 However, the orphan status granted to lenalidomide results 
in 100% reimbursement for lenalidomide compared with an 80% of reimbursement for 
bortezomib during our study period. Consequently, accessibility might be an issue, 
especially for bortezomib.
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Previous research studied accessibility and use of expensive drugs in The Nether-
lands;200,201 however, it remains unclear whether the Dutch policy actually guarantees 
equal access to expensive inpatient drugs. We investigated whether equal access to 
bortezomib has been achieved in The Netherlands. We analysed bortezomib use pat-
terns by means of aggregate sales data and conducted interviews to shed light on 
perceived or real prescription barriers.
Methods
We took a two-pronged approach. First, seven in-depth interviews were conducted to 
qualitatively investigate the existence of accessibility issues and prescription barriers. 
Interviewees were representatives of stakeholders in the Dutch health care system: (i) 
a representative of the Dutch Health Care Authority (NZa), (ii) a representative of the 
Health Care Inspectorate (IGZ), (iii) a hospital director of finance, (iv) four haematologists 
from hospitals varying in size and country location (the North-West, East, South-West, 
and South). Respondents were selected based on their involvement and knowledge of 
expensive inpatient drug regulations (NZa and IGZ) or geographical location and type 
of hospital (haematologists and director of finance). All semi-structured interviews were 
recorded and analysed according to the steps of Creswell,202 including transcription, 
coding, interpretation, and description.
Second, we quantitatively investigated the use of bortezomib in daily practice. Because 
data on bortezomib use at the individual patient level are not available, we combined 
Dutch sales data (excluding use in clinical trials) from 2004–2009 from the manufacturer, 
Janssen Pharmaceutical Companies of Johnson & Johnson with incidence and preva-
lence data from The Netherlands Cancer Registry.203 Figure 8.1 provides the flowchart of 
data used, intermediate and final outcomes and the underlying assumptions.
To estimate the number of treated patients ([A] in Figure 8.1), the number of vials sold 
was divided by the average number of vials used per patient. The average number of 
vials per patient (18.24) was based on a Dutch observational study of 72 bortezomib 
patients treated in daily practice from 2004–2008.204
To investigate bortezomib use across regions, we used the regional division of the 
nationwide Netherlands Cancer Registry distinguishing eight Comprehensive Cancer 
Centres.203 Since these regions differ in size, prescription rates were expressed relative to 
the number of patients per region. We assumed that equal accessibility to bortezomib 
would be achieved if the proportion of vials used per region was similar to their propor-
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tion of national incidence or prevalence. Regional shares in incidence were calculated 
over the years 1989–2009. For example, the share in incidence in 2009 for Comprehensive 
Cancer Centre Amsterdam (IKA) was 18.8%. We calculated this percentage by dividing 
the incidence of IKA (201) by the national incidence (1069).
Because prevalence numbers were only available for IKA (462 patients in 2004) for one 
year, we estimated other regional prevalence (B) from their relative shares in incidence. 
Hereby we assumed (i) IKA to be representative for the other regions and (ii) the share 
in incidence per region is equal to the share in prevalence (e.g., if IKA has 19% of the 
incidence it will also have 19% of the prevalence), and (iii) an annually increasing preva-
lence of 2.5% (average annual increase over the years 1989–2009203) per year because 
of rises in incidence.198 Detailed additional information about incidence and prevalence 
estimates per year is available from the authors upon request.
To obtain a regionally comparable percentage of treated patients (C), we divided the 
estimated number of treated patients (A) by the estimated prevalence (B). To put re-
gional percentages in perspective, we compared our computed use with the expected 
percentage of MM patients eligible for bortezomib treatment as estimated by the Dutch 
professional association of haematologists (the Dutch-Belgian Cooperative Trial Group 
for Haematology and Oncology [HOVON]). HOVON estimated that about 1600 patients 
would be eligible for MM treatment per year. Of these patients, one-third would not 
qualify for treatment with either bortezomib or lenalidomide due to age, patient’s 
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multiple myeloma 
patients per region per 
year 2004-2009
Incidence data 
(per region and national 
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Figure 8.1 Flowchart of data input, intermediate and final outcomes
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condition or preferences. As result, 1070 patients are eligible for advanced therapy each 
year.205 Since patients treated with bortezomib might also be eligible for treatment with 
lenalidomide and vice versa, HOVON assumed that the number of patients treated with 
each drug would be similar (50%). To compare the HOVON estimation with the propor-
tion of patients treated with bortezomib per region, we divided the 535 eligible patients 
(i.e., 1070 divided by 2) by HOVON’s estimated prevalence (i.e., 2000 patients), resulting 
in an estimation of 27% patients.
Furthermore, since bortezomib was a novel treatment, clinical trials were conducted 
during our years of investigation. Because MM patients are often included in clinical 
trials, relatively high or low trial participation could distort our computed daily practice 
use and identified regional differences. Therefore, we selected the two largest clinical 
studies including bortezomib during our investigated time period and studied trial 
participation at the regional level. Calculation methods were similar: we divided the 
number of patients included in trials by regional prevalence to obtain regional trial 
participation rates for the years 2005–2009. We then combined trial participation with 
regional daily practice use to compare similarities and differences across regions.
Results
Interview results
Interviewees of the NZA and IGZ did not reveal any accessibility issues for expensive 
drugs. The IGZ representative, however, admitted that the body had no active role in 
investigating such issues.
Hospitals regulate financial management in various ways. As a result, it may differ 
per hospital who is responsible for the budget and who is making the financial deci-
sions. According to the interviewed physicians, their financial department divided the 
total hospital budget by department, whereas physicians organised the division and 
implementation of the budget within departments. These assumptions were verified 
and confirmed by the hospital financial manager. Based on these results, we concluded 
that in the studied hospitals financial management, of both treatment decisions and 
organisation of care, was the physicians’ responsibility.
Generally, all physicians agreed that access to bortezomib is guaranteed in The Nether-
lands for patients in need. The existence of strict quantitative restrictions was explicitly 
denied. Physicians adhered to professional guidelines as far as treatment is concerned, 
which were frequently mentioned as important. Consultation with colleagues and 
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patient characteristics also seemed to be important factors in the decision (how) to 
treat. Apart from some variation immediately after the introduction of bortezomib, 
respondents believed that all eligible patients had equal access.
The Dutch policy of 2006–2012 aimed to facilitate prescription and guarantee access 
while maintaining incentive for efficiency. According to haematologists, the effects of 
this policy were two-sided. An additional budget of 80% facilitated prescription but the 
remaining 20%, financed from the general hospital budget, could hinder prescription. 
The policy was therefore perceived as ambiguous: while the government relieved the 
high financial burden, the remainder still had to be financed from the general hospital 
budget. The situation stimulated local initiatives to manage access to expensive drugs, 
resulting in a local expensive drug committee to judge appropriate use and structures 
for consultations with more experienced physicians. Although expensive drugs were 
perceived as a high financial burden, according to the respondents, budget played no 
role in treatment choices.
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Figure 8.2 Percentage of multiple myeloma patients treated in daily practice with bortezomib per region 
from 2004-2009
IKA: Comprehensive Cancer Centre Amsterdam
IKL: Comprehensive Cancer Centre Limburg
IKMN: Comprehensive Cancer Centre Netherlands Central
IKNO: Comprehensive Cancer Centre North East
IKO: Comprehensive Cancer Centre East
IKR: Comprehensive Cancer Centre Rotterdam
IKW: Comprehensive Cancer Centre West
IKZ: Comprehensive Cancer Centre South
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Data results
Daily practice use
Figure 8.2 shows the percentage of patients treated with bortezomib from 2004–2009 ir-
respective of treatment line. As mentioned in the method section, HOVON estimated 27% 
of MM patients are eligible for bortezomib treatment in daily practice. This is presented 
as a horizontal line in Figure 8.2. The figure reveals relatively low use in 2004–2005 for all 
regions, which was expected since bortezomib was then an innovative treatment and 
not included on the expensive drug list until 2006. Three regions did not use bortezomib 
in 2004; all regions used it in 2005. Differences across regions exist in all years with no 
stable pattern; sometimes regions switched from a high prescription rank in 2005 and 
2006 to a low one in 2008. In 2008, two years after inclusion on the expensive drug 
list, differences between the regions decreased. In 2009, Comprehensive Cancer Centre 
East (IKO) was the highest prescribing region and Comprehensive Cancer Centre South 
(IKZ) the lowest, revealing that in one region 24% of patients received bortezomib while 
in another only 13% received bortezomib. In all the regions the prescription rate was 
below the 27% of eligible patients as estimated by HOVON.
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Figure 8.3 Percentage of multiple myeloma patients treated in clinical trials (HOVON 65 and HOVON 86) 
per region from 2005-2009
IKA: Comprehensive Cancer Centre Amsterdam
IKL: Comprehensive Cancer Centre Limburg
IKMN: Comprehensive Cancer Centre Netherlands Central
IKNO: Comprehensive Cancer Centre North East
IKO: Comprehensive Cancer Centre East
IKR: Comprehensive Cancer Centre Rotterdam
IKW: Comprehensive Cancer Centre West
IKZ: Comprehensive Cancer Centre South
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Use in trials
Figure 8.3 shows the participation in the HOVON 65206 (phase I/II study) and HOVON 
86207 study (Phase III randomised controlled trial) per region in the 2005–2009 period. 
We observed different trial participation rates and, as Figure 8.3 illustrates, trial partici-
pation increased from 2005–2007, and decreased in 2008 to almost no participation in 
2009. A comparison of Figure 8.2 and Figure 8.3 reveals that the percentage of patients 
treated in trials is lower than daily practice use of bortezomib.
Finally, Figure 8.4 presents the regional percentages of treated patients aggregated over 
the years 2005–2009. Comprehensive Cancer Centre Netherlands Central (IKMN) had the 
highest daily practice use and trial use (19% were either treated with bortezomib or 
included in one of the larger trials); IKZ had the lowest (10%). Figure 8.4 also shows that 
although differences remain, the fluctuation reduced over time. In general, regions with 
above average daily practice use also had above average trial participation rates.
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Figure 8.4 Percentage of multiple myeloma patients treated in daily practice and clinical trials 2005-2009
IKA: Comprehensive Cancer Centre Amsterdam
IKL: Comprehensive Cancer Centre Limburg
IKMN: Comprehensive Cancer Centre Netherlands Central
IKNO: Comprehensive Cancer Centre North East
IKO: Comprehensive Cancer Centre East
IKR: Comprehensive Cancer Centre Rotterdam
IKW: Comprehensive Cancer Centre West
IKZ: Comprehensive Cancer Centre South
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Discussion
The aim of our study was to investigate whether bortezomib treatment conformed to 
policy regulations that were designed to guarantee equal access to expensive inpatient 
drugs in The Netherlands. Interviews revealed that physicians feel some financial pres-
sure but do not experience prescription barriers and believe that access to expensive 
cancer drugs is guaranteed. In addition, at that time there were no signs of accessibility 
issues among IGZ and NZa. Our results, however, also showed that (i) after the introduc-
tion of bortezomib, it took one to two years before the drug was prescribed regularly in 
all regions; (ii) the percentage of patients treated is below the expected 27% of eligible 
patients; and (iii) there are unexplained regional differences.
In order to investigate accessibility issues and compare regional use levels we had 
to make several assumptions, especially to calculate the percentage of MM patients 
treated with bortezomib. While the regions defined by the Dutch cancer registry vary 
in size, population and available hospital facilities, we expect the baseline patient 
characteristics to be comparable across regions. Since accurate prevalence numbers 
were unavailable, we assumed prevalence could be obtained from the distribution of 
incidence after verifying that the regional distribution of incidence was stable over a 
long period with a maximum deviation of only 3%. Some uncertainty surrounding total 
prevalence, however, remains.
Although these assumptions influence the percentage of patients treated, we believe 
our conclusion of low prescription rates will not be effected. Levels of use would only 
be closer to HOVON’s expected use of 27% if the prevalence of multiple myeloma was 
much lower (i.e., less than 1700 patients). Considering incidence is 1100 patients per 
year, prevalence of less than 1700 seems highly unlikely.
Nevertheless, the share in incidence per region was remarkably stable confirming a 
stable division between the regions over time. If prescription rates per region were simi-
lar, we expected the regions to be accountable for a similar share in bortezomib as their 
share in incidence. Therefore, regional variation was definitely established, although 
violations of our assumptions could enlarge or reduce the differences.
Observed regional variation, in both daily practice and trial use, indicates either differ-
ences in prescription behaviour or referral of patients to, for example, more experienced 
hospitals. Because we used sales data aggregated per hospital, we cannot distinguish 
between patients living in the region and patients referred to the region. Both causes 
–prescription behaviour and patient referral– limit accessibility. IKZ may have been 
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especially sensitive to regional border crossing because it is the only region without 
an academic hospital. In this region, use and trial participation is low while relatively 
high numbers are observed in its neighbouring region (i.e., IKMN). Bortezomib admin-
istration, however, does not require specialised skills or hospital facilities, implying that 
expertise may have been a valid reason for referral immediately after the introduction in 
2004, but should be of minor importance in subsequent years.
We studied treatment patterns at an aggregated level, hence neglected other treat-
ment options such as thalidomide and lenalidomide. Because thalidomide is relatively 
inexpensive in The Netherlands, accessibility should not be an issue. Lenalidomide 
was accepted for reimbursement at the end of 2007 in Dutch daily practice, creating a 
competitive alternative treatment option for the years 2008 and 2009 in our analyses. 
However, lenalidomide does not compensate the low levels of bortezomib prescription. 
In 2007, 75 patients were treated with lenalidomide and this number increased to 452 
and 671 in 2008 and 2009, respectively.205,208
Regional differences and under-provision have been previously reported in The Nether-
lands. Large regional differences and under provision of trastuzumab in The Netherlands 
were, according to the Dutch Breast Cancer Association,192 mainly due to cost. After the 
accessibility issues of trastuzumab, the Dutch policy for expensive drugs was revised 
in 2006. Although bortezomib has been on the market since 2004, it was not until it 
was admitted to the expensive drug list in 2006 that its use in daily practice doubled 
compared with the previous year. The increase might indicate that the implemented 
policy facilitated prescription. Other developments occurred simultaneously however, 
including changes in professional guidelines that recommended bortezomib in ear-
lier treatment phases. The relatively low use in the first years may have been caused 
by a long adjustment period of physicians who needed to be familiarised with a new 
drug.209,210 Bortezomib was, apart from the re-introduction of thalidomide, the first new 
innovative treatment option for multiple myeloma patients in four decades. It is impor-
tant that physicians and policymakers are aware of such lags in the regular use of a new 
innovative and effective drug. Their implementation should receive more attention to 
accelerate diffusion by, for example, providing feedback about daily practice use. Groot 
et al.200 showed that the use of bortezomib in 2005 was almost three times higher in 
Sweden and France compared with The Netherlands. Furthermore, Dutch use in 2007 
was a little less than 35 mg per 100,000 inhabitants while the European average (Austria, 
Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Spain, Swe-
den, Switzerland and the UK) was above 50 mg per 100,000 inhabitants.201 Our results 
also showed that use was below HOVON’s expected rate. Despite financial assistance, 
use and accessibility issues may thus still exist.
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It remains subject to further research whether observed regional differences are due to 
physician prescription behaviour or referral to more experienced or wealthier hospitals. 
Differences seem to have decreased compared with previous outcomes of the trastu-
zumab study in 2005, which might be a result of the changes in the policy regulations. 
However, we should note that the trastuzumab study analysed patients with breast 
cancer, whose prevalence is much higher than multiple myeloma.
Wagelaar et al.211 studied accessibility of two expensive drugs in The Netherlands, bort-
ezomib and trastuzumab, mainly by investigating whether prescription was in accor-
dance with guidelines at the individual patient level. Medical files were examined and 
interviews were conducted with physicians, members of hospital boards of directors, and 
patients. They concluded that guidelines were strictly followed and that recommenda-
tions by the professional association and patient characteristics determined treatment 
decisions. Although the budget of 80% was insufficient according to their respondents, 
accessibility was not an issue. Interestingly, while their results align with our interview 
results, they are in contrast with our quantitative findings and our research shows that 
differences in accessibility might not be revealed by using a qualitative research method 
only.
In 2012, changes in the regulations increased the earmarked budget to full coverage 
of the ‘add-on’ diagnoses-related group (i.e., 100% reimbursement of expensive drugs 
but hospitals and insurers negotiate on the price of the ‘add-on’). Although hospital 
resources remain scarce, this might improve access and reduce remaining regional dif-
ferences. It will be interesting to closely follow the consequences of this new policy.
We investigated equality in access to bortezomib in the context of Dutch policy regula-
tions for expensive drugs. Use of bortezomib has increased over time although regional 
differences are still present. We obtained different conclusions using two methods. 
While interviews did not reveal absolute prescription barriers, regional differences and 
possibly underutilisation were observed by comparing sales data with incidence and 
prevalence data. It seems that appropriate drug use and thus also accessibility depends 
on various factors, regulatory and organisational characteristics of a health care system 
being two important ones. An evaluation of health policies should therefore be based 
on mixed methods and data triangulation. Such an evaluation provides insight and 
valuable feedback that can enhance evidence-based decision making for both health 
care providers and policymakers. This could improve appropriate drug use and ensure 
equal access to health care. In the end, efficient and equitable use of scarce resources 
increases society’s benefits from a health care system.
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Abstract
The aim of this study was to investigate the practical feasibility to develop evidence on 
drug use and cost-effectiveness in oncology practice.
Feasibility was examined using three Dutch case studies. Each case study investigated 
the degree of appropriate drug use and its incremental cost-effectiveness. Detailed data 
were retrospectively collected from hospital records. In total, 391, 316 and 139 patients 
with stage III colon cancer, metastatic colorectal cancer and multiple myeloma were 
included in 19, 29, and 42 hospitals, respectively.
The methods used in the case studies were feasible to develop evidence on some 
aspects of drug use including types of treatments used, dosages, dose modifications, 
and health care costs. Aspects such as baseline patient characteristics, reasons to start 
or stop a treatment, and treatment effects were less feasible because of missing values. 
Despite difficulties to correct for confounding by indication, it was possible to estimate 
incremental cost-effectiveness by synthesising evidence in two of the three case studies.
It is possible to generate evidence about drug use and cost-effectiveness in oncology 
practice to facilitate informed decision making by both payers and physicians. This can 
improve quality of care and enhance the efficient allocation of resources. However, the 
optimal approach differs between drugs and their indications. Generating high-quality 
evidence requires active interdisciplinary collaboration. Patient registries can facilitate 
data collection but cannot resolve all issues. In most circumstances it is inevitable to use 
data-synthesis to obtain valid incremental cost-effectiveness estimates, but for some 
indications it will not be feasible to derive a valid and precise estimate.
Feasibility of outcomes research 143
Ch
ap
te
r 9
Introduction
The increasing number of expensive oncology drugs is making it extremely difficult to 
strike an optimal balance between ensuring timely access to ‘promising’ drugs and hav-
ing sufficient evidence of their comparative benefits and risks. In the last decade, gov-
ernments have therefore introduced policies linking reimbursement to a requirement 
for additional data collection.18,24-26 It has been claimed that the resulting ‘schemes’ or 
requirements, such as ‘patient access schemes’,27 ‘managed entry agreements’,28 ‘access/
coverage with evidence development’,29,30 comparative effectiveness research,212,213 or 
outcomes research,32,33,214 can result in better evidence by addressing uncertainty arising 
from the gap between clinical trials and everyday practice.
The initiatives to promote and implement such requirements have initiated a stream 
of literature, touting its potential as well as highlighting the myriad of methodological 
challenges to its feasibility.212,213,215-221 In particular, one of the major concerns raised has 
been the lack of a randomised controlled setting, which results in problems with internal 
validity.219,222-224 Moreover, other challenges have been debated such as the role of data 
synthesis and modelling,25,212,223,225 use of existing data sources,212,213,216,220,226 applicability 
of outcome measures,25,33 timeliness,26,227 and generalisability.228 However, these issues 
have mainly been discussed on the basis of theoretical expectations and expert opinion; 
studies of the practical feasibility are scarce.
Experience with conducting outcomes research has already been gained in The Neth-
erlands as a result of policy regulations for expensive inpatient drugs implemented in 
2006. If a drug is included in this policy, hospitals receive an additional ear-marked bud-
get of 80% of its acquisition costs.229 However, this early access is linked with the obliga-
tion to gather data on appropriate drug use and incremental cost-effectiveness.193,229 In 
practice, this means that after four years of use, a reassessment will determine whether 
or not additional financing will continue to exist.
This paper describes our experiences in The Netherlands regarding the practical fea-
sibility of different aspects of outcomes research in oncology. These experiences were 
based on three different outcomes research studies which examined the feasibility to 
gather evidence on appropriate drug use and estimate incremental cost-effectiveness 
of a particular drug.
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Methods
We conducted outcomes research of two expensive drugs for three indications in can-
cer: oxaliplatin as adjuvant treatment in stage III colon cancer, oxaliplatin as palliative 
treatment in metastatic colorectal cancer and bortezomib as palliative treatment in 
relapsed or refractory multiple myeloma. Each of the studies was used to investigate 
the feasibility to develop evidence on appropriate drug use and to estimate incremental 
cost-effectiveness. For appropriate drug use, we examined the feasibility to develop 
evidence in the following areas: types of treatments and regimes (‘treatments’), dosages 
and dose modifications (‘dosages’), baseline patient characteristics (‘patients’), reasons 
for choosing a particular treatment and starting or stopping treatment (‘reasons’), and 
treatment outcomes (‘effects’ and ‘costs’). To investigate the feasibility of data collection, 
we examined which data were available through existing databases and which data 
required retrieval from hospital records. For incremental cost-effectiveness, we investi-
gated the feasibility to obtain comparable patient groups, identify treatment compara-
tors, obtain information from literature, and estimate incremental cost-effectiveness. We 
explored issues with internal validity, data synthesis and modelling, outcome measures 
and generalisability.
Description of the case studies
In the two oxaliplatin studies, patients were identified using the population-based regis-
try of the Dutch Comprehensive Cancer Centres. This registry enabled the identification 
of all Dutch patients who received chemotherapy (2249 stage III colon cancer patients 
diagnosed in 2005 and 2006; 1957 metastatic colorectal cancer patients diagnosed in 
2003 and 2004). Since this registry did not contain all of the required data, we had to 
contact individual hospitals. Most of the Dutch hospitals (72%) were approached to 
expedite the data collection and we continued to include hospitals in order of response 
until the desired number of patients had been reached (stage III colon cancer: n=391; 
metastatic colorectal cancer n=316). Using hospital records, additional data were retro-
spectively collected on baseline patient characteristics, known prognostic information, 
considerations for choosing a treatment, types of treatments, disease free survival, 
and overall survival. For a randomly selected subgroup (stage III colon cancer: n=206; 
metastatic colorectal cancer n=130), detailed data were collected on dosage schemes, 
adverse effects and all hospital resource use. Table 9.1 and Table 9.2 present relevant 
findings of the oxaliplatin studies.
In the bortezomib study, patients (n=543) were identified using a trial database (HO-
VON50 study230) for first line treatment. We approached Dutch hospitals for data collec-
tion for outcomes research and continued to include hospitals until the desired number 
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Table 9.1 Summary table oxaliplatin in stage III colon cancer
Study design   Retrospective observational study
Number of patients
Population-based cancer registry   2249 (diagnosed in 2005 and 2006)
Additional/ detailed data collection 
(hospital records)
  391/ 206
Number of hospitals visited
(% of Dutch hospitals)
  19 (17%)
Treatments
Treatments received in everyday practice FL + oxaliplatin
FOLFOX or CAPOXa (n=281)
FL alone
5FU/LV or capecitabine (n=110)
5FU/LV 48% 15%
Capecitabine 54% 85%
Dosagesb
Oxaliplatin dose according to guidelines 1,020 mg/m2 n/a
Percentage of planned dose given 81% for FOLFOX
71% for CAPOX
n/a
Patients
Prognostic baseline characteristics  % Missing    % Missing
Eligible for pivotal registration trial 82% 14% 63% 23%
Age [median (range)] 61 (22–82) 73 (41–85)
Co-morbid conditions ≥ 2 11% 25%
Depth of invasion T2-T3 (T4) 85% (15%) 88% (12%)
Nodes involved N1 (N2) 60% (40%) 66%
Abnormal CEA levelsc 18% 14% 8% 22%
Reasons b
Reasons for not prescribing oxaliplatin Hospital policy (18%), advanced age (21%), patient refusal (19%), 
poor health status (10%), combination of these factors (7%), specific 
contra-indication (2%), and unknown (23%)
Regimes requiring dose modifications 56% 66%
Toxicity requiring hospitalisation 7% 6%
Effects
2-year disease-free survival probability
Eligible [Mean (95% CI)] 78.4% (72.5%–84.3%) 82.8% (72.5%–93.0%)
Ineligible [Mean (95% CI)] 56.7% (41.4%–72.0%) 83.7% (70.5%–96.8%)
Costs b
Total costs [mean (median)] €19,639 (€20,230) €5,055 (€4,482)
Minimum – maximum €1708–€60,149 €316–€12,127
a  FL: Fluoropyrimidines; FOLFOX: oxaliplatin combined with 5FU/LV; CAPOX: oxaliplatin combined with
      capecitabine
b  Based on a representative subsample of 206 patients
c CEA: serum carcinoembryonic antigen levels
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Table 9.2 Summary table oxaliplatin in metastatic colorectal cancer
Study design Retrospective observational study
Number of patients
Population-based cancer registry 1957 (diagnosed in 2003 and 2004)
Additional/ detailed data collection 
(hospital records)
316/130
Number of hospitals visited
(% of Dutch hospitals)
29 (26%)
Treatments
First-line treatments received in everyday 
practice
FL + oxaliplatin
FOLFOX/CAPOX a
(n=92)
FL alone
5FU/LV a or 
capecitabine
(n=198)
(FL +) irinotecan
alone/FOLFIRI/
CAPIRI a
(n=26)
Dosagesb
Mean total cumulative dose of oxaliplatin 1274 mg n/a n/a
Patients receiving 2nd (3rd) line treatment 57% (22%) 52% (22%) 32% (20%)
Patients
Prognostic baseline characteristics % Missing % Missing  % Missing
Eligible for clinical trial 85% 63% 73%
Age [median (range)] 60(29–81) 64(30–92) 59(39–73)
WHO performance status ≥ 2 13% 41% 23% 39% 6% 35%
Abnormal lactate dehydrogenase levels 46% 13% 52% 20% 47% 27%
Resection of primary tumour 65% 4% 61% 3% 58% 8%
Reasonsb
Toxicity in first line
Requiring hospitalisation 6% 13% 6%
Causing termination of treatment 20% 1% 20%
Effects
Overall Survival in months
Eligible [Mean (median)]
95% CI
18.6 (14.1)
15.5–21.8
14.9 (11.3)
12.8–17.0
27.1 (21.3)
18.0–36.3
Ineligible [Mean (median)]
95% CI
18.4 (17.8)
12.3–24.5
11.0 (6.6)
8.2–13.7
9.2 (6.9)
3.6–14.9
Costs b
Total costs [mean (median)] €27,711 (€23,172) €19,236 (€16,208) €39,375 (€38,754)
Minimum – maximum €2,200–€95,118 €462–€65,288 €10,258–€109,139
a FL: Fluoropyrimidines; FOLFOX: oxaliplatin combined with 5FU/LV; CAPOX: oxaliplatin combined with  capecitabine;
 FOLFIRI: irinotecan combined with 5FU/LV; CAPIRI: irinotecan combined with capecitabine
   b Based on a representative subsample of 130 patients
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Table 9.3 Summary table bortezomib in relapsed/ refractory multiple myeloma
Study design Retrospective observational study
Number of patients
HOVON trial database/ detailed data 543/ 139
Number of hospitals visited
(% of Dutch hospitals)
41 (38%)
Treatments
Treatments received in everyday practice Ever bortezomib a (n=72) Never bortezomib (n=67)
Bortezomib combination therapy 71% n/a
One other drug (dexamethasone) 80% (58%) n/a
Two/ three or more other drugs 12%/ 7% n/a
Dosages
Bortezomib total dose compared to pivotal registration 
trial
87% n/a
Number of bortezomib cycles in everyday practice 
(pivotal registration trial)
4 (6) n/a
Patients
Prognostic factors at start of 2nd line treatment % Missing % Missing
Age [mean (range)] 57 (34-69) 58 (35-68)
WHO performance status 0/ 1/ ≥ 2 59%/ 33%/ 8% 8% 35%/ 42%/ 22% 7%
Present with neurotoxicity 49% 10% 26% 3%
Serum B2 (mg/l) [mean (range)] 4 (1.3–16.7) 64% 3 (1.1–5.7) 79%
Albumin (g/l) [mean (range)] 40 (27.0–59.0) 31% 38.4 (16.6–52.0) 37%
Haemoglobin (mmol/l) [mean (range)] 7.5 (5.0–9.5) 31% 7.1 (2.1–10.0) 31%
First line HOVON50 experimental TAD arm 40% 27%
Received allogeneic stem cell transplantation 27% 1% 15%
Maintenance treatment
None/ IFNα 43%/ 21% 63%/ 24%
Thalidomide 36% 13%
Best response first line treatment 6%
Complete response/ Partial & minor response 16%/ 80% 10%/ 76%
No change/ Progressive disease 3%/ 1% 4%/ 9%
Time until first progression in months
[median (SD) {range}]
27.6 (12.8)
{2.0–57.9}
1% 22.4 (15.8)
{1.9–61.4}
1%
Reasons
Reasons to start a treatment regime b b
Regimes requiring dose modifications 52.5% n/a
Due to toxicity 79% 14% n/a
Effects
Overall Survival from start of relapsed/ refractory disease 
in months [mean (median)]
29.5 (33.2) 28 (21.6)
Confidence interval (95%) 25.1–38.8 14.6–50.4
Costs
Total costs [mean (median)] €81,626 (€72,182) €52,760 (€36,882)
Minimum – maximum €17,793–€229,783 €748–€179,571
a In total 25, 35 and 12 patients received bortezomib in 2nd, 3rd, and 4th line or later, respectively
  b Not part of data collection because this was generally not reported in medical records
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of patients who received off-protocol treatment for relapsed or refractory disease had 
been reached (n=139). Because many patients (49%) were treated in more than one 
hospital, we had to collect data in 42 hospitals. Using hospital records, detailed data 
were retrospectively collected on baseline patient characteristics, known prognostic 
information, types of treatments, dosage schemes, treatment response, time to progres-
sion, time till next treatment, adverse effects, survival and all hospital resource use. Table 
9.3 presents relevant findings of the bortezomib study.
Results
Feasibility to develop evidence on appropriate drug use
Table 9.4 summarises the results regarding the feasibility to develop evidence on differ-
ent aspects of appropriate drug use.
‘Treatments’ (types of treatments and regimes)
In all three studies it was feasible to ascertain the types of treatments used and their 
regimes using data from hospital records. Both oxaliplatin studies showed that patients 
were treated in a way that was similar to the regimes used in clinical trials and described 
in professional guidelines.231 In contrast, the bortezomib study revealed a high degree 
of treatment variation.232 More importantly, treatments differed significantly from those 
described in both the pivotal registration trial and professional guidelines.
Table 9.4 Feasibility to develop evidence on appropriate drug use
Oxaliplatin
in stage III colon 
cancer
Oxaliplatin
in metastatic 
colorectal cancer
Bortezomib
in multiple 
myeloma
Feasibility to use existing databases to 
identify patients
+ + +
Feasibility to obtain a complete dataset using 
hospital records
+ +/− +/−
Feasibility to develop evidence on:
Treatments + + +
Dosages + + +
Patients + + +/−
Reasons + + −
Effects: intermediate and final outcomes + + +/−
Effects: safety outcomes +/− +/− +/−
Costs + + +
+ = good; +/− = moderate; − = poor
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‘Dosages’ (treatment dosages and dose modifications)
Details on dosages and dose modifications were well reported in hospital records. How-
ever, retrieval of these details required a great deal of time, which significantly reduced 
the efficiency of data collection. Both oxaliplatin studies showed that the received 
dosages were comparable to those observed in clinical trials.231 The bortezomib study 
showed that patients received lower dosages (13%) and fewer treatment cycles (4 vs. 6) 
compared to patients in the pivotal registration trial.
‘Patients’ (baseline patient characteristics)
For the oxaliplatin studies, the cancer registry provided information on age, gender, 
date of diagnosis, disease stage, and tumour location. Additional data on prognostic 
baseline characteristics required data from hospital records. For the bortezomib study, 
the HOVON database provided information on age, gender, date of diagnosis, and 
disease stage. Other baseline characteristics required data from hospital records. In all 
three studies it was impossible to compile a complete dataset, including prognostic 
factors. For example, 13% of serum carcinoembryonic antigen levels (stage III colon 
cancer) and 40% of performance scores (metastatic colorectal cancer), and 71% of se-
rum β2-microglobulin levels (multiple myeloma) were missing. Nevertheless, based on 
available baseline characteristics, it seemed like patients treated with oxaliplatin231 and 
bortezomib233 were comparable to trial patients.
‘Reasons’ (reasons for starting or stopping a treatment)
The rationale for choosing a particular treatment was often retrievable (74%) from the 
hospital records in stage III colon cancer. It was possible to determine the most frequent 
reasons for dose modifications or treatment interruptions in both oxaliplatin studies. 
In contrast, in the bortezomib study the reasons to start a treatment, reduce its dose or 
stop a treatment were often not reported.
‘Effects’ (health effects)
In both oxaliplatin studies, the cancer registry only provided survival data, whereas 
hospital records provided data on disease-free survival, adverse effects, and survival. 
Similarly, in the bortezomib study, the HOVON database provided survival data and 
hospital records data on treatment response, adverse effects, and survival. However, in 
all three studies, treatment responses and adverse effects were often not reported using 
standardised outcome measures (e.g., Response Evaluation Criteria in Solid Tumours 
[RECIST], European Group for Blood and Marrow Transplant [EBMT] response criteria, 
Common Toxicity Criteria [CTC] toxicity grading scale). Although these results could 
probably be estimated using for instance laboratory test results, this lack of data severely 
limited a retrospective assessment using outcome measures as treatment response and 
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time to progression often found in clinical trials. Lastly, hospital records did not provide 
any standardised data on quality of life (e.g., European Organisation for Research and 
Treatment of Cancer Quality of Life Questionnaire [EORTC-QLQ-C30], EuroQol Quality of 
Life Questionnaire [EQ-5D] or Short Form [SF36] Health Survey).
‘Costs’ (costs of a treatment)
In all three studies it was possible to collect data on hospital resource use of individual 
patients. However, due to feasibility constraints, unit costs for laboratory services were 
based on a detailed inventory of a subsample of patients. Similarly, in the bortezomib 
study detailed data collection on concomitant medication was extremely time-intensive. 
Therefore, detailed data were only collected for a subsample of 18 patients.
Feasibility to estimate incremental cost-effectiveness
Table 9.5 summarises the results regarding the feasibility to estimate incremental cost-
effectiveness.
Table 9.5 Feasibility to estimate incremental cost-effectiveness
Oxaliplatin
in stage III colon 
cancer
Oxaliplatin
in metastatic 
colorectal cancer
Bortezomib
in multiple 
myeloma
Comparability of baseline characteristics between 
treatment arms
− +/− −
Feasibility of using data from everyday practice:
To correct for bias − +/− −
To identify treatment comparator + + −
To estimate incremental cost-effectiveness − − −
Comparability of eligible everyday practice patients 
(treated with oxaliplatin/ bortezomib) and clinical trial 
patients
+ + +/−
Feasibility of data synthesis: + + −
To obtain additional data from the literature on:
quality of life +/− +/− −
efficacy + + +/−
effectiveness − +/− −
costs +/− +/− −
Feasibility to estimate (using data synthesis):
Internally valid incremental
cost-effectiveness
+ + −
Precise incremental cost-effectiveness +/− +/− −
Externally valid incremental
cost-effectiveness
+ + −
+ = good; +/− = moderate; − = poor
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Case 1: Oxaliplatin in stage III colon cancer
Due to the strong preference of physicians to use oxaliplatin whenever indicated, pa-
tients receiving the comparator treatment were significantly different regarding impor-
tant prognostic factors. To correct for the resulting confounding, different adjustment 
techniques were applied to the Cox multivariate regression model, such as average 
covariate adjustment, regression adjustment by propensity score matching, and survival 
analysis matched on propensity score matching. However, our sample size (n=391) was 
not powered for this purpose. This, in combination with missing data on prognostic 
factors, resulted in possibly biased estimates with wide confidence intervals. It was not 
feasible to estimate incremental cost-effectiveness using only everyday practice data. 
Therefore, we developed a Markov model to estimate incremental cost-effectiveness. In 
this model we synthesised effectiveness data from everyday practice with efficacy data 
from the pivotal registration trial. Patients were categorised ‘eligible’ or ‘ineligible’, de-
pending on whether the patients fulfilled the trial eligibility criteria. Ineligible patients 
(18%) had a worse prognosis compared to eligible patients (82%), but trial patients and 
eligible case study patients had similar two-year disease-free survivals (80% vs 78%). 
Effectiveness of the comparator was modelled using trial results. All costs were based 
on the case study. Applying scenario analyses, incremental cost-effectiveness ratios 
ranged from €8,247 to €12,289 per quality adjusted life year. Sensitivity analyses of input 
parameters and model assumptions produced little differences, supporting robustness 
of the results. Data synthesis resulted in internally valid incremental cost-effectiveness 
estimates generalisable to Dutch everyday practice.
Case 2: Oxaliplatin in metastatic colorectal cancer
As with case 1, patients receiving oxaliplatin were not comparable to patients not receiv-
ing oxaliplatin. In this case, the differences in baseline prognosis were less pronounced 
than in stage III colon cancer, but correction for confounding was hindered by missing 
values. Although not performed, modelling evidence from the literature with evidence 
from the case study would have been feasible.
Case 3: Bortezomib in relapsed or refractory multiple myeloma
Rapid developments in treatment for multiple myeloma resulted in great heterogene-
ity. Patients treated with bortezomib were not comparable to other patients regarding 
prognostic factors. It was impossible to identify a single treatment comparator; more 
than 10 drugs were given in more than 20 different combinations. Therefore, our com-
parator included any treatment besides bortezomib. Similar to the oxaliplatin cases, dif-
ferent adjustment techniques were applied to the Cox multivariate regression model to 
obtain a valid overall survival estimate. However, none succeeded in correcting for the 
observed confounding. New evidence from extended follow-up and other trials com-
152 Chapter 9
paring different treatments and combinations became available. No information was 
published on treatment-related costs or quality of life. The great heterogeneity caused 
by many treatment arms made it impossible to develop a feasible model to estimate 
incremental cost-effectiveness.
Discussion
We investigated the feasibility of different aspects of outcomes research in oncology. 
Our results show that the degree of feasibility depends on both the aspect and treat-
ment indication. To our knowledge, this is the first feasibility study of outcomes research 
in oncology that is based on empirical evidence.
Based on theoretical expectations and expert opinion, the lack of a randomised con-
trolled setting is one of the major concerns.219,222-224 As expected, our results confirm that 
heterogeneity resulted in incomparable patient groups and the inability to correct for 
confounding. Therefore, it was not possible to estimate incremental cost-effectiveness 
only using everyday practice data. However, our results also show that it may still be 
feasible to obtain internally valid and generalisable incremental estimates by synthesis-
ing everyday practice data with trial data, provided that everyday practice patients fulfil 
the eligibility criteria of trials in which these drugs were tested. Furthermore, our results 
confirm that current databases do not provide sufficient information.212,213,216,220,226 The 
need for additional data required the retrieval and scrutiny of hospital records. Regard-
ing applicability of outcome measures,25,33 our results show that measures used in clini-
cal trials are susceptible to bias due to missing data and the lack of standardisation in 
their reporting in hospital records. The choice of relevant outcome measures depends 
on the disease. For example, survival is often the primary outcome measure in oncology, 
but not in diseases such as rheumatoid arthritis or COPD where quality of life is more 
relevant. Moreover, timeliness26,32,227 can differ per drug and disease. While a three-year 
time frame was sufficient for the oxaliplatin studies, the bortezomib study revealed that 
treatment advances limited the relevance of the gathered evidence with such a time 
frame. The challenge of generalisability228 might be of lesser concern. In our studies, the 
ability to select representative samples (e.g., by means of the cancer registry), was a key 
to ensuring generalisability.
The feasibility of outcomes research also depends on its study design. The main limita-
tion of our case studies was the use of retrospective research designs. As a consequence, 
we faced a great deal of important missing information. A prospective design, using a 
registry, would offer greater control over data collection as well as the opportunity to 
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collect data on quality of life. However, in many prospective designs, including registries, 
data are still retrospectively collected and rely on information provided by others (e.g., 
physicians, research assistants). Moreover, such a design would still not solve the issue 
of randomisation. Although a pragmatic trial would be a solution for this, these trials are 
often impossible due to ethical or feasibility considerations.
Our study was only based on three case studies. However, we believe that our findings 
can be extended to other oncological diseases. We intentionally selected different 
indications in cancer reflecting different types of disease populations (small vs. large), 
expectations regarding practice variation (small vs. large), and relevant outcome mea-
sures (intermediate vs. final endpoints).
Our study provides important insight into the implementation of evidence development 
schemes. We believe that data from everyday practice results in valuable evidence, ad-
dressing uncertainties arising from the gap between clinical trials and everyday practice. 
Above all, it is essential to have a comprehensive understanding of the disease and the 
treatment effect and this requires interdisciplinary collaboration.
Active interdisciplinary collaboration will result in an enhanced research design focus-
ing on feasible objectives for a particular treatment in a specific indication. It will also 
reduce problems with missing information and lack of standardisation in reporting. 
Because current databases do not provide sufficient information, patient registries can 
offer an opportunity to build new research infrastructures. Although patient registries 
cannot resolve all issues, if they are used by an active interdisciplinary collaborative re-
search group, they could increase efficiency of data collection and help to reduce issues 
of generalisability, incomparability of patient groups, missing information, and lack of 
standardisation in reporting. For orphan drugs, international registries may be the best 
means to obtain a sufficient amount of evidence (e.g., Pompe Registry234). Furthermore, 
registries can also be used to monitor and improve quality of care beyond outcomes 
research.
In conclusion, our results show that it is feasible to generate evidence about drug use in 
everyday oncology practice. For some aspects of appropriate drug use, this will require 
improvements in reporting in hospital records or compiling data in registries. The fea-
sibility to estimate incremental cost-effectiveness depends on the drug and its indica-
tion. We believe that in most circumstances it is inevitable to synthesise data to obtain 
valid and precise estimates. However, it is essential to realise that for some drugs and 
indications, it may sometimes be impossible to estimate sufficiently valid and precise 
incremental cost-effectiveness.
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In the end, the generation of more evidence will improve the quality of decisions made 
by both payers and physicians. This, in turn, can improve quality of care and enhance the 
efficient allocation of resources and thereby help to ensure long-term sustainability of 
health care systems.
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Abstract
Dutch policy regulations require outcomes research for the assessment of appropriate 
drug use and cost-effectiveness after four years of temporary reimbursement. We in-
vestigated whether outcomes research reduced policymaker uncertainty regarding the 
question whether the costs are worth public funding.
Our cohort study included 139 patients with relapsed/refractory multiple myeloma who 
were treated outside of a clinical study; 72 received bortezomib and 67 did not receive 
bortezomib. Detailed data were retrospectively collected from medical records in 38% 
of Dutch hospitals.
All patients received second-line treatment; 65%, 40%, and 14%, received three, four, 
five or more lines of therapy. Neither a specific treatment sequence nor an appropri-
ate comparator could be identified because of large variation in regimes. Kaplan-Meier 
curves showed an increased overall survival (mean [median] OS 29.5 [33.2] vs. 28.0 [21.6] 
months) for bortezomib patients (Wilcoxon p=0.01). Total mean costs were €81,626 
(range: €17,793–229,783) and €52,760 (range: €748–179,571) for patients receiving 
bortezomib and patients not receiving bortezomib, respectively. Patients treated with 
bortezomib, however, were not comparable to other patients despite attempts to cor-
rect for confounding. Therefore, it was impossible to develop a feasible model to obtain 
a valid incremental cost-effectiveness estimate.
It was possible to develop evidence on bortezomib’s use, effects and costs in everyday 
practice. Much uncertainty, however, remained regarding its cost-effectiveness. Policy-
makers should carefully consider if outcomes research sufficiently decreases uncertainty 
or whether other options (e.g., finance- and/or outcomes-based risk-sharing arrange-
ments) are more appropriate to ensure sufficient value for money of expensive drugs.
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Introduction
Rising health care expenditures are making it extremely difficult to manage early access 
to promising innovative, often expensive, drugs while ensuring value for money. Glob-
ally, health care systems have therefore introduced policies to reduce initial decision 
makers’ uncertainty regarding the clinical and economic performance of novel drugs. 
These policies address clinical and/or finance uncertainty, for example by means of 
finance-based34,35 or outcomes-based35,36 risk sharing agreements such as coverage with 
evidence development schemes29-31 or outcomes research requirements.32,33
Although outcomes research and evidence development requirements increasingly 
seem an attractive policy option, many unanswered questions remain regarding their 
actual value31,35,235 and feasibility.215,218,236 In The Netherlands, outcomes research re-
quirements were first implemented in 2006 for expensive inpatient drugs. From 2013 
onwards, this policy has been extended to specific groups of outpatient drugs. In the 
Dutch coverage with evidence development policy, early access is linked with the obli-
gation to conduct outcomes research in accordance to guidelines,193 namely to gather 
data in everyday practice on appropriate drug use (e.g., patient characteristics, types of 
treatments, dosages, and dose modifications) and real-world cost-effectiveness. After 
four years of use, a reassessment will determine whether or not the drug will continue 
to be reimbursed.229 Notably, recent Dutch experiences revealed insufficient data to per-
form a reassessment after four years of outcomes research (i.e., omalizumab, infliximab, 
and ranibizumab).
In 2006, bortezomib was added on the expensive drug list for relapsed/refractory mul-
tiple myeloma, an incurable malignant plasma cell disorder. At the time of the initial 
reimbursement decision, Dutch policymakers only had information from one pivotal 
phase III trial,196 which found bortezomib to be superior to high dose dexamethasone 
in terms of increased time to progression (6.22 vs. 3.49 months), response rates (38% 
vs. 18%), response duration (8 vs. 5.6 months), and one-year survival rate (80% vs. 
66%). Costs were estimated at €27,432 per treated patient, which was solely based on 
the price of bortezomib vials; no data on cost-effectiveness were available.237 Despite 
favourable trial results, the scarcity in available evidence (i.e., one phase III trial in 669 
patients) implied a high degree of uncertainty for policymakers regarding bortezomib’s 
value in everyday practice in terms of real-world effectiveness, health care costs, and 
cost-effectiveness. Because bortezomib was added on the expensive inpatient drug list, 
outcomes research needed to be conducted to facilitate a re-evaluation of the initial 
reimbursement decision.
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This article describes our experiences in The Netherlands in performing outcomes 
research of bortezomib in relapsed/refractory multiple myeloma. We investigated 
whether outcomes research reduced initial policymaker uncertainty regarding real-
world use, effectiveness, health care costs, and cost-effectiveness after data collection in 
everyday practice. To our knowledge, this is the first study evaluating cost-effectiveness 
of bortezomib based on real-world data only.
Methods
Patient population and data collection
To identify patients who were eligible for bortezomib treatment in everyday practice, 
we selected our patient population from patients previously enrolled in a clinical trial 
(HOVON50). The phase III HOVON50 trial enrolled 556 (543 Dutch) patients from No-
vember 2001 to June 2005 to investigate the treatment effect of thalidomide in patients 
aged 18–65 years newly diagnosed with Durie-Salmon stage II/III multiple myeloma.230 
Patients who went off-protocol from this trial regime no longer received protocol-based 
therapy and were therefore eligible for our outcomes research study because they were 
treated for relapsed/refractory multiple myeloma in everyday clinical practice.
We approached Dutch hospitals to obtain permission for data collection. We continued 
to include hospitals until the desired number of patients who received off-protocol 
treatment for relapsed/refractory disease had been reached. Power calculations (two-
sided, α=0.05, power= 0.7) of the desired sample size (n>124) were based on differences 
in response percentages (0.38 vs. 0.18) in the Assessment of Proteasome inhibition for 
Extending Remissions (APEX) trial.196 In total, 139 patients were included; 72 received 
bortezomib and 67 did not receive bortezomib. Because many patients (49%) were 
treated in more than one hospital, data were collected in 42 hospitals (38% of all Dutch 
hospitals, and approximately 57% of Dutch hospitals treating haemato-oncology pa-
tients). Figure 10.1 shows the flowchart of the patient selection process.
Detailed data for outcomes research were retrospectively collected from hospital re-
cords from the time of first relapsed/refractory disease until end of follow-up. Data were 
collected on baseline patient characteristics, types of treatments and regimes, dosage 
schemes, adverse effects, treatment response, response rate, time to progression, time 
till next treatment, survival and resource use.
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Drug use and real-world cost-effectiveness
To assess drug use, we examined baseline patient characteristics, types of treatments 
received, dosages, and dose modifications. To estimate overall survival (OS) and time to 
next treatment, Kaplan-Meier curves were computed from start of relapsed/refractory 
treatment stratified by receipt of bortezomib. Different adjustment methods, such as av-
erage covariate adjustment, regression adjustment by propensity scores, and matched 
analysis, were applied to the Cox multivariate regression model to correct for differences 
        HOVON50 study population
               543 Dutch patients
 No 2nd treatment line recorded
 in HOVON50 database:
 293 patients excluded
 Off protocol HOVON50
 Receiving 2nd line treatment
 (HOVON registration)
 n=250
 Secondary Malignancy:
 7 patients excluded
 Received bortezomib
 in an RCT setting
 31 patients excluded
 ≤6 HOVON50 patients in hospital:
 25 patients excluded
 Patient treated ≥ 3 hospitals:
 1 patient excluded
 Medical Records inaccessible:
 3 patients excluded
 
 NEVER received  EVER received
 bortezomib in daily practice  bortezomib in daily practice
 n=75  n=108
 
 Sufficient sample size:  Sufficient sample size:
 8 patients excluded  36 patients excluded
 NEVER  EVER 
 received bortezomib  received bortezomib
 n=67  n=72
Figure 10.1 Flowchart of the patient selection process
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in baseline characteristics between patients receiving bortezomib and patients not 
receiving bortezomib.
Treatment costs were computed from a hospital perspective. Costs for individual 
patients were determined by applying unit costs to individual resource use of the fol-
lowing cost components: outpatient, emergency room, and day-ward visits; hospital 
admissions; consultations by telephone; radiotherapy; (surgical) procedures; laboratory 
services; medical imaging services; treatment; and concomitant treatment. One-way 
sensitivity analyses were carried out by varying the unit costs of hospital visits (inpatient 
care, outpatient visits, and day-care treatment) between 50% and 150%. Details of the 
unit costs and cost-analysis are reported elsewhere.238
For cost-effectiveness, we investigated the feasibility of obtaining comparable patient 
groups, identifying treatment comparators, and estimating (incremental) cost-effective-
ness.
Statistical analysis was conducted with the statistical software program SAS, version 9.1 
(SAS Institute Inc., Cary, NC).
Results
Baseline patient characteristics
Missing values on baseline characteristics were common. Low numbers of available 
prognostic data occurred, for example, for serum β2-microglobulin levels (71% miss-
ing), albumin levels (34% missing), performance status (8% missing), and neurotoxicity 
assessment (6% missing).
Based on available data, baseline characteristics at start of relapsed/refractory treat-
ment differed between patients treated and not treated with bortezomib (see Table 
10.1). Significant differences were observed for the proportion of patients presenting 
with neurotoxicity (p=0.01), WHO performance status (p=0.03), type of maintenance 
therapy (p=0.01) and time until first progression (p=0.03). As a result, prognosis at start 
of relapsed/refractory disease varied greatly between both the patient groups.
Types of treatments received, dosages and dose modifications
Treatment details including type of treatment, dosages and dose modifications were 
well reported in hospital records. On account of the rapid advances in recent years in 
treatment options available for multiple myeloma, variation was observed in treatments 
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received by patients. Table 10.2 shows the number of patients receiving treatment by 
treatment line. All 139 patients received second-line treatment, 65% received third-
line, 40% fourth-line, 14% fifth-line, 6% sixth-line, 2% seventh-line and 1% eighth-line 
treatment. Because of a large degree of variation, it was impossible to identify a general 
treatment pattern. Nevertheless, the percentage of patients treated with thalidomide 
decreased over the lines, whereas lenalidomide usage increased. Of all patients receiv-
ing bortezomib, 79% were previously treated with thalidomide, which coincided with 
Dutch treatment guidelines. Six patients received bortezomib in more than one line.
As Table 10.2 reveals, a combination of treatments was common practice; more than 10 
drugs were given in more than 20 different combinations. The most frequent combina-
tions were thalidomide/dexamethasone (n = 57), lenalidomide/dexamethasone (n = 38), 
melphalan/prednisone (n = 32) and vincristine/adriamycin/dexamethasone (n = 22).
Bortezomib was given as mono-therapy in 29% and as combination therapy in 71% of 
the administrations. It was combined with one other treatment in 58%, two other treat-
ments in 9% and three or more other treatments in 5% of the administrations. It was 
most often combined with dexamethasone (41%). Most of the patients were treated 
in cycle regimes similar to the pivotal registration trial (i.e., APEX trial196,239). Patients in 
everyday practice, however, received fewer treatment cycles (4 vs. 6) as well as lower 
dosages (13%).
It was not feasible to establish a pattern for dose modifications according to toxicities. 
Often, no reason for dose modification was reported or physicians only reported that 
the condition of the patient required a dose modification without describing the reason 
for poorer condition. In total, 53% of bortezomib regimes required a dose modification. 
As expected, the most common reported toxicity was neurotoxicity (61%).
Treatment effects
Policymakers generally prefer OS and quality adjusted life years (QALYs) as outcome 
measures in reimbursement decision making240 Therefore, OS from start of relapsed/
refractory disease was used to analyse the treatment effect of bortezomib. Moreover, 
using either time to progression or progression-free survival as effectiveness measures, 
which is usual in clinical trials, was deemed inappropriate because physicians seemingly 
used less strict criteria in comparison to clinical trials, which dictate response criteria.
The mean follow-up duration was 26.0 (SD 14.4) and 21.5 (SD 16) months for patients 
treated and patients not treated with bortezomib, respectively. At the end of data collec-
tion, 37 patients treated with bortezomib and 31 patients not treated with bortezomib 
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were still alive. Kaplan-Meier curves (see Figure 10.2) from start of relapsed/refrac-
tory treatment showed a longer mean (29.5 vs. 28.0 months) and median (33.2 vs. 21.6 
months) OS for patients receiving bortezomib (Logrank p=0.31; Wilcoxon p=0.01). The 
crossing of curves might be due to the low number of patients still in follow-up after 
approximately 36 months (i.e.,14 patients in each group). It could also be related to great 
heterogeneity within the patient groups or between the groups (i.e., patients groups are 
incomparable).
Previous research found that receiving thalidomide as first-line treatment is associated 
with reduced OS after relapsed/refractory treatment.241,242 Therefore, we stratified the 
Kaplan-Meier curves [not shown] by HOVON50 treatment arm (Thalidomide, Adria-
mycin, and Dexamethasone (TAD) arm vs. Vincristine, Adriamycin and Dexamethasone 
(VAD) arm). This revealed an increased survival (Logrank p=0.056; Wilcoxon p=0.015) in 
favour of the non-experimental HOVON50 arm (mean [median] OS for patients treated 
with bortezomib in the VAD arm 30.9 [33.6] and the TAD arm 27.0 [29.2] months; and 
for patients not treated with bortezomib in the VAD arm 29.9 [31.1] and the TAD arm 
13.7 [15.9] months). Moreover, differences (Logrank p=0.41; Wilcoxon p=0.04) in survival 
[not shown] were also found between the treatment lines in which bortezomib was 
administered (mean OS 18.8, 31, 31.6 months, and median OS 24.0, 35.4, 32.5 months 
for receiving bortezomib in second-, third-, or fourth-line or later, respectively). As Figure 
10.3 shows, however, further stratifying all the four groups by HOVON50 treatment arm 
 
Figure 10.2 Kaplan-Meier OS curves from start of relapsed/ refractory treatment stratified by treatment 
with bortezomib
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resulted in a statistically insignificant effect on OS (Logrank p=0.16; Wilcoxan p=0.08). 
This was mainly due to the small number of observations in each group (numbers 
ranged from 5 to 25 in the bortezomib groups).
Despite applying different adjustment techniques (i.e., average covariate adjustment, 
regression adjustment by propensity scores and matched analysis) to the Cox multi-
variate regression model, none succeeded in correcting for differences between patient 
groups. This suggests that residual confounding by indication exists on account of miss-
ing information. Consequently, patients receiving bortezomib were incomparable to 
patients not receiving bortezomib and thus any comparison between the groups would 
be invalid.
Treatment costs
Table 10.3 presents the total mean costs for patients treated with bortezomib (n = 72) and 
patients not treated with bortezomib (n = 67). Total mean costs for patients treated with 
bortezomib amounted to €81,626 but varied widely between patients (range: €17,793 
to €229,783). Active treatment (costs excluding stem cell transplantation €30,733; SD 
€24,654) was the most important cost driver accounting for 44% of total costs. Bortezo-
mib accounted for 57% and lenalidomide for 35% of the active treatment costs. Total 
mean costs for patients receiving bortezomib in second-line (n = 25), third-line (n = 35), 
and fourth-line or later (n = 12) were €53,726, €95,962, and €97,937, respectively. These 
 
Figure 10.3 Kaplan-Meier OS curves form start of relapsed/ refractory treatment stratified by treatment 
with bortezomib, bortezomib treatment line and HOVON50 treatment arm
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Table 10.3 Total mean costs from start of relapsed/ refractory treatment stratified by treatment with bort-
ezomib
Ever received bortezomib Never received bortezomib
  (n = 72) (n = 67)
Costs (Euro 2009) Mean SD Mean SD
Hospital admissions        
Haematology/ internal/ surgical ward € 12,294 € 13,750 € 12,168 € 13,843
Intensive care unit € 607 € 2,909 € 2,297 € 6,071
Hospital visits        
Outpatient € 5,676 € 3,902 € 3,732 € 4,023
Day-care € 4,799 € 2,993 € 1,132 € 1,653
Emergency room visits € 160 € 216 € 65 € 111
Telephone consults € 51 € 65 € 30 € 53
Radiotherapy € 1,971 € 3,139 € 1,698 € 2,623
Surgery € 766 € 2,058 € 1,383 € 3,035
Diagnostics (e.g., laboratory & radiology) € 7,497 € 5,246 € 6,417 € 7,264
Concomitant medication € 13,103 € 8,855 € 9,017 € 8,637
Acute € 2,521 € 4,882 € 802 € 1,683
Chronic/ prophylactic € 10,582 € 7,591 € 8,215 € 8,398
Therapy € 37,118 € 28,790 € 16,496 € 28,140
Bortezomib € 17,407 € 11,143 € 0 € 0
Lenalidomide € 10,769 € 18,062 € 8,923 € 24,282
Thalidomide € 514 € 708 € 818 € 957
Dexamethasone € 103 € 127 € 67 € 69
Adriamycin € 133 € 268 € 39 € 105
Vincristine € 25 € 61 € 6 € 20
Melphalan € 76 € 202 € 67 € 124
Prednisone € 21 € 78 € 7 € 15
Interferon alpha € 22 € 134 € 6 € 49
Cyclophosphamide € 17 € 40 € 9 € 23
Donor leukocyte infusions € 1,594 € 3,015 € 467 € 1,310
Stem cell transplantation € 3,969 € 13,313 € 4,412 € 10,937
Other € 52 € 269 € 0 € 0
Total costs        
Mean € 81,626 € 47,246 € 52,760 € 45,865
Minimum € 17,793   € 748  
Maximum € 229,783   € 179,571  
SD = standard deviation
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differences were most likely because most of the patients (68%) treated in second line 
were still in follow-up at the time of data collection compared to 54% and 8% of patients 
in third-line and fourth-line or later, respectively.
Total mean costs for patients not treated with bortezomib amounted to €52,760 and also 
varied widely between patients (range: €748 to €179,571). The most expensive patients 
consumed substantially high proportions of their total costs for hospital stays, resource 
use, and active treatment. Inpatient hospital days (€12,168; SD €13,843) was the most 
important cost driver (23%), followed by active treatment (€14,821; costs excluding stem 
cell transplantation €10,409; SD €24,340). Lenalidomide (€8,923; SD €24,282) accounted 
for 60% of the active treatment costs and 17% of the total costs; stem cell transplant 
(€4,412; SD €10,937) accounted for 30% of the active treatment costs and 8% of the total 
costs.
One-way sensitivity analysis by varying the unit costs of inpatient hospital days, day-
care treatments, and outpatient visits appeared to have a rather modest effect on the 
total mean costs. The greatest effect was obtained by varying the unit price for inpatient 
hospital days (range for patients treated with bortezomib €75,176–€88,076; range for 
patients not treated with bortezomib €45,527– €59,993).
Real-world cost-effectiveness
Because of great differences in baseline prognosis, the inability to correct for these 
differences, and extensive treatment variation, it was impossible to develop a feasible 
model to obtain valid and precise incremental cost-effectiveness estimates of bortezo-
mib compared to other treatments. Without the intention to make direct comparisons, 
however, it was possible to estimate costs per month of survival for patients receiving 
bortezomib and patients not receiving bortezomib.
The costs from start of relapsed/refractory treatment for patients treated with bort-
ezomib were €2,767 per month of survival (total mean costs: €81,626; mean OS: 29.5 
months). Similarly, for patients treated with bortezomib in second-line, the costs were 
€2,858 per month of survival (total mean costs: €53,726; mean OS: 18.8 months). Costs 
for patients receiving bortezomib in third-line and fourth-line or later were €3,096 (total 
mean costs: €95,962; mean OS 31.0 months) and €3,099 (total mean costs: €97,937; 
mean OS 31.6 months) per month of survival, respectively.
The costs from start of relapsed/refractory treatment for patients not treated with bort-
ezomib were €1,884 per month of survival (total mean costs: €52,760; mean OS: 28.0 
months).
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Discussion
Despite favourable findings of bortezomib’s registration study, there was a high degree 
of uncertainty for policymakers whether the high drug costs were worth public funding. 
Although outcomes research and evidence development requirements globally seem 
to be popular as well as promising policy options to reduce decision maker uncer-
tainty,29,32,243 our results show that its actual value might depend on the type of evidence 
required and type of uncertainty addressed.
The reimbursement decision was based on one phase III trial.196 No data were avail-
able on long-term survival and health care costs besides the price of bortezomib vials. 
Consequently, policymakers were uncertain of bortezomib’s effects, costs and cost-
effectiveness in everyday practice. The registration trial compared bortezomib with 
high-dose dexamethasone. In contrast, outcomes research showed that treatment in 
clinical practice was far more heterogeneous. Although real-world patients received 
fewer treatment cycles (4 vs. 6) as well as lower dosages (13%) compared with trial pa-
tients, time to progression (6.8 vs. 6.22 months) and response rates (complete response: 
8% vs. 6%; very good, partial, and minimal response: 55% vs. 41%) seemed reasonably 
similar. One-year survival rate, however, was lower in everyday clinical practice (66% 
vs. 80%). (A detailed comparison between our real-world patients and trial patients is 
reported elsewhere244). Furthermore, outcomes research showed detailed health care 
costs beyond the price of bortezomib itself. Thus, outcomes research provided valuable 
information on types of treatments received, which patients received or did not receive 
bortezomib, dosages, dose modifications, (overall) survival, treatment costs, and costs 
per month of survival. Hence, outcomes research reduced initial policymaker uncer-
tainty about bortezomib’s use, effects and costs in everyday practice.
Outcomes research, however, did not reduce the uncertainty of the societal value of 
bortezomib compared with other treatments. Because of extensive treatment variation, 
it was not possible to identify appropriate treatment comparators. Furthermore, as 
expected, our results confirm previous concerns219,222-224 that great heterogeneity and 
a lack of randomisation in everyday practice resulted in incomparable patient groups. 
Although other observational studies successfully used the propensity score matching 
technique,245-249 essential prerequisites,250 such as large patient numbers and consis-
tency in comparator, were missing in our study. Despite applying different adjustment 
techniques to the Cox multivariate regression model, none succeeded in correcting 
for differences between patient groups mainly on account of small patient numbers, 
extensive treatment variation and missing data. Consequently, we concluded that it 
was impossible to compare patients receiving bortezomib and patients not receiving 
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bortezomib; any comparison between the groups would be invalid. Therefore, a feasible 
model to estimate real-world incremental cost-effectiveness of bortezomib compared 
to other treatments remains to be demonstrated. Only with a feasible model it would 
be useful to perform uncertainty analysis of input parameters to report the uncertainty 
surrounding the outcomes (e.g., stochastic, parameter, and structural uncertainty251).
At the time of reassessment, policymakers could, besides our outcomes research results, 
make use of published literature providing information from various studies describ-
ing the efficacy of bortezomib as mono-therapy or combination therapy as well as 
describing the efficacy of other new multiple myeloma therapies. Only a few cost stud-
ies252-254 and economic evaluations255-257 were published in relapsed/refractory multiple 
myeloma. Previous cost-studies, however, were based on conventional therapies,252 did 
not apply micro-costing techniques,253 nor provided information on the use of novel 
agents.254 Previous economic evaluations were based on synthesising data and expert 
opinions and did not use patient level data.255-257 Therefore, our results provided, to our 
knowledge, the first results based on real-world data only.
We believe that our results illustrate the value of outcomes research as well as its chal-
lenges and thus provide important lessons for policymakers. We acknowledge that we 
base our conclusions on one outcomes research study in multiple myeloma. Therefore, 
our conclusions might not be generalisable to outcomes research for all other drugs. 
Our findings, however, regarding missing data, incomparability of patients, treatment 
heterogeneity due to rapid treatment advances, and low patient numbers are most 
likely generalisable to other drugs in comparable diseases. A limitation of our study 
was that we used the HOVON50 population to select patients who received bortezomib 
outside of a clinical trial. Many patients, however, received bortezomib within a clini-
cal trial. Consequently, we might have induced selection bias. This is, however, partly a 
consequence of only using everyday practice data. Even if we would have increased our 
sample size, outcomes research may be infeasible for a low prevalence disease. Another 
limitation was the use of a retrospective research design. Because of this, we faced a 
great deal of important missing information and we could not collect data on quality of 
life. Although we believe that a prospective design, using a registry, would offer greater 
control over patient selection and data collection, a registry will not resolve all issues as 
shown by four Dutch registries for patients with cancer.258 Population-based registries 
might however enable the selection of sufficient numbers of similarly treated patients 
and reduce issues with generalisability, missing information, and lack of standardisation 
in reporting in hospital records. Furthermore, registries can also be used to monitor and 
improve quality of care beyond outcomes research. If medical records are to be used 
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for data collection, however, it is important to emphasise that there is a high need to 
improve reporting of clinical data.
The survival of multiple myeloma has improved in the past decade in which new inno-
vative drugs became available.197,259 The question arises, however, why new innovative 
drugs need to be so expensive.260,261 In the case of bortezomib, outcomes research was 
probably not the best option to reduce policymaker uncertainty regarding the initial 
question of whether the additional costs are worth public funding because the data on 
relative outcomes were invalid and thus could not resolve the questions about value 
for money from a societal perspective. It was however useful in generating real-world 
evidence on clinical outcomes and the costs of the patients receiving the drug in daily 
practice, which can be used to better manage the allocation of public funding within a 
particular disease. In contrast to the Dutch policy, the manufacturer and the UK depart-
ment of health agreed, after first receiving a negative advice from the National Institute 
for Health and Care Excellence, on a performance-based response-rebate scheme for 
bortezomib.262 Although outcomes research has been the only option in The Nether-
lands, the Dutch minister announced the implementation of risk-sharing arrangements 
from 2013 onwards.168
Several taxonomies exist that classify different risk-sharing arrangements,18,34,235,243,263 but 
many issues related to various arrangements are known. For example, monitoring issues, 
administrative burden, and time-consuming procedures for filling claims unfortunately 
resulted in many missing claims in the UK bortezomib response-rebate scheme.264 Also 
other studies35,36,185,186,243 reported issues related to risk-sharing arrangements, such as 
high implementation and transaction costs, administrative burden, lack of transparency, 
challenges in measuring treatment effect, and a lack of appropriate data infrastruc-
tures. Accordingly, the first schemes in the United Kingdom included outcomes-based 
(response-rebate) schemes whereas in the later years most patient access schemes 
concerned finance-based agreements (e.g., dose-capping), which are easier to imple-
ment in practice. Recent Dutch experiences revealed insufficient real-world evidence to 
perform a reassessment after four years of data collection (i.e., omalizumab, infliximab, 
and ranibizumab); a few revisions have been converted into other risk-sharing agree-
ments (i.e., a pay-for-performance184 and a finance agreement190).
Nevertheless, at the time of the initial reimbursement decision, potential issues chal-
lenging outcomes research of bortezomib might have been in line with expectations re-
garding relapsed/refractory multiple myeloma treatment (i.e., small patient population, 
rapid advances in treatment). It also remains debatable, however, whether an outcomes-
based risk-sharing agreement, such as in the United Kingdom, decreases policymaker 
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uncertainty regarding whether the high drug costs are worth public funding. Although 
such an agreement requires less data and great patient heterogeneity would not be an 
issue, other issues are likely to exist (e.g., validity of the outcome measure, monitoring 
issues, and administrative burden). Instead of requiring outcomes research in general, 
as in the Dutch case, policymakers could also consider requesting additional data on 
specific uncertain items –for example, prioritised by a Value of Information analysis– to 
enhance outcomes of investments of valuable resources. Policymakers could also con-
sider requesting Bayesian updating of the existing model, which is trial-based, stochas-
tic or model input parameter uncertainty analysis, or a synthesis of evidence from the 
real-world with trial follow-up and other published information.
There is currently, however, no flowchart available to policymakers that outlines the 
policy options available to best address the various types of uncertainty regarding value 
for money of a new health care technology under consideration for reimbursement. 
Future research might consider developing guidelines that assist policymakers in select-
ing the most appropriate arrangement addressing the type of uncertainty in question. 
Such guidelines should preferably provide a flowchart describing different options (e.g., 
conditional reimbursement, finance- or outcomes-based risk-sharing arrangements, 
and patient registry) and appropriate time frames while taking into account the type of 
uncertainty (e.g., medical or economic uncertainty), the type of disease (e.g., population 
size, acute vs. chronic), and characteristics of the drug.
To conclude, outcomes research provided valuable information on real-world patients, 
types of treatments, dosages, dose modifications and health care costs. Assessing (incre-
mental) effectiveness and cost-effectiveness, however, was challenged by small patient 
numbers, missing data, extensive treatment variation, and great patient heterogeneity 
in everyday practice. Although the generated evidence improved informed decision 
making regarding the value of the drug in everyday practice, much uncertainty remained 
regarding its incremental cost-effectiveness. At reimbursement decision making, policy-
makers should carefully consider what type of disease-specific evidence could lead to 
an acceptable reduction in uncertainty regarding the question whether the (high) drug 
costs are worth public funding at its re-evaluation. Instead of implementing outcomes 
research requirements in general, policymakers should carefully consider which option 
(e.g., finance- or outcomes-based risk-sharing arrangement) will appropriately reduce 
uncertainty and ensure sufficient value for money and is worth the costs of implementa-
tion.
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Background
Due to ever increasing health care expenditure, many countries developed policies and 
decision structures to contain expenditure. Although such policies can be directed at all 
(innovative) health care technologies in the basic benefit package, most of them have 
been directed at pharmaceutical products.11 After demonstrating the efficacy, quality 
and safety of a pharmaceutical product to gain market approval from the market licens-
ing authority (e.g., the European Medicines Agency, and the United States Food and Drug 
Administration), many countries require additional HTA evidence for reimbursement 
decision making. This additional requirement has been labelled as the ‘fourth hurdle’ 
to obtain market access.12 There are differences in drug reimbursement systems across 
countries, and there has been a lack of evidence on the efficiency and sustainability of 
the diverse systems. Analytically oriented studies enhance understanding of drug reim-
bursement systems and their strengths and weaknesses,13,14 and thus facilitate policy 
learning and provide lessons on how to improve system efficiency and sustainability.
This thesis focusses on decision making in drug reimbursement. The overall aim is to 
describe, analyse and evaluate systems that make decisions on reimbursement of drugs. 
The thesis is structured in three parts addressing six main research questions. As explor-
ative introduction, part A investigates the social preferences for the goals of a health 
system. Part B focusses on drug reimbursement procedures, processes and criteria. Part 
C evaluates the coverage with evidence development policy tool to handle uncertainty 
of evidence in reimbursement decision making. This final section discusses the main 
findings, presents suggestions on how to improve decision making in drug reimburse-
ment, and explores challenges for future research.
What are the objectives of a health system?
Chapter two explored the theoretical foundation of an international framework for 
cross-country health system performance comparison and elicited social relative pref-
erences of five independent health system objectives. Health related objectives were 
valued most importantly (equitable distribution of health [0.34] and average level of 
health [0.29]), followed by financial fairness (0.29), and process related objectives (utility 
derived from the process [0.07], and its distribution [0.06]).
At the national level, however, most health care systems share three main objectives 
for policymaking. The overarching objective is to improve or maintain health, but for 
policymaking within the constraints of limited resources and social preferences with re-
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spect to equity and accessibility. The three policy objectives can be seen as the poles of 
a triangle (see Figure 11.1), where the aim of policymaking is to balance these objectives 
according to a socially acceptable equilibrium. Policymakers from different countries 
may differ in how they trade-off between these objectives, and hence, where they are 
situated within the triangle.
What criteria are important in drug reimbursement decision making?
Chapter three and four showed that the five studied countries (Austria, Belgium, France, 
The Netherlands, and Sweden) use reasonably comparable criteria for decision making 
related to drug reimbursement. The criteria reflect the main policy objectives of the 
systems. Addressing the quality of care objective, therapeutic value was found to be, 
by far, the most important criterion in all five countries. The therapeutic value judgment 
is mainly based on an evaluation of the efficacy, effectiveness, safety, and adverse ef-
fects of a drug. In all five countries, added therapeutic value was reflected in a higher 
reimbursement basis.
Addressing the sustainability objective, cost-effectiveness and budget impact are for-
mal criteria at the national or regional level in all five countries (cost-effectiveness only 
recently for new drugs in France). The assessment of cost-effectiveness, however, varies 
across countries from evaluating the quality of evidence to evaluating the actual cost-
effectiveness ratio. None of the five countries applies a strictly defined or transparent 
cost-effectiveness threshold (range).
Sustainability 
Equity &
Quality of care
  
accessibility
Figure 11.1 Health care system policy objectives
Source: Le Polain, Franken et al.15
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Finally, addressing the equity and accessibility objective, the severity of the disease is 
an important criterion in reimbursement decision making. The more severe a disease is, 
the higher the chance to get the treatment reimbursed (and at a higher reimbursement 
rate), especially in case of a rare disease without an alternative treatment. As such, the 
disease severity criterion is related to the medical necessity, therapeutic, and social need 
for a particular treatment.
How do drug reimbursement decision-making systems handle 
uncertainty of evidence?
Policymakers often face the pressure ensuring timely access to promising drugs for pa-
tients in need. Uncertainty may exist on the actual clinical benefit, the adoption and dif-
fusion rate, value for money, and the economic impact of a new drug.18 The five studied 
countries vary in how they handle uncertainty of evidence in decision making. None of 
the five countries, however, seems to systematically postpone the initial reimbursement 
decision (i.e., delay access) until sufficient evidence becomes available,16 nor systemati-
cally links the price paid for drug to the quality of the available evidence.23
Austria is the only country that has no system of systematic revisions, although ad hoc 
evaluations can be initiated. Belgium and The Netherlands have an evaluation proce-
dure for specific groups of drugs (class I drugs in Belgium, and medical specialist drugs 
-formerly expensive inpatient drugs- in The Netherlands); an evaluation occurs within a 
window of one-and-a-half to three years in Belgium or four years in The Netherlands. 
In contrast, France systematically revises all reimbursed drugs every five years. Sweden 
evaluates all enlisted drugs from the old scheme (listed before 2002) according to 
therapeutic classes, and additionally, decides on a case-by-case basis whether a decision 
requires evaluation after a time period.
Many systems introduced a variety of policies to reduce uncertainty by making reim-
bursement conditional on additional evidence development.18,24-26 Although such 
policies aim to guarantee early access to all patients in need (addressing the equity and 
accessibility objective), this is at the risk of failure towards the quality of care and sus-
tainability objective (i.e., a wrong decision if the drug is not sufficiently (cost) effective 
or not sufficiently safe).
Part C evaluated the Dutch coverage with evidence development policy regarding its 
effectiveness, feasibility and appropriateness. This policy was first implemented in 2006 
for expensive inpatient drugs, and from 2013 onwards, this policy has been extending 
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to specific groups of outpatient drugs. If a drug was included in this policy, hospitals 
temporarily received an additional ear-marked budget. Since the Dutch policy changed 
towards risk-based package management (2012), drugs included are eligible for condi-
tional funding (i.e., hospitals negotiate with the insurance companies on the price paid 
for the add-on Diagnoses Treatment Combination). Conditional funding (previously 
temporarily additional funding) is, however, linked with the obligation to gather data on 
appropriate drug use and cost-effectiveness in everyday clinical practice.229 After four 
years of use, an evaluation determines whether or not (additional) funding continues 
to exist.
Chapter eight assessed whether the Dutch coverage with evidence development policy 
was effective in reaching its objective (guaranteeing equal access). Although physicians 
needed a long adjustment period to get familiarised with the new drug, they did not 
indicate experiencing prescription barriers. The use of the drug significantly increased 
after the introduction of the policy. Some unexplained regional differences, however, 
continued to exist. This indicates that the policy had a positive effect on prescribing 
behaviour and was thus, at least partially, effective in reaching its objective.
Coverage with evidence development seems to be a promising policy option to reduce 
policymaker uncertainty by guaranteeing early access to all patients in need while 
ensuring the possibility to revise the initial decision, which was based on (highly) 
uncertain evidence on the drug’s real world value. It is, however, debatable whether 
it is always feasible to obtain sufficient evidence from everyday clinical practice for an 
evaluation relating to whether the high drug costs are worth public funding. Chapter 
nine showed that this may depend on the drug and the disease. The three case studies 
confirmed theoretical expectations and expert opinions219,224 that the lack of randomi-
sation in everyday practice result in incomparable patient groups and the inability to 
correct for confounding. However, the chapter also revealed that it still may be feasible 
to obtain internally valid and generisable incremental cost-effectiveness estimates by 
synthesising everyday practice data with trial data (in the oxaliplatin cases). Moreover, 
we showed that the gathered data from everyday practice resulted in valuable evidence 
for policymakers regarding various initial uncertainties arising from the gap between 
clinical trials and everyday practice.
In all three case studies it was possible to reduce uncertainty regarding the drug’s use, 
effects and costs in everyday practice patients. Such evidence can improve quality of 
care and enhance efficient allocation of scarce health care resources. However, we also 
showed that for some drugs and indications it may be impossible to estimate sufficiently 
valid and precise incremental cost-effectiveness estimates (in the bortezomib case). It is 
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highly debatable whether a coverage with evidence development policy is always the 
best option to reduce policymaker uncertainty. Chapter ten showed that other options 
such as finance or outcomes based agreements may be more appropriate for some 
drugs or indications.
To what extent do the drug reimbursement systems satisfy the 
conditions of legitimate decision making?
Policymakers are forced to make trade-offs between the objectives of their health care 
system. These trade-offs are a matter of normative choice; the aim of policymaking is to 
balance the system objectives according to a socially acceptable equilibrium. Therefore, 
drug reimbursement systems cannot be compared on the outcomes of the trade-offs, 
but they can only be assessed according to what extent the decision-making process 
satisfies the conditions of legitimate decision making in line with social values of a 
country. We used the theoretical ethical accountability for reasonableness framework 
developed by Daniels and Sabin102 to operationalise legitimacy of decision making. 
According to the Daniels and Sabin framework, a fair and legitimate procedure satis-
fies four conditions: (i) publicity of the decision rationale, (ii) relevance of the decision 
criteria, (iii) revisability of the decision in light of new evidence and arguments, and iv) 
enforcement of these three criteria.102
Publicity of the decision rationale
Although all five systems use reasonably similar reimbursement criteria, the actual role 
of each criterion in the decision-making process is often not transparent. Assessment 
reports are usually published (except in Austria). The weighing process (i.e., appraisal) 
which leads to the advice (or decision), is, rarely published, however. Similarly, assess-
ment criteria are clearly defined whereas appraisal criteria are often far less explicit. 
Although interviewees in our study acknowledged that therapeutic value is the most 
important criterion, none of the countries applies a formal hierarchy of the criteria and 
the actual role of each criterion relatively to other criteria is not transparent. None of the 
countries applies an explicit cost-effectiveness threshold (range). The role of appraisal 
criteria particularly lacks the publicity of the decision rationale. Chapter five showed, 
for example, that policymakers experience substantive difficulties in operationalising 
the disease severity concept and, subsequently, seem to struggle in making its actual 
role in the decision making process explicit. Remarkably, this chapter also revealed that 
policymakers, above all, prefer maintaining discretionary decision power and thus prefer 
continuing implicitly weighing all decision criteria.
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In Sweden, applicants can withdraw their reimbursement request (e.g., if leaning towards 
a decision to reject reimbursement), in which case no report is published. This practice 
guarantees confidentially, but at the cost of transparency. Similarly, price-volume agree-
ments in France, and recently also in The Netherlands, aim to control the budgetary 
impact, but because of confidentiality, they decrease the transparency of the decision 
rationale. Remarkably, even though The Netherlands has a separate appraisal commit-
tee, reimbursement decision rationales on outpatient drugs are hardly ever discussed at 
appraisal committee meetings.
Relevance of the decision criteria
This condition requires that all involved stakeholders understand the decision problem 
and acknowledge that choices need to be made to meet the system objectives. Involve-
ment of all those who are affected by the decision increases the likelihood that the 
rationales for the decision will be considered relevant and acceptable.107,265 The system 
objectives are reflected by the main reimbursement criteria (the therapeutic value, cost-
effectiveness and budgetary impact, and disease severity criterion reflect the quality of 
care, sustainability, and accessibility and equity objective, respectively). This does not, 
however, guarantee that the general public truly understands the decision rationale. All 
five systems satisfactorily seem to ensure stakeholder involvement, either through di-
rect representation in the expert advisory committee (Belgium and Austria), or through 
consultation of relevant stakeholders in case the committee consists of scientific ex-
perts (France, The Netherlands, and Sweden). It should be noted that only Sweden has 
a patient representative in the expert committee; this committee also makes the final 
decision.
Revisability of the decision in light of new evidence and arguments
Especially in case of high uncertainty and/or rapid advances in treatment and, subse-
quently, changes in clinical guidelines, the option of revising a decision is important 
whenever new evidence becomes available. Although variation exists, the five systems 
make limited use of policies that enforce systematic collection of new evidence and/
or policies to systematically evaluate previous decisions. Only France and Sweden sys-
tematically conduct group revisions. In addition, France revises the status of all drugs 
every five years, and Sweden revises a decision, case-by-case, in case of important initial 
uncertainty. Belgium and The Netherlands only evaluate decisions for specific groups of 
drugs. Conversely, Austria has no system of systematic revisions.
Remarkably, however, our study revealed that, although the Dutch coverage with 
evidence development policy addresses the revisability condition, Dutch policymakers 
experienced great difficulties in enforcing the consequences of the first revisions for 
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expensive inpatient drugs. If reimbursement is to be made conditional on evidence 
development, the consequences of evaluating the new evidence (e.g., delisting, alter-
ing the price) should be enforceable. In contrast, results from systematic revisions in 
France93,95 and Sweden96 are promising.
Enforcement of these three criteria
All five countries legally instituted a designated national reimbursement agency that 
falls under ministerial responsibility. All systems satisfactorily implemented formal 
appeal procedures for stakeholders. Although the agencies are audited or certified by 
external committees, self-evaluation is lacking in relation to performance of the system 
on the processes and outcomes. The outcome of the system is mainly monitored on 
pharmaceutical expenditure (addressing the sustainability objective). The systems 
rarely conduct an evaluation regarding the quality of care, and equity and accessibility 
objectives.
Limitations of the Daniels and Sabin framework
One of the main limitations of this thesis may be the use of the Daniels and Sabin frame-
work. Although this framework has emerged as a leading framework for fair priority 
setting,266 others have criticized it. The framework focuses on procedures that ensure 
fairness and legitimacy of a just decision; the generated outcomes are not important, 
however, and thus, an important gap remains at the content level.267 Friedman268 sug-
gested revising the legitimacy conditions because they are not sufficiently adequate for 
ensuring decisions that are acceptable to everyone. Moreover, Schokkaert269 claimed 
that the framework does not contribute anything to the substantive debate how to 
make difficult choices in priority setting. Nevertheless, empirical evidence suggests that 
priority setting processes that fulfil the four conditions for accountability for reasonable-
ness are perceived as being legitimate and fair.106-108 We believe that using the Daniels 
and Sabin framework has provided us in-depth insights into reimbursement decision 
making, and therefore, has been extremely useful as a first step towards identifying 
strengths of and challenges for the systems.
What are the strengths of and challenges for drug reimbursement 
systems?
Our study provided important insight into the strengths of and challenges for drug 
reimbursement decision-making systems. Nevertheless, it should be noted that the rela-
tive small sample of countries can be seen as one of the main limitations. The five coun-
tries may not necessarily be representative of other European countries. We observed 
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similarities as well as important differences in structure, organisation, and procedures 
of the systems, however. Because of the degree of detail of our analysis, we believe that 
this was only feasible in a relatively small number of countries. We also believe that only 
little benefit would have been gained if we had included more countries. Another limita-
tion was that we only studied the coverage with evidence development tool regarding 
three indications in cancer using retrospective research designs in The Netherlands. 
Some of our conclusions may therefore not be generalisable to all drugs in different 
contexts. Nevertheless, we believe that our research enhanced understanding of drug 
reimbursement decision-making procedures and processes. Especially the information 
regarding challenges for the systems facilitates policy learning on how to improve the 
decision-making process.
Strengths of the systems
All five countries have a national system that evaluates whether or not a drug should be 
reimbursed out of public revenue. All share similar and clear policy objectives which are 
reflected by the main criteria for reimbursement. The therapeutic value criterion mainly 
reflects the quality of care objective, the cost-effectiveness criterion mainly reflects the 
sustainability objective, and the severity of disease criterion mainly reflects the equity 
and accessibility objective. Performance of the systems is monitored in terms of phar-
maceutical expenditure (addressing the sustainability objective). Information based on 
health technology assessment is used at several phases in the decision-making process 
in order to trade-off between the system objectives.
All systems are prepared to pay out of public pocket for drugs with sufficient added 
therapeutic value. Stakeholders are involved in the process either through consultation 
or direct representation in the expert advisory committee. Implementation of reim-
bursement decisions is facilitated by means of guidelines and drug formularies.
Challenges for the systems
This thesis has put forward three main challenges: (i) transparency of the decision-
making process, (ii), cyclical decision making and (iii) decision making based on value 
for money.
Transparency of the decision-making process
Transparency of the decision-making process is the first condition of legitimate decision 
making (publicity of the decision rationale). Theoretically, assessment and appraisal are 
two separate phases in the reimbursement decision-making process (see Figure 1.1). 
Assessment is purely descriptive in terms of evaluating the quality of and quantifying 
the available evidence, while appraisal entails weighing up the outcomes and thus con-
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tains a value judgment. Chapter four revealed, however, that assessment and appraisal 
are often strongly intertwined processes in actual decision-making practice. None of 
the countries applies a formal hierarchy of the reimbursement criteria, nor applies an 
explicit cost-effectiveness threshold; the actual role of each criterion in the decision-
making process lacks transparency. Especially the appraisal (i.e., appraisal criteria and 
the weighing process) is not sufficiently transparent.
Cyclical decision making
A cyclic decision-making process entails four phases (see Figure 1.1). After the assess-
ment, appraisal, and decision-making phase, follows the evaluation phase. The evalua-
tion phase entails (i) ascertaining the consequences of the decision, and (ii) evaluating 
(restart the cycle of assessment, appraisal, and decision making) whether the initial 
decision is still appropriate in case new evidence has become available.
Regarding ascertaining the consequences, all five systems monitor the performance 
of the systems in terms of pharmaceutical expenditure (addressing the sustainability 
objective). None of the systems, however, systematically evaluates the impact of the 
system against the other two system objectives (i.e., the quality of care, and the equity 
and accessibility objective).
Regarding evaluating whether the initial decision is still appropriate, we could demon-
strate that the systems only make limited use of policy tools to systematically evaluate 
drugs´ relative value throughout their life cycle, although variation exists. All five systems 
have a so-called supply driven system: the process starts with a manufacturer´s request 
for reimbursement and proceeds on a case-by-case basis. This may, however, lead to 
pragmatic incrementalism,91 risking a low degree of consistency across decisions. Not all 
systems are sufficiently equipped to systematically deal with uncertainty of evidence in 
the decision making. Consequently, the systems seem to experience substantial difficul-
ties to fulfil the revisability condition of legitimate decision making.
Decision making based on value for money
Budgetary impact and drug expenditures are monitored in all five systems, this does 
not, however, guarantee value for money in the decision making. It should be noted that 
all five countries have an ‘open-ended’ pharmaceutical budget (i.e., there is no absolute 
budget maximum or maximum relative share of health care expenditure). In contrast 
to budgetary impact, information on cost-effectiveness can be used to base decisions 
on value for money. Cost-effectiveness is a formal reimbursement criterion in all five 
countries (only recently for new drugs in France). However, none of the countries applies 
a strictly defined or transparent cost-effectiveness threshold (range). Moreover, none of 
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the countries explicates the importance of cost-effectiveness relatively to other criteria. 
This is even true for Sweden, which is the only one of the five studied countries that has a 
value-based pricing system. Value-based pricing implies a direct link between the gains 
and the costs of a pharmaceutical product.
Remarkably, cost-effectiveness does not seem to play a major role in actual decision-
making practice. Chapter six showed that, in the period January 2005 to July 2011, 
reimbursement dossiers for only eleven drugs included a full economic evaluation (i.e., 
cost-effectiveness and/or cost-utility analysis270) in both Sweden and The Netherlands. 
In The Netherlands, only 12% of all outpatient drug applications (35% of List 1B ap-
plications -non-interchangeable drugs and/or drugs with an added therapeutic value-) 
included pharmacoeconomic evidence. Although more pharmacoeconomic evidence 
was available in Sweden (97%), only 33% of dossiers included a full economic evalua-
tion. Furthermore, chapter seven revealed that Dutch policymakers experienced great 
difficulties in putting restrictions on reimbursement based on cost-effectiveness, even 
in case of extreme high costs per Quality Adjusted Life Year.
Suggestions to improve decision making in drug reimbursement
This thesis enhanced the understanding of drug reimbursement systems by obtaining 
insights into reimbursement procedures, processes, criteria, and insights into the effec-
tiveness, feasibility, and applicability of the coverage with evidence development policy 
tools to handle uncertainty of evidence in the decision making process. Therefore, our 
study contributed to the scientific evidence base for improving reimbursement systems’ 
legitimacy, efficiency and sustainability. The strengths of, and especially the identified 
challenges for the systems can be seen as opportunities for furthering the aim to im-
prove current drug reimbursement decision-making practice.
The main overarching challenge is improving the legitimacy of the decision-making pro-
cess. It should be noted, however, that even if decisions are made following a legitimate 
process, this does not guarantee that the outcomes are always perceived to be accept-
able to the general public or politicians. As described above, according to the Daniels 
and Sabin framework,102 a fair and legitimate procedure satisfies four conditions. Each 
of the following recommendations addresses, in no specific order, one of the legitimacy 
conditions. The list of recommendations is not exhaustive, but restricted to recommen-
dations that arose from the main study findings.
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Building on existing strengths
In all five systems reimbursement decisions are made at the national level. A dedicated 
national system fulfils the fourth condition of legitimate decision making, because it 
can enforce the first three conditions. Theoretically, a national decision system ensures 
equitable allocation of health care resources. The main system objectives are reflected 
by the existing reimbursement criteria. Therefore, these criteria sufficiently facilitate 
making trade-offs between the system objectives even within the constraints of limited 
resources and social preferences with respect to equity and accessibility. Thus in prin-
ciple, the existing systems are equipped for their imposed responsibilities. However, if 
budget responsibility is allocated, for example, to regions (as in Sweden) or to hospitals 
(as in The Netherlands), equitable access may not be guaranteed for patients in need, 
and variation in access may occur within a country. It is, therefore, important to closely 
monitor the outcomes of a system regarding all three policy objectives.
Increasing the transparency of the decision-making process
One of the main challenges for the systems is improving the transparency of the deci-
sion-making process (addressing the publicity condition of legitimate decision making). 
Especially the use of appraisal criteria and their role in the decision-making process 
lacks transparency. Because assessment and appraisal are often strongly intertwined 
processes, the systems can better disentangle assessment and appraisal. Surprisingly, 
even in The Netherlands, which has a separate appraisal committee, assessment and 
appraisal are strongly intertwined processes. Moreover, outpatient drugs are hardly ever 
discussed in Dutch appraisal committee meetings. If an appraisal committee is estab-
lished next to an assessment committee, reimbursement applications and evaluations 
are likely to be discussed at both committee meetings; especially in the case of relatively 
high costs and limited health gains.
Conversely, chapter five revealed that policymakers prefer maintaining discretionary 
decision power. This implies a great challenge for policymakers if the decision-making 
process is to be made more transparent. It is debatable why policymakers experience 
such difficulties in explicating their decision base. It could be that it is easier to make 
‘happy’ decisions (i.e., grant reimbursement) that satisfy all stakeholders compared to 
making ‘unhappy’ decisions (i.e., denying reimbursement). Klein271 stated, for instance, 
“Ministers will always be tempted to take credit for generosity, even while seeking to avoid 
blame for parsimony.” However, priority setting choices need to be made in order to 
keep the system sustainable in the long-term. It is, therefore, of utmost importance to 
improve the transparency of the decision-making process.
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None of the five countries uses an explicit decision framework. In chapter four, we 
present an explicit framework that can be used as a first step to improve the legitimacy 
of the decision-making process. The framework addresses both the transparency and 
the relevance condition of legitimate decision making. It consists of five key questions 
including their relevant criteria, relating to (i) the medical, therapeutic, and/or societal 
need, (ii) preparedness to pay for treating a particular condition, (iii) preparedness to pay 
for a particular treatment, (iv) preparedness to pay more compared with its alternatives, 
and (v) actual willingness to pay from public sources. The framework brings a certain 
logic in the order of the questions that need to be answered in reimbursement decision 
making; it allows the reconstruction of the decision-making process. The framework 
can be seen as a tool to allow better structuring of the decision-making process; all five 
questions need to be answered subsequently. Therefore, it can facilitate consistency of 
decision making and support the justification of decisions and, by clearly reporting the 
answer to each question, it can ensure the transparency of the decision-making process.
Make the reimbursement process more cyclic
Reimbursement decisions are inherently made under uncertain conditions. It is, there-
fore, crucial to ensure a cyclic decision-making process and thus evaluate a drug’s social 
value throughout its entire life cycle. An initial reimbursement decision ought to be 
revisable in case of new arguments or in case that new evidence becomes available 
(addressing the revisability condition of legitimate decision making).
This thesis showed that the five systems make limited use of systematic revisions and 
that not all systems are sufficiently equipped to systematically deal with uncertainty of 
evidence in the decision making. Nevertheless, in recent years an increasing number 
of risk-sharing schemes and conditional reimbursement policies have been introduced 
and seem to gain more attention. Results from systematic revisions in France93,95 and 
Sweden96 are promising.
There is, however, much room for improvement. If policymakers are prioritising early 
access to promising drugs with high uncertainty on their actual value in everyday prac-
tice, it is even more important that evaluation options exist. Moreover, evaluation 
policies need to be embedded in the system (addressing the enforcement condition of 
legitimate decision making). Furthermore, Part C showed that it is important to evaluate 
policies regarding their effectiveness, feasibility and appropriateness. After a new policy 
has been instituted, the policy needs to be evaluated as to whether it fulfils its objectives 
and whether or not it requires adjustments. For instance, the Dutch coverage with evi-
dence development policy was partly triggered by signs of ‘postal code prescribing’ of 
an expensive drug for breast cancer.192 Chapter eight revealed, however, that although 
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the use of the drug significantly increased after the introduction of the policy, some 
unexplained regional differences remained. Thus the policy was only partially effective 
in reaching its objective (equitable access to expensive drugs); adjustment of the policy 
may still be necessary.
Coverage with evidence development schemes seem to be increasingly popular as 
policy instrument to handle uncertainty of evidence, and thus to ensure a cyclic process. 
It is, however, debatable whether it is always feasible to obtain sufficient evidence from 
everyday clinical practice for an evaluation regarding whether the high drug costs are 
worth public funding. This may depend on the type of drug and type of disease; as 
chapter nine showed, for some drugs and indications it may be impossible to obtain 
sufficiently valid and precise incremental (cost) effectiveness estimates using real-world 
data. Therefore, it is important to carefully consider what type of policy appropriately 
ensures sufficient reduction of the initial uncertainty of the evidence at the time of 
evaluation for the particular drug in question.
Furthermore, if the reimbursement process is to be made more cyclic, the consequences 
of an evaluation (e.g., delisting, altering the price) ought to be transparent at the initial 
decision and enforceable in the evaluation phase. New policies may require different 
approaches using other tools, and they may induce important new responsibilities for 
policymakers. For example, we revealed that Dutch policymakers experienced great 
difficulties in enforcing the consequences of the first evaluations for expensive inpatient 
drugs. However, guaranteeing early access without implementing and, if required, 
executing exit strategies is not sustainable in the long term. In some cases, it may even 
be more appropriate to reject (conditional) reimbursement at the initial phase. It should 
be noted that it requires political courage to revise a decision and delist a drug that was 
previously reimbursed; this may even be more difficult in case when media attention is 
present and/or if there is publicity surrounding identifiable individuals who may suffer 
from delisting.
Encourage reimbursement of drugs that deliver social value for money
All five systems can improve decision making based on value for money. All require evi-
dence on cost-effectiveness; there is, however, much room for increasing its actual role in 
the decision making. Chapter six and seven revealed that cost-effectiveness may not be 
that important in actual decision making. It is debatable if this is sustainable in the long 
term, especially because new innovative drugs are inclined to increase exponentially in 
price. For instance, between 2003 to 2013, expenditure for cancer drugs increased in The 
Netherlands from 270 to 733 million Euros per year.272 Furthermore, there seems to be 
a rising trend of using combination(s) of expensive treatments for the same indication. 
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The question arises why new innovative drugs need to be so expensive,260,261 and how 
the systems can encourage appropriate price setting for drugs to ensure social value for 
money.
Above all, if reimbursement decision making is to be based on value for money, cost-
effectiveness ought to play an important role in decision-making practice. The systems 
could explicate the actual role of cost-effectiveness relatively to other reimbursement 
criteria. Besides cost-effectiveness, other criteria may complement sustainable deci-
sion making. For instance, the Dutch Commission for the Assessment of Oncological 
Resources (Commission BOM) suggested a minimal expected gain of two months in 
life expectancy.191 This links closely to pleas for only reimbursing interventions that, at 
least, produce a non-negligible health gain.154 Using both an explicit cost-effectiveness 
threshold range and an explicit minimal health gain facilitates transparency of the deci-
sion making and thus may help to gain public trust in the system.
Although it is often claimed that an explicit cost-effectiveness threshold range may 
induce strategic behaviour, such behaviour may also be observed in case of an implicit 
threshold. For instance, it seems that the incremental cost-effectiveness ratio of out-
patient drugs that obtained reimbursement in the last few years in The Netherlands 
continue to rise far above the reimbursement agency’s suggested threshold maximum 
(€80,000 per Quality Adjusted Life Year120). Remarkably, several of these decisions 
concerned outpatient drugs that were not even discussed at Dutch appraisal commit-
tee meetings. Conversely, in England it seems generally acceptable that the National 
Institute for Health and Care Excellence (NICE) uses cost-effectiveness as reimbursement 
criterion and applies an explicit cost-effectiveness threshold range in decision making.273 
This shows that decision making can be transparently based on cost-effectiveness. 
Although the threshold may incentivise to set a price just below the threshold, it may, 
on the other hand, also incentivise to keep the price below this threshold (instead of 
continually rising prices to implicitly seek for a maximum as seems to be the case in The 
Netherlands). Nevertheless, it should be noted that political unacceptability of some of 
NICE decisions to reject reimbursement has led to arrangements such as patient access 
schemes,274 the Cancer Drugs Fund,135 as well as to changes to NICE’s decision framework 
(e.g., the End of Life premium275).
It is important, however, to determine who is responsible for setting the threshold 
range, and who is responsible for executing the threshold. For example, in 2012 the 
Dutch agency considered a negative advice for three specialist orphan drugs for Pompe 
and Fabry disease. Preliminary reports were leaked to the press, which resulted in a 
turbulent episode. After a considerable amount of public debate and political pressure, 
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the Dutch agency modified its advice, recommending the continuation of funding be-
cause of the high severity of the disease, the high costs per individual patient, and the 
relatively low budgetary impact.188 Remarkably, the Dutch agency did not have any new 
scientific evidence. The minister accepted the advice and in 2013 made a confidential 
price agreement with the manufacturer.190 It is, however, highly questionable whether it 
was feasible to agree on a price that ensures social value for money (e.g., Myozyme for 
classic Pompe disease was estimated to cost €300,000 to €900,000 per Quality Adjusted 
Life Year188).
Although the Dutch agency previously suggested a threshold range depending on 
the severity of the disease (i.e., €10,000–€80,000 per Quality Adjusted Life Year120), 
this was never confirmed nor endorsed by the minister. It is, however, a question of 
debate whether the Dutch reimbursement agency, only having an advisory role, should 
take the lead in determining the Dutch threshold. This is especially as they not only 
will carry all the negative publicity, but may also be subsequently overruled by the 
Minister. Moreover, although medical guidelines should consider cost-effectiveness 
and physicians should be involved in the rationing debate, it is highly questionable 
whether rationing decisions should be entirely delegated to the individual physician 
who actually treat the patient in need. In June 2014, the Dutch Cancer Society (KWF 
Kankerbestrijding) published a monitoring report acknowledging that there ought to 
be limits to the costs for a treatment, and advising the minister to set up a committee 
to propose a cost-effectiveness threshold range.272 Interestingly, the social acceptability 
of denying treatments seems to have changed even in the last few years. For example, 
medical professionals were reluctant to base treatment decisions on cost-effectiveness 
in the discussion regarding Pompe and Fabry disease, while currently they specifically 
ask for transparency regarding a cost-effectiveness threshold (range) imposed by the 
government.
It is of utmost importance that the rationale for priority setting comes into the public 
debate. In 2013, the Dutch reimbursement agency organised focus group discussions 
with patients and the general public regarding this debate. They concluded that there 
was no sense of urgency for such a public debate; this was due to a lack of knowledge 
of the focus group participants, and because there was a general feeling of denying ‘the 
right to health care’ for which the average citizen pays a high price.276 Based on this, the 
Dutch reimbursement agency decided to not (yet) begin a wider social debate on cost-
effectiveness. We believe, however, that medical professionals as well as the general 
public need to be involved in the debate as to how much society is willing to pay for 
a treatment. Consequently, it is essential to appropriately inform the general public to 
overcome the current lack of sense of urgency and the associated gap in knowledge. 
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Although politicians seem to be unwilling to set an explicit (maximum) threshold, they 
have to take their responsibility, as solidarity in health care may be at risk. Decision mak-
ing based on value for money may induce new tasks and responsibilities for policymak-
ers and may require a different approach taking into account the interests of all involved 
stakeholders.
Furthermore, a cost-effectiveness threshold may also act as gatekeeper for conditional 
reimbursement. In the case of extremely high costs, the drug will, even in case of opti-
mistically estimated health gains, inevitably fail to meet the maximum of any realistic 
threshold. Similarly, in such cases it will most likely be impossible to agree on a price 
reduction (e.g., by means of a financial risk sharing agreement) which ensures social 
value for money. Policymakers could make better use of this knowledge at the initial 
decision and thus reject (conditional) reimbursement at the initial decision instead of 
postponing the difficult decision, for example, by means of a coverage with evidence 
development scheme. Policymakers could also consider linking the reimbursed price to 
the quality of the available evidence to ensure value for money.23 Remarkably, only in 
the Swedish value based pricing system, the reimbursement and price decision is one 
combined decision that is made by one committee. Most systems have no, or only a 
relatively loose link between the price and reimbursement decision. If value based pric-
ing is the future, drugs should be priced according to their actual value and thus a closer 
link should be established between the price decision and the reimbursement decision.
Regarding risk sharing schemes, it is important that policymakers are aware of the pros 
and cons of such schemes. Although financial risk sharing agreements divide the surplus 
between payers and manufacturers and results from the price-volume agreements in 
France are promising,93,94 such agreements do not reflect value for money. Moreover, 
such agreements are most often confidential in order to maintain a high list price. This 
is, however, at the cost of transparency. In contrast, agreements based on outcome 
guarantee value for money (i.e., no cure no pay agreement). However, many issues 
have been reported for this sort of agreement including high implementation and 
transaction costs, administrative burden, and challenges in accurately measuring treat-
ment effect.35,36,185,186 Although coverage with evidence development schemes require 
an evaluation after a certain time period, and thus may ensure value for money in the 
long term, it is important to mention that during the first years the payer takes all the 
financial risks. Moreover, such schemes often heavily rely on real-world observational 
data. As chapter ten showed, observational data may not always sufficiently reduce the 
uncertainty regarding a drug’s value for money.
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Consequently, policymakers need a variaty of tools that address the various types of 
uncertainty. Depending on the type of drug and type of disease, policymakers should 
carefully consider, case-by-case, which option is most appropriate and will sufficiently 
reduce the initial uncertainty and also ensure value for money in the long term and is 
worth its costs of implementation.
Challenges for future research
This thesis contributed to the scientific evidence base on reimbursement procedures, 
processes, criteria, and provided insights into the effectiveness, feasibility, and appli-
cability of the coverage with evidence development policy tool. There are, however, 
important challenges for future research.
Our study revealed that none of the five countries studied used quantitative rating 
methods to support decision making. Similarly, Noorani et al.277 found that HTA agencies 
in health care priority setting seldomly use quantitative rating methods. Although we 
acknowledge that quantitative methods should not impose decisions and some discre-
tionary decision power should be maintained, we also believe that quantitative methods 
may be used as guidance to support decision making and may increase the consistency 
and transparency of the decision-making process. Future research could aim to develop 
a quantitative multi criteria decision analysis (MCDA) framework for policymakers that 
facilitates the incorporation of assessment and appraisal considerations (including value 
for money) in drug reimbursement decision making. Such a framework could be used by 
policymakers of the respective reimbursement agencies, expert advisory committees, 
appraisal committees, and ministries of health to improve the transparency of decision 
making on the basis of value for money. MCDA aims to facilitate decision making by 
applying a set of methods and approaches to explicate the impact on the decision of all 
applied criteria and the relative importance attached to them.278-280 The MCDA method 
has been previously tested in drug reimbursement decision making (the EVIDEM frame-
work). It was found to be extremely useful by the Canadian drug advisory committee as 
it supported a consistent approach and a systematic consideration of a broad range of 
appraisal criteria.281,282
Furthermore, systems increasingly use different policy tools to make the process more 
cyclic in order to deal with uncertainty of evidence and to improve value for money in 
the long term. There is, however, little evidence on the actual impact of the various tools 
and there is no guideline available that outlines how best to make the process cyclic 
and which policy tools best address which type of uncertainty. Future research could 
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aim to investigate in detail the effectiveness, and the relative strengths and weaknesses 
of these different tools and assess their actual impact on transparency in the decision-
making process, and evaluate to what extent they address decision making based on 
value for money. A further aim could be the development of guidelines that assist poli-
cymakers in (i) selecting the most appropriate tool addressing the type of uncertainty in 
question, and (ii) determining the evaluation procedure. Moreover, the best case would 
be to incorporate these guidelines within the MCDA decision framework.
It should be noted, however, that although MCDA facilitates decision making, it does 
not provide a solution for all the current issues. For instance, the experienced dilemma 
of making difficult rationing choices (i.e., denying access to treatments) remains. It is 
therefore important that the rationale for priority setting is open for public debate. 
Policymakers need to take their responsibility and the general public needs to be in-
volved in this difficult debate. Nevertheless, we believe that it is important to continue 
developing (current) methods that support decision making in actual practice in order 
to further advance evidence based decision making. The use of a comprehensive MCDA 
framework may increase the consistency and the transparency of the four phases of the 
decision-making process, and thus will improve legitimacy of social decision making on 
drug reimbursement. This may result in greater confidence in the system of the general 
public. It may also facilitate a closer link between the way HTA research evaluates tech-
nologies and the way governments allocate health care budgets. It is therefore essential 
that HTA researchers and policymakers work closely together, and make use of each 
other’s expertise.
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Introduction
In many countries life expectancy is increasing but, simultaneously, continuously rising 
health care expenditure has increased the pressure on the sustainability of the systems. 
To contain expenditure, many countries developed policies and decision structures to 
manage the basic benefit package; most of them have been directed at pharmaceutical 
products. After demonstrating the efficacy, quality and safety of a pharmaceutical prod-
uct to gain market approval from the market licensing authority, many countries require 
additional Health Technology Assessment (HTA) evidence for reimbursement decision 
making (also called the ‘fourth hurdle’ to obtain market access). Due to differences in 
health care organisation across countries there are differences in drug reimbursement 
systems and reimbursement policies.
This thesis focuses on decision making in drug reimbursement. The overall aim was to 
describe, analyse and evaluate systems that make decisions on reimbursement of drugs. 
The thesis consists of three parts. Part A explores the preferences for the objectives of a 
health system. Part B investigates drug reimbursement procedures, processes and crite-
ria in five European countries. Part C evaluates the coverage with evidence development 
policy tool to handle uncertainty of evidence in reimbursement decision making.
Part A: Social preferences for health system objectives
In chapter two, we identify a comprehensive international framework facilitating cross-
country comparison of health system performance, and provide its theoretical founda-
tion. The framework consists of five independent health system objectives. Besides health 
itself, we included the process of health care delivery in a utility framework supporting 
that the process of care giving is an independent objective, irrespectively whether it 
affects health. We used a discrete choice experiment to elicit relative preferences for 
the five system objectives. Health related objectives were valued most importantly 
(equitable distribution of health [0.34] and average level of health [0.29]), followed by 
financial fairness [0.24], and process related objectives (utility derived from the process 
[0.07], and its distribution [0.06]). Compared to previous research, our weights, elicited 
from behind a ‘veil of ignorance’, placed much greater emphasis on health and health 
inequality than on process outcomes.
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Part B: Drug reimbursement procedures, processes and criteria
To obtain insight into drug reimbursement decision making, chapter three provides 
a comparative analysis of five European systems (Austria, Belgium, France, The Nether-
lands, and Sweden). The five systems share three main objectives for policymaking: (i) 
equitable access, (ii) quality of care, and (iii) sustainability of the system. The aim of poli-
cymaking is to balance these objectives according to a socially acceptable equilibrium. 
In the five systems, a national agency evaluates, on a case-by-case basis, whether or not 
a drug is worth public funding. The systems use comparable reimbursement criteria, 
which reflect the main systems’ objectives. All are prepared to pay for drugs with suffi-
cient added value. System impact, however, is mainly assessed by drug expenditure. The 
minister has discretionary decision power to alter the reimbursement advice in three of 
the five countries (Belgium, France and The Netherlands). The five systems make limited 
use of policies to systematically evaluate a drug’s relative value for money throughout 
its life cycle.
Although the five systems make efforts to increase transparency in the decision-making 
process, none of the systems uses formal hierarchical reimbursement criteria nor applies 
an explicit cost-effectiveness threshold value. All five could improve the transparency 
of the decision-making process; especially appraisal lacks transparency. Based on these 
findings, we developed an explicit framework that can be used as a first step to improve 
the legitimacy of the decision-making process. Our framework, presented in chapter 
four, consists of five key questions including their relevant criteria, relating to (i) the 
medical, therapeutic, and/or societal need, (ii) preparedness to pay for treating a par-
ticular condition,( iii) preparedness to pay for a particular treatment, (iv) preparedness 
to pay more compared with its alternatives, and (v) actual willingness to pay from public 
sources. The framework can be seen as a tool to better structure the decision-making 
process; all five questions need to be answered subsequently. Systematic use of this 
framework in actual reimbursement decision making can facilitate consistency of de-
cision making and support the justification of decisions and, by clearly reporting the 
answer to each question, it can ensure the transparency of the decision-making process.
Our study continues with exploring the importance of two reimbursement criteria (the 
disease severity and cost-effectiveness criterion) in actual decision making. Chapter 
five shows that the severity of the disease is an important consideration in Belgian, 
Dutch, French, and Swedish decision making; especially in case of high severity. All four 
countries could, however, improve the transparency of its actual importance relatively 
to the other criteria in the decision making. The operationalisation differs across the 
four countries. The Netherlands operationalised disease severity using the propor-
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tional shortfall approach. Sweden uses categories to give an indication of the severity. 
However, in both countries disease severity only plays an implicit role in the decision 
whether to reimburse a drug. In Belgium and France, it additionally plays an explicit 
role in determining the willingness to pay out of public sources because both countries 
use disease severity in setting reimbursement levels. Our study revealed that none of 
the interviewees considered quantitative information on the severity of the disease, 
additional to qualitative information, to be of decisive importance.
Furthermore, we found the relative importance of cost-effectiveness far more modest 
than would generally be expected, especially in The Netherlands. Chapter six provides 
a comparative analysis of the role of pharmacoeconomic evidence in actual Dutch and 
Swedish reimbursement decision making. More economic evaluations were available in 
Sweden than in The Netherlands (97 vs. 31, respectively), mainly due to the numerous 
exemptions from pharmacoeconomic evidence in The Netherlands (65%). In The Nether-
lands, only 35% of the 118 applications on List 1B (i.e., claiming added therapeutic value) 
were found to include pharmacoeconomic evidence in the period January 2005 to July 
2011. In all cases where drugs were rejected for reimbursement, the pharmacoeconomic 
evidence had been judged insufficiently robust. However, pharmacoeconomic evidence 
also had been judged insufficiently robust in 21% of the cases where drugs obtained 
reimbursement. In Sweden, drugs that were rejected for reimbursement had been 
judged either not cost effective (74%) or not supported by sufficiently credible data 
(26%). Nearly all drugs that obtained reimbursement in Sweden had been judged cost 
effective (92%). However, 53% of these judgements were based on a price comparison 
and 10% on a cost-minimisation analysis; only 33% were based on a full economic evalu-
ation. Moreover, dossiers for only 11 drugs included a full economic evaluation in both 
countries; of these, the reimbursement decisions differed for four drugs.
Chapter seven specifically focuses on the actual impact of cost-effectiveness in Dutch 
decision making. Although HTA already informed Dutch policymaking in the early 
1980s, evidence of health economic evaluations is only systematically used in drug re-
imbursement decision making. Even in drug reimbursement, however, the availability of 
evidence of health economic evaluations remains rather low. The chapter reveals that it 
is highly questionable whether health economic evaluations currently play a role in ac-
tual Dutch reimbursement decision making. Although the requirements exist in policy 
procedures, recent cases showed that Dutch policymakers experience great difficulties 
in putting restrictions on reimbursement based on evidence from health economic 
evaluations, even in case of extreme high costs per Quality Adjusted Life Year.
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Part C: Handling uncertainty in drug reimbursement decision making
Reimbursement decisions are inherently made under uncertain conditions. The Dutch 
coverage with evidence development policy addresses these uncertainties by making 
the decision conditional on additional evidence development. This policy was first 
implemented in 2006 for expensive inpatient drugs, and from 2013 onwards, this policy 
has been extending to specific groups of outpatient drugs.
Chapter eight assesses whether the Dutch policy was effective in reaching its objective 
(guaranteeing equal access of expensive drugs). Although interviews revealed aware-
ness of the high treatment costs, physicians did not express experiencing prescription 
barriers. Nevertheless, our study showed that physicians needed a long adjustment 
period to get familiarised with the new drug bortezomib. The use of bortezomib signifi-
cantly increased after the introduction of the policy (prescription rates increased from 
treating 2% of patients in 2004 to 17% in 2009), but remained below the rate estimated 
by the professional association of haematologists (27%). We found regional differences 
for everyday practice use (e.g., ranging from 13–27% in 2009) as well as clinical trial 
participation (e.g., ranging from 1–12% in 2006). Although our results indicate that the 
Dutch policy was thus, at least partially, effective in reaching its objective, the remaining 
regional differences may indicate the existence of residual inequality in access.
Consequently, coverage with evidence development seems to be a promising policy 
option to reduce policymaker uncertainty by guaranteeing early access to all patients 
in need while ensuring the possibility to revise the initial decision. Chapter nine inves-
tigates the feasibility to obtain sufficient evidence from everyday clinical practice for an 
evaluation regarding whether the high drug costs are worth public funding. The meth-
ods used in the three case studies were feasible to develop evidence on some aspects 
of drug use including types of treatments used, dosages, dose modifications, and health 
care costs. However, aspects such as baseline patient characteristics, reasons to start or 
stop a treatment, and treatment effects were less feasible because of important missing 
values. Despite difficulties to correct for confounding by indication, it was possible to 
estimate incremental cost-effectiveness by synthesising evidence in the two oxaliplatin 
case studies. This was, however, not possible in the bortezomib case study. The optimal 
approach may differ between drugs and their indications.
Chapter ten continues with evaluating whether a coverage with evidence development 
policy is always the best option to reduce policymaker uncertainty regarding the ques-
tion whether the costs are worth public funding. Our study shows that the gathered data 
from everyday practice can provide valuable new evidence for policymakers regarding 
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various initial uncertainties arising from the gap between clinical trials and everyday 
practice. Even though patients in everyday practice received fewer treatment cycles (4 
vs. 6) as well as lower dosages (13%) compared with trial patients, time to progression 
(6.8 vs. 6.2 months) and response rates (complete response 8% vs. 6%; very good, partial, 
and minimal response 55% vs. 41%) seemed reasonably similar. Moreover, the gathered 
evidence provided detailed data on treatment costs in everyday clinical practice. Patients 
treated with bortezomib were, however, not comparable to patients not treated with 
bortezomib despite attempts to correct for confounding. It was, therefore, impossible 
to develop a feasible model to obtain a valid incremental cost-effectiveness estimate. 
It is essential that policymakers carefully consider if a coverage with evidence develop-
ment policy will sufficiently decrease initial uncertainty or whether other options (e.g., 
finance- and/or outcomes-based risk-sharing arrangements) may be more appropriate 
to ensure sufficient value for money of expensive drugs.
Discussion
Chapter eleven discusses the main research findings and presents suggestions on 
how to improve the decision making in drug reimbursement. We evaluate the systems 
regarding the extent to which their decision-making process satisfies the conditions of 
legitimate decision making according to the Daniels and Sabin accountability for rea-
sonableness framework. Regarding the publicity of the decision rationale condition, we 
found that the systems lack in sufficiently satisfying transparency of the decision-making 
process; especially appraisal lacks transparency. Regarding the condition of relevance 
of the decision criteria, we found that the reimbursement criteria reflect the system 
objectives, and the five systems satisfactorily seem to ensure stakeholder involvement. 
Regarding the revisability condition, we found that the systems make limited use of 
policies to systematically evaluate a drug’s social value throughout its life cycle. Finally, 
regarding the enforcement condition, we found that all systems implemented a desig-
nated national agency responsible for reimbursement decision making.
Based on this evaluation, we identified strengths of and challenges for the systems; 
especially the challenges can be seen as opportunities for furthering the aim to improve 
current drug reimbursement decision-making practice. We then put forward four rec-
ommendations for the reimbursement systems. First, the systems can build upon their 
existing strengths. A shared strength is that all systems have a national system that 
evaluates whether or not a drug should be reimbursed out of public sources; all share 
similar and clear policy objectives. Second, all systems can improve transparency of their 
decision-making process. Hereto, we developed a framework that can be used as a tool 
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to better structure the decision-making process by transparently answering five key 
questions. Third, the systems can make the reimbursement process more cyclic in order 
to deal with uncertainty of evidence, for instance by implementing a coverage with 
evidence development policy, or other outcomes-based or financial-based risk-sharing 
schemes. It is important to carefully consider what type of policy will appropriately 
ensure a sufficient reduction of the initial uncertainty. This may depend of the type of 
drug and type of disease. It is, however, essential to enforce the consequences of an 
evaluation. Finally, we recommend encouraging reimbursement of drugs that deliver 
social value for money. In order to maintain the sustainability of the systems in the long 
term, all can improve decision making based on social value for money. There is much 
room for increasing the role of cost-effectiveness in actual decision-making practice.
This thesis contributes towards a better understanding of drug reimbursement systems. 
It provides empirical insights into reimbursement procedures, processes, and criteria, 
and additionally provides insights into the effectiveness, feasibility, and applicability 
of the coverage with evidence development policy tool to handle uncertainty of the 
evidence in the decision making.
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Introductie
De gemiddelde levensverwachting neemt toe in veel landen. Dit gaat gepaard met 
stijgende kosten, waardoor de financiële houdbaarheid van verschillende gezondheids-
zorgsystemen gevaar loopt. Veel landen hebben daarom de afgelopen jaren kosten be-
heersende beleidsmaatregelen genomen. De meeste van deze maatregelen betreffen 
de vergoeding van geneesmiddelen. Om op de markt gebracht te mogen worden, moet 
eerst de effectiviteit, kwaliteit en veiligheid van een geneesmiddel worden bewezen. 
Veel landen vereisen bovendien aanvullend bewijs van een medisch evaluatie onder-
zoek (ook wel Health Technology Assessment [HTA] genoemd) voor de besluitvorming 
over de vergoeding van het geneesmiddel. Dit laatste wordt vaak de vierde horde voor 
markttoegang genoemd. Aangezien ieder land de gezondheidszorg op verschillende 
wijze kan inrichten, bestaan er ook verschillen in de manier waarop wordt besloten of 
geneesmiddelen wel of niet vergoed worden uit algemene middelen.
Dit proefschrift richt zich op de besluitvorming op het gebied van geneesmiddelen-
vergoeding. Het overkoepelende doel was om geneesmiddelenvergoedingssystemen 
te beschrijven, te analyseren en te evalueren. Het proefschrift bestaat uit drie delen. 
Deel A beschrijft de doelen van een gezondheidszorg systeem en onderzoekt de 
maatschappelijk preferenties voor deze doelen. Deel B geeft een beschrijving van vijf 
Europese geneesmiddelenvergoedingssystemen. Dit deel richt zich op de vergoedings-
procedures en processen en geeft inzicht in het gebruik van vergoedingscriteria in deze 
landen. Deel C evalueert de beleidsmaatregel ‘coverage with evidence development’. 
Dit instrument wordt binnen de geneesmiddelenvergoeding gebruikt om de gevolgen 
van onzekerheid in de besluitvorming te verminderen.
Deel A: Maatschappelijke preferenties voor de doelen van de 
gezondheidszorg
Hoofdstuk twee beschrijft een uitgebreid internationaal raamwerk dat het mogelijk 
maakt om uitkomsten van gezondheidszorgsystemen met elkaar te vergelijken. Het 
hoofdstuk geeft tevens een theoretische onderbouwing voor dit kader. Het raamwerk 
bestaat uit vijf onafhankelijke doelen. Wij includeerden naast gezondheid zelf tevens 
het proces van zorg verlenen in ons utiliteitsraamwerk. Het zorgproces is namelijk een 
op zichzelf staand doel, onafhankelijk van of het de gezondheid beïnvloedt. Vervolgens 
werden de maatschappelijke preferenties gemeten voor deze vijf doelen met behulp van 
een discrete keuze-experiment. Gezondheidsgerelateerde doelen werden het meest be-
langrijk bevonden (rechtvaardige verdeling van gezondheid [0,34] en het gemiddelde 
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niveau van gezondheid [0,29]), gevolgd door financiële eerlijkheid [0,24], en proces 
gerelateerde doelen (nut afgeleid van het proces [0,07], en de verdeling ervan [0,06]). In 
vergelijking met eerder onderzoek vonden respondenten in ons onderzoek gezondheid 
en de ongelijkheid in gezondheid veel belangrijker. Dit verschil kwam mogelijk doordat 
onze respondenten de vragen beantwoordden vanachter een ‘veil of ignorance’ (sluier 
der onwetendheid). Proces gerelateerde uitkomsten kregen een lagere waardering.
Deel B: Geneesmiddelenvergoedingsprocedures, processen en criteria
Dit deel van het proefschrift richt zich op de besluitvorming op het gebied van genees-
middelenvergoeding in vijf Europese landen (België, Frankrijk, Oostenrijk, Nederland en 
Zweden). Hoofdstuk drie vergelijkt het geneesmiddelenvergoedingssysteem in deze 
vijf landen. De vijf systemen hebben gemeenschappelijke doelen: (i) eerlijke en gelijke 
toegang tot zorg, (ii) kwaliteit van zorg, en (iii) houdbaarheid van het systeem. Het doel 
van het beleid is het op een sociaal aanvaardbare wijze in evenwicht brengen van deze 
drie doelen. Ieder systeem heeft een onafhankelijk instituut dat evalueert of geneesmid-
delen moeten worden gefinancierd vanuit het basispakket. De vijf systemen gebruiken 
hiervoor vergelijkbare vergoedingscriteria. Over het algemeen is men bereid genees-
middelen met voldoende meerwaarde te vergoeden. De impact van het systeem wordt 
voornamelijk gemonitord aan de hand van het geneesmiddelen budget. Een opvallend 
verschil is dat in drie landen de minister discretionaire beslissingsbevoegdheid heeft 
(België, Frankrijk en Nederland), terwijl in twee landen dit niet het geval is (Oostenrijk 
en Zweden). De vijf systemen maken beperkt gebruik van beleidsmogelijkheden om 
geneesmiddelen doorlopend te evalueren.
De vijf systemen trachten met toenemende mate transparant te zijn in hun besluitvor-
mingsproces, maar geen van de systemen past een formele hiërarchie toe van de vergoe-
dingscriteria of maakt gebruikt van een expliciete kosteneffectiviteit drempelwaarde. 
Ons onderzoek toont aan dat de transparantie van het besluitvormingsproces verbeterd 
kan worden in alle vijf systemen; vooral de appraisal fase is onvoldoende transparant. In 
hoofdstuk vier presenteren wij een kader dat gebruikt kan worden om de legitimiteit 
van het besluitvormingsproces te vergroten. Dit kader bestaat uit vijf belangrijke vragen 
inclusief de daarbij behorende vergoedingscriteria. Deze vragen hebben betrekking op 
de (i) medische, therapeutische, en/of maatschappelijke noodzaak, (ii) bereidheid te 
betalen voor het behandelen van een bepaalde aandoening, (iii) bereidheid te betalen 
voor een bepaalde behandeling, (iv) bereidheid om meer te betalen in vergelijking tot 
alternatieve behandelingen, en de (v) daadwerkelijke bereidheid om deze behandeling 
te betalen uit publiekelijk gefinancierde middelen. Het door ons ontwikkelde kader 
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biedt een hulpmiddel om het besluitvormingsproces beter te structureren. Hiertoe 
dienen alle vijf vragen achtereenvolgens beantwoord te worden. Het systematisch 
beantwoorden van de vijf vragen verbetert de consistentie van de beslissingen en hun 
onderbouwing. Bovendien wordt door het duidelijk rapporteren van het antwoord op 
iedere vraag de transparantie van het besluitvormingsproces verbeterd.
Vervolgens richt het onderzoek zich op het gebruik van twee specifieke vergoedingscri-
teria (ziektelast en kosteneffectiviteit). Hoofdstuk vijf toont aan dat ziektelast een be-
langrijke overweging is in de besluitvorming in België, Frankrijk, Nederland en Zweden. 
Dit is vooral het geval indien de ziektelast hoog is. Ondanks dat zijn de landen weinig 
transparant in hoe belangrijk ziektelast is ten opzichte van de andere vergoedingscri-
teria. Het begrip ziektelast wordt in de vier landen op verschillende wijzen geoperati-
onaliseerd. Het Nederlandse systeem gebruikt de ‘proportional shortfall’ methode om 
de ziektelast weer te geven, terwijl in Zweden de ernst van de ziekte wordt uitgedrukt 
in een aantal categorieën. Echter, in beide landen speelt ziektelast enkel een impliciete 
rol in de daadwerkelijke besluitvorming met betrekking tot de vergoeding van een 
geneesmiddel. In België en Frankrijk speelt ziektelast tevens een expliciete rol bij het 
bepalen van de maatschappelijke betalingsbereidheid. Beide landen gebruiken de ernst 
van de ziekte bij het bepalen van het vergoedingsniveau. Ons onderzoek toonde aan 
dat geen enkele respondent kwantitatieve informatie over de ernst van de ziekte (naast 
kwalitatieve informatie) van doorslaggevende waarde vond in de besluitvorming.
Tevens hebben wij de rol van kosteneffectiviteit in het besluitvormingsproces in Neder-
land en Zweden nader onderzocht (hoofdstuk zes). De rol van dit criterium lijkt veel 
bescheidener dan vaak wordt gesteld. Vooral in Nederland lijkt de daadwerkelijke rol 
vrij beperkt te zijn. In Zweden was veel vaker informatie van economische evaluaties 
beschikbaar dan in Nederland (97 vs 31, respectievelijk). Dit verschil leek voornamelijk te 
kunnen worden verklaard door het grote aantal gegeven vrijstellingen voor het aanle-
veren van doelmatigheidsonderzoek in Nederland (65%). In de periode van januari 2005 
tot juli 2012 was slechts doelmatigheidsbewijs aanwezig in 35% van de 118 Nederlandse 
vergoedingsdossiers voor bijlage 1B (dat wil zeggen dossiers voor geneesmiddelen 
met aangetoonde therapeutische meerwaarde). Het doelmatigheidsonderzoek werd 
als onvoldoende onderbouwd beoordeeld voor alle geneesmiddelen die een negatief 
vergoedingsadvies kregen. Echter, tevens 21% van het doelmatigheidsonderzoek 
voor geneesmiddelen die een positief vergoedingsadvies kregen, werd beoordeeld 
als zijnde onvoldoende onderbouwd. Geneesmiddelen die in Zweden een negatief 
vergoedingsadvies kregen, werden niet kosteneffectief bevonden (74%) of kregen 
het oordeel dat er onvoldoende bewijs was met betrekking tot de kosteneffectiviteit 
(26%). Geneesmiddelen met een positief vergoedingsbesluit werden bijna allemaal als 
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kosteneffectief beschouwd (92%). Het is van belang om op te merken dat 53% van deze 
beoordelingen enkel gebaseerd was op een prijsvergelijking en 10% op een kosten-
minimalisatie studie. Slechts 33% van de positieve beoordelingen was gebaseerd op 
een volledig uitgevoerde economische evaluatie studie. Opvallend was dat er slechts 
voor 11 geneesmiddelen in zowel Nederland als Zweden een volledige economische 
evaluatie studie was uitgevoerd. Het vergoedingsbesluit verschillende voor 4 van de 11 
geneesmiddelen.
Hoofdstuk zeven richt zich vervolgens specifiek op de rol van doelmatigheid in de be-
sluitvorming in Nederland. HTA informatie was al in de 80-er jaren beschikbaar voor be-
leidsmakers. HTA informatie wordt echter alleen systematisch vereist bij besluitvorming 
betreffende geneesmiddelenvergoeding; maar ook hier lijkt de rol van doelmatigheid 
tamelijk gering. Ondanks dat het aanleveren van doelmatigheidsbewijs noodzakelijk is 
voor bepaalde groepen geneesmiddelen, is het de vraag of doelmatigheid wel daad-
werkelijk een rol speelt in de dagelijkse besluitvorming. Uit recente casussen bleek dat 
Nederlandse beleidsmakers grote moeilijkheden ondervonden om beperkingen te stel-
len aan de vergoeding van bepaalde geneesmiddelen op basis van doelmatigheid. Dit 
was zelfs het geval bij extreem hoge kosten per voor kwaliteit gecorrigeerd levensjaar.
Deel C: Omgaan met onzekerheid in de besluitvorming
Het besluit om een geneesmiddel wel of niet te vergoeden wordt inherent gemaakt 
met een mate van onzekerheid in het bewijs over de waarde van het geneesmiddel. 
In Nederland werd in 2006 een beleidsmaatregel (coverage with evidence development) 
ingevoerd voor dure intramurale geneesmiddelen. Deze maatregel werd ingesteld om 
gelijke toegang tot geneesmiddelen te garanderen en richt zich op de onzekerheid in 
het bewijs tijdens de initiële besluitvorming. Voor een positief vergoedingsadvies geldt 
de voorwaarde dat er aanvullend bewijs over het geneesmiddel moet worden verza-
meld door middel van uitkomstenonderzoek in de dagelijkse praktijk. Vanaf 2013 is de 
toepassing van deze maatregel verder uitgebreid naar specifieke groepen extramurale 
geneesmiddelen. Hoofdstuk acht onderzoekt of de ingestelde beleidsmaatregel het 
gewenste effect bereikte in Nederland (het garanderen van gelijke toegang tot dure 
geneesmiddelen) voor één van de geneesmiddelen (bortezomib) die onder de maatre-
gel viel. Uit interviews bleek dat medisch specialisten zich bewust waren van de hoge 
kosten van het geneesmiddel maar dat zij geen barrières ondervonden om het middel 
in de dagelijkse praktijk te gebruiken. De studie toonde tevens aan dat artsen een lange 
periode nodig hadden voordat zij het middel regelmatig voorschreven. Ondanks dat 
het gebruik van het middel toe nam na het invoeren van conditionele aanvullende 
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vergoeding aan ziekenhuizen (van 2% in 2004 tot 17% in 2009), bleef het gebruik onder 
het niveau geschat door de beroepsvereniging van hematologen (27%). Verder toonde 
het onderzoek regionale verschillen aan: zowel in het gebruik in de dagelijkse praktijk 
(variërend van 13% tot 27% in 2009) als ook in deelname aan klinische studies (variërend 
van 1% tot 12% in 2006). Het onderzoek toonde enerzijds aan dat de beleidsmaatregel 
een positief effect had op de toegang tot het geneesmiddel, maar anderzijds bleek dat 
er nog steeds regionale verschillen waren die duiden op een ongelijke toegang tot het 
geneesmiddel.
De beleidsmaatregel ‘coverage with evidence development’ lijkt een veelbelovende 
beleidsoptie aangezien het zowel een snelle toegang tot nieuwe geneesmiddelen waar-
borgt als ook gelijktijdig de mogelijkheid biedt om het vergoedingsbesluit te herzien. In 
hoofdstuk negen onderzoeken wij of het haalbaar is om voldoende bewijs te verzame-
len, door middel van uitkomstenonderzoek in de dagelijkse klinische praktijk, voor een 
beoordeling of geneesmiddelen moeten worden gefinancierd vanuit het basispakket. 
De methoden die wij hebben gebruikt in drie case studies maakten het mogelijk om 
voldoende bewijs te verzamelen over welke patiënten worden behandeld, hoe genees-
middelen worden gebruikt in de dagelijkse praktijk (dosis, dosisaanpassingen), en welke 
kosten dit met zich meebrengt. Echter, deze methoden bleken minder goed om bewijs 
te verzamelen over patiënt karakteristieken, redenen om te starten of stoppen met een 
behandeling, en de effecten van een behandeling. Het grootste probleem was dat er 
veel belangrijke informatie miste. In twee case studies (oxaliplatin bij twee indicaties) 
was het mogelijk om een incrementele kosteneffectiviteitsratio te schatten ondanks 
dat er problemen waren met het corrigeren voor verstorende variabelen (confounding 
by indication). In de derde case studie (bortezomib) bleek dit echter niet mogelijk. De 
optimale aanpak van uitkomstenonderzoek kan verschillend zijn per geneesmiddel en 
per indicatie.
Vervolgens wordt in hoofdstuk tien besproken of het toepassen van deze beleids-
maatregel de beste oplossing biedt voor het omgaan met onzekerheid in het bewijs. 
Onze studie laat zien dat uitkomstenonderzoek waardevolle informatie opleverde voor 
beleidsmakers ten aanzien van diverse onzekerheden als gevolg van verschillen tussen 
behandelingen gegeven in klinische trial onderzoeken en behandelingen gegeven in 
de dagelijkse praktijk. Patiënten die werden behandeld in de dagelijkse praktijk ont-
vingen minder behandelingscycli (gemiddeld 4 versus 6) en werden behandeld met 
lagere doseringen (13% lager) in vergelijking tot patiënten die werden behandeld in 
trial verband. De respons op de behandeling leek vergelijkbaar (tijd tot progressie 6.8 
versus 6.2 maanden; complete respons 8% versus 6%; zeer goede, gedeeltelijke en mi-
nimale respons 55% versus 41%). Uitkomstenonderzoek leverde tevens gedetailleerde 
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gegevens over de kosten van de behandeling in de dagelijkse praktijk. Patiënten die met 
bortezomib waren behandeld waren echter niet vergelijkbaar met patiënten die niet 
met bortezomib waren behandeld, ondanks pogingen te corrigeren voor verstorende 
variabelen. Het bleek daarom onmogelijk om een haalbaar model te ontwikkelen dat 
een valide incrementele kosteneffectiviteitsratio zou berekenen. Het is essentieel dat 
beleidsmakers zorgvuldig overwegen of uitkomstenonderzoek voldoende informatie 
oplevert om de initiële onzekerheid te verminderen of dat andere beleidsmaatregelen 
(bijvoorbeeld een prijsovereenkomst of een op uitkomsten gebaseerde overeenkomst) 
wellicht meer geschikt zijn om een betere kosten baten verhouding voor dure genees-
middelen te garanderen.
Discussie
Hoofdstuk elf geeft een overzicht van de belangrijkste onderzoeksresultaten en geeft 
suggesties ter verbetering van het besluitvormingsproces. Het geneesmiddelenvergoe-
dingssysteem hebben wij geëvalueerd naar de mate waarin het besluitvormingsproces 
voldoet aan de legitimiteitsvoorwaarden analoog aan het Daniels en Sabin ‘accounta-
bility for reasonableness’ raamwerk. Ten aanzien van de voorwaarde ‘publiciteit van de 
beslissing rationale’, toonde ons onderzoek aan dat de vijf bestudeerde geneesmidde-
lenvergoedingssystemen onvoldoende transparant zijn in hun besluitvormingsproces; 
vooral de appraisal fase is onvoldoende transparant. Ten aanzien van de voorwaarde 
‘relevantie van de beslissingscriteria’, zagen wij dat de doelstellingen van het systeem 
gereflecteerd werden in de toegepaste vergoedingscriteria. Bovendien leek ieder sys-
teem de betrokkenheid van stakeholders voldoende te garanderen. Ten aanzien van de 
revisie voorwaarde, toonde ons onderzoek aan dat de systemen maar beperkt gebruik 
maken van de mogelijkheid om de maatschappelijke waarde van een geneesmiddel 
doorlopend te evalueren. Tenslotte, met betrekking tot de handhavingsvoorwaarde, 
vonden we dat alle systemen een nationale instantie hadden aangesteld, verantwoor-
delijk voor de besluitvorming betreffende geneesmiddelenvergoeding.
Op basis van het onderzoek in deze thesis was het mogelijk om sterke punten van en uit-
dagingen voor geneesmiddelenvergoedingssystemen te benoemen. Op basis hiervan 
geven wij vier aanbevelingen om het systeem te verbeteren. Ten eerste is het belangrijk 
dat de systemen voortbouwen op hun bestaande sterke punten. Alle systemen beschik-
ken over een nationaal orgaan dat adviseert/beoordeelt of een geneesmiddel moet wor-
den vergoed uit publiekelijk gefinancierde middelen; de systemen hebben vergelijkbare 
en duidelijke doelstellingen. Ten tweede is het voor alle systemen aan te bevelen om 
de transparantie van het besluitvormingsproces te verbeteren. Wij ontwikkelden een 
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raamwerk om het besluitvormingsproces beter te structureren en de transparantie van 
het proces te bevorderen. Ten derde is het belangrijk dat de systemen hun besluitvor-
mingsproces meer cyclisch maken om zodoende om te gaan met onzekerheid in het 
initiële bewijs. Dit kan bijvoorbeeld door een voorwaardelijk vergoedingstraject af te 
spreken onder de conditie dat er aanvullend bewijs wordt verzameld, of door het delen 
van risico’s door middel van een op uitkomsten gebaseerde of een financieel gebaseerde 
overeenkomst. Het is belangrijk om zorgvuldig af te wegen welke overeenkomst het 
beste past bij welk type onzekerheid; dit kan per type geneesmiddel en per indicatie 
verschillend zijn. Daarnaast is het essentieel om het vergoedingsbeleid zo nodig aan te 
passen op basis van de uitkomst van de herbeoordeling. Als laatste promoten wij het 
vergoeden van geneesmiddelen die voldoende maatschappelijke waarde bieden. Het 
is voor alle systemen mogelijk om vergoedingsbeslissingen in grotere mate te baseren 
op ‘value-for-money’; kosteneffectiviteit kan een veel grotere rol spelen in de dagelijkse 
besluitvorming. Dit komt ten goede aan de duurzaamheid van het systeem.
Dit proefschrift draagt  bij aan een beter inzicht in de besluitvorming op het gebied 
van geneesmiddelenvergoeding. Het geeft empirische inzichten in vergoedingsproce-
dures, processen en criteria. Bovendien geeft het proefschrift inzicht in de effectiviteit, 
haalbaarheid en toepasbaarheid van een beleidsmaatregel (‘coverage with evidence 
development’) om de gevolgen van onzekerheid in de besluitvorming te verminderen.
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Promoveren, wie had dat ooit gedacht? Na ruim 10 jaar als verpleegkundige te hebben 
gewerkt, voornamelijk op de afdeling hartbewaking en intensive care in Arnhem, was 
het al wel een tijd duidelijk: ik wil wat anders, ik wil meer uitdaging in mijn werk! Die 
uitdaging zocht ik eerst in het buitenland. In Nieuw Zeeland waar ik, wederom op de 
afdeling hartbewaking, als verpleegkundige heb gewerkt en natuurlijk niet te vergeten, 
de fantastische tijd die Jason en ik samen rondtrokken door Nieuw Zeeland, Australië, 
Pacific eilanden en zuidoost Azië. Toen ik na 3 jaar te zijn weggeweest precies 1 week 
terug was in Nederland, begon ik in 2005, nog enigszins gedesoriënteerd aan het scha-
keljaar van de BMG.
Tijdens de HEPL master kwam het idee al eens in mij op, misschien wil ik wel bij het iMTA 
werken. Toen er een vacature voor junior onderzoeker beschikbaar kwam, hoefde ik dan 
ook niet lang na te denken. Ook toen wist ik nog niet of ik wilde gaan promoveren, het 
is immers nogal een grote overstap van verpleegkundige naar wetenschapper. Ondanks 
dat ik dit ook eerlijk vertelde in mijn sollicitatiegesprek werd ik wel aangenomen. Carin 
en Marc, jullie hadden dit goed in geschat, jullie boden mij de uitdaging die ik nodig 
had, met als resultaat dit proefschrift, en dus ja, promoveren!
Graag wil ik iedereen bedanken die op welke manier dan ook heeft bijgedragen aan 
de totstandkoming van dit proefschrift. Iemand die mij goed kent, weet dat ik het 
dankwoord hier eigenlijk bij zou willen laten. Maar, de afgelopen zes jaar is duidelijk 
geworden dat het dankwoord het meest gelezen hoofdstuk van een proefschrif is, en 
een hoofdstuk met één zin is geen hoofdstuk. Bovendien heb ik natuurlijk zelf kunnen 
ervaren dat je een proefschrift niet alleen schrijft en daarom wil ik dan ook graag een 
aantal mensen persoonlijk bedanken.
Allereerst wil ik mijn promotor Carin Uyl-de Groot en mijn co-promotor Marc Koopman-
schap bedanken. Jullie gaven mij veel meer dan alleen een baan. Carin, bedankt voor 
al het vertrouwen dat je mij vanaf het begin hebt gegeven, en voor de ruimte die je 
mij biedt om verder te groeien. Jouw onderzoek is belangrijk voor patiënten, je onder-
zoekshart ligt op de goede plek. De plek waar de patiënten dit heel hard nodig heb-
ben, namelijk het bevorderen van kwaliteit van zorg en een eerlijke toegang tot zorg. 
Ondanks je drukke agenda, is het toch altijd mogelijk om een gaatje te vinden. Zelfs als 
dit bijna onmogelijk lijkt, creëert ‘onmisbare’ Cobi toch een gaatje, of biedt Whatsapp 
alsnog gegarandeerd succes! Marc, we hebben heel wat uurtjes samen zitten bomen, 
onderzoek moet nuttig zijn en meer inhouden dan alleen wetenschap bedrijven. We 
hebben samen in het Escher project veel verder kunnen kijken dan de standaard ‘kruis-
jesschema’s’ en daardoor veel over het beleid en beleidsmakers geleerd. Ons onderzoek 
hebben we uitgebreid kunnen presenteren, zowel bij Nederlandse beleidsmakers als 
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ook op verschillende congressen. Jammer dat het ons tot nu toe nog niet gelukt is om 
verdere financiering te vinden om ons onderzoek te vervolgen. Misschien moeten we 
toch niet te vaak hardop zeggen dat economische evaluaties alleen maar dienen om 
HTA onderzoekers aan het werk te houden?
Tevens wil ik mijn tweede promotor Ton de Boer graag bedanken. Ook al was je wat meer 
op afstand betrokken bij mijn proefschrift, jouw feedback was een goede aanvulling en 
daardoor kon je ons onderzoek naar een hoger niveau brengen, mede jouw ervaring als 
lid van de wetenschappelijke adviesraad van het zorginstituut was inhoudelijk belang-
rijk.
De promotiecommissie wil ik graag bedanken voor het lezen en beoordelen van dit 
proefschrift en voor het opponeren bij de verdediging.
De hoofdstukken in dit proefschrift zijn geschreven in samenwerking met collega on-
derzoekers. Ik ben alle coauteurs dankbaar voor hun inbreng, kennis en inzichten. Graag 
wil ik een aantal in het bijzonder bedanken: Jennifer Gaultney, Chantal van Gils, Ken 
Redekop, Hedwig Blommestein en Irina Cleemput. Jennifer en Chantal, wij begonnen 
niet precies tegelijkertijd aan de pilot uitkomstenonderzoek studies, maar wel alle drie 
even gedreven. Hoera, dit is het laatste proefschrift, kunnen we dan nu eindelijk het 
feestje vieren dat de pilot studies echt afgelopen zijn? Jennifer, wij hebben samen heel 
hard aan die onmogelijke bortezomib studie gewerkt, en onze powerpoint slide met die 
enorme behandelvariatie hebben we al heel vaak op veel verschillende plekken terug 
gezien. Ik weet zeker dat ook het laatste artikel van bortezomib gepubliceerd gaat wor-
den, ik geloof er nog steeds in! Chantal, ook nadat je bij iMTA wegging bleven we samen 
werken, onze opgedane pilot kennis konden we goed gebruiken om de melanoom 
studies beter op te zetten en uit te voeren. Jammer dat onze samenwerking nu eindigt, 
maar ik wens je veel plezier met je nieuwe baan in Brussel. Ken, ook jij was betrokken bij 
de pilots, ik heb heel veel geleerd van je kritische reflecties. Hedwig, je begon als student 
assistent bij de bortezomib pilot, inmiddels ben je al jaren een fantastische collega en 
nog steeds bezig met multipel myeloom. Blijf zoals je bent! Irina, we hebben samen hard 
gewerkt aan de vijf landen vergelijking, wat ontzettend leuk dat jij nu opponeert bij mijn 
verdediging.
Ik kijk terug op ruim zes fijne jaren bij GE-iMTA, collega’s dank hiervoor, jullie hebben 
hier aan bijgedragen. Heel bijzonder vond ik onze deelname aan de ROPARUN, ik vond 
het fantastisch, ik zou het zo weer doen (inclusief de TravelJohns). Henk Sonneveld, jij 
was maar voor 1 jaar mijn kamergenoot, maar dit was wel ons beider eerste jaar bij de 
iBMG, waardoor we veel konden delen. Ik vind het leuk dat we elkaar nog af en toe zien. 
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Rian Rijnsburger, de jaren erna was jij mijn kamergenote, wij hebben veel meer gedeeld 
dan alleen de echte lekkere koffie. Ik weet niet wie van ons het meest verslaafd is, maar 
jij lijkt wel degene te zijn die onthoudingsverschijnselen krijgt als er geen echte koffie 
is. Ik wil me hierbij nog eenmaal verontschuldigen voor al die hoge stapels waar jij altijd 
tegen aan moest kijken, jouw stapeltjes waren altijd netter en veel meer georganiseerd 
dan die van mij. Wat jammer dat je de iBMG gaat verlaten, ik ga je gezelligheid missen. 
Ik wens je heel veel plezier in je nieuwe baan!
En dan natuurlijk, niet het minst belangrijk, mijn paranimfen: Anja Mallison en Anouk 
O’Prinsen. Anja, ik moest gaan rekenen om te bedenken hoe lang wij elkaar al niet ken-
nen. Ik ben maar gestopt bij 30 jaar, anders lijken we zo oud. In die jaren hebben wij zo 
ontzettend veel gedeeld, het is jammer dat we elkaar mede door de afstand niet vaker 
zien, maar eigenlijk maakt het niet uit of jij nu in Duitsland, Amerika, of Engeland woont, 
of dat ik in Nieuw Zeeland of Nederland woon of ergens anders op de wereld vertoef. 
Gelukkig is er altijd een goedkope telefoonaanbieder te vinden! Wat fijn dat jij mijn pa-
ranimf bent. Anouk, wij hebben elkaar leren kennen in het schakelprogramma en samen 
de HEPL master gedaan. Tijdens onze opleiding, maar ook nu nog steeds bediscussiëren 
wij regelmatig hoe dat nou toch zit in die klinische studies of doelmatigheidsstudies. Jij 
hebt de vorderingen in mijn proefschrift de afgelopen jaren steeds bijgehouden, waar-
schijnlijk ben je een van de weinige die de meeste hoofdstukken van mijn proefschrift 
heeft gelezen.
Tot slot vrienden en familie, een aantal van jullie heeft heel hard meegeholpen met de 
pilot testen van hoofdstuk twee. Verder hebben jullie natuurlijk op allerlei verschillende 
manieren indirect bijgedragen aan dit proefschrift. Nathalie, speciaal voor jou, het laat-
ste hoofdstuk van de Libelle is hierbij klaar! Jason, bedankt voor alle ruimte die ik altijd 
van je krijg. Tess, jij brengt zoveel vrolijkheid en gezelligheid in ons leven!
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